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ABSTRACT 
 
 
The presence and replication of E.coli within Crohn’s Disease (CD) tissue has been 
confirmed by multiple authors and is hypothesised to be pivotal in the development of  
CD. In this thesis, quantification of E.coli bacteria within endoscopic biopsies has 
been achieved with high efficiency, sensitivity and reproducibility using PCR plasmid 
technology, and the technique’s utility demonstrated by quantifying E.coli within the 
biopsies of CD patients in clinical relapse and remission as well as within the first 
lesions present in CD relapse, aphthous ulcers. These studies showed some interesting 
correlations with clinical, macroscopic, and histological data, obtained during a 
clinical trial of soluble plantain fibre supplementation for prevention of relapse in CD. 
These included increased quantities of E.coli in tissues from the mucosa of patients in 
clinical relapse whose ileum was macroscopically normal yet histologically inflamed, 
and significant falls in the quantities of E.coli over time in the biopsy tissues of 
patients who were in clinical remission.  
 The ability of a specific group of E.coli, the adherent invasive E. coli (AIEC), 
to replicate within macrophages, is increasingly perceived to be fundamental in CD 
pathogenesis. The replication of E.coli within the phagolysosomes of macrophages is 
implicated in the release of pro-inflammatory cytokines, granuloma formation, and 
the consequent mucosal injury seen in CD. The pharmacological inhibition of AIEC 
replication in this work within murine macrophage tissue in vitro by the  
immunosuppressive  azathioprine and its active metabolite 6-thioguanine as well as 
by the antibiotic ciprofloxacin at clinically relevant concentrations is supportive of 
this central hypothesis, and also suggests new treatment combinations that might be 
trialled in active CD. Interestingly and unexpectedly the steroid hydrocortisone also 
inhibited AIEC replication within macrophages, suggesting that sepsis-related 
complications seen with steroid use clinically may be related to its effects on 
neutrophil recruitment, rather than on phagocytic killing of bacteria. 
 The diarrhoeal pathogens EPEC, ETEC, and C. difficile represent a large 
disease burden in terms of infantile, travellers’, and antibiotic-associated diarrhoea 
respectively with C. difficile also sometimes implicated in the exacerbation of CD. 
Plantain (banana) non starch polysaccharide (NSP) has previously been demonstrated 
to inhibit AIEC adhesion to mucosal tissues, and this work demonstrates  the 
inhibition of the adherence  of ETEC and C. difficile to intestinal cells in vitro with 
two different modalities, using concentrations of soluble plantain fibre that are readily 
achievable in the distal intestinal lumen. Previous work on AIEC inhibition with 
plantain was confirmed, whilst oat fibre and apple pectin did not significantly inhibit 
ETEC adherence. EPEC was not inhibited by plantain fibre, which may be due to its 
unique epithelial interaction. These foodstuffs, if prepared as suitable supplements, 
may offer new prophylactic therapeutic interventions for global and institutional 
diarrhoeal illness following appropriate clinical trials.  
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CHAPTER ONE:  
INFLAMMATORY BOWEL DISEASE 
 
 
1.1 Natural History of Inflammatory Bowel Disease 
 
Inflammatory bowel disease (IBD) comprises mainly Crohn’s disease (CD) 
and ulcerative colitis (UC). These diseases affect mainly the small (CD) and large 
(CD and UC) intestines, and their pathogenesis  involves genetic and environmental 
factors that include alterations in innate immunity, the function of the mucosal barrier 
and the intestinal microbiota (1).  
 
1.1.1 CD  
 
CD is characterised by deep inflammation with granulomata, and may affect 
any part of the gastrointestinal tract, although it most commonly affects the distal 
ileum and caecum. CD may affect the buccal cavity (9%) with inflammation causing 
aphthous or granulomatous ulcers as well as disfiguring infiltration of the lips that is 
commoner in children with CD, and precedes the development of intestinal symptoms 
in 60% of patients (2). The oesophagus may less commonly be affected (3). 
Gastroduodenal inflammation has been reported in 20% of CD endoscopy cases, 
mainly as H. Pylori negative focal gastritis with 40% involvement histologically but 
with less than 4% clinically symptomatic from these lesions (4). Duodenal 
involvement is commoner in younger patients and may be particularly troublesome 
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with upper GI stricturing (5). Rarely high fistulae complicate CD with 5 cologastric 
(0.6 %) and 1 ileogastric (0.08 %) fistulae seen in a series of cases over 30 years at 
Mount Sinai Hospital, New York (6). Acute Pancreatitis (AP) is a rare extra-intestinal 
complication of IBD, but much more commonly precedes IBD diagnosis in children 
than adults with one retrospective analysis involving 3960 patients showing a rate of 
2.17% AP preceding IBD in children versus 0.06% in adults (7). Another 
retrospective analysis of 230 children demonstrated 30% having gastric, oesophageal, 
or duodenal involvement, with 3 patients having CD confined to the upper 
gastrointestinal tract (1.3%). It was also observed that children were significantly 
(33%) more likely to have upper gastrointestinal pathology if they had both large and 
small intestinal CD involvement compared to either small or large intestinal disease in 
isolation (8). Diffuse small intestinal disease, jejunoileitis, is difficult to treat, but is 
uncommon with its exact incidence unknown, though most gastroenterologists feel its 
prevalence is increasing, and again it is more frequently seen in patients presenting in 
childhood (see table 1.2, figure 1.1, and (9). Disease is commonly seen in the terminal 
ileum (16-25%) and proximal colon, with ileocolonic disease present in 37-41%. 
Isolated colonic disease occurs in about 1/3 to 1/2 of cases (35-47%)(10), but here 
distinction from UC may be difficult (see later).  The commonest site of involvement 
in CD varies with ethnicity and for south Asians living in London is predominantly 
colonic (46.8%),compared with the higher prevalence of ileocolonic disease (40.5%) 
in North European north London inhabitants (see table 1.1). Lesions in CD are 
typically discontinuous, frequently spare the rectum and can give a characteristic 
‘cobblestone’ appearance. The colonic aphthous ulcer is a lesion seen in early active 
CD (11) and is highly suggestive of the diagnosis. 
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Fistulae in CD in general have a cumulative incidence of 33% 10 years after 
diagnosis, and 50% 20 years after diagnosis (12), whilst peri-anal disease including 
fistulae (abnormal connections between two epithelial surfaces), fissures, and 
abscesses affects 25-80 % of patients with CD (13), and is an independent predictor of 
change in CD from an initial non-stricturing non-perforating behaviour to other 
disease phenotypes (14), & table 1.3.    
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Table 1.1 Prevalence of pathology in CD by location and surgery risk   
 
*** = statistics from paediatric cohorts only 
** = predicts development of complicated disease and surgery 
* = 50% combined risk of resection during median 7 year follow up (mixed 
 cohort) 
RR = relative risk AD = at diagnosis  (References (3-10;12;13;15)   
Location of CD %, or % range affected Long term prognosis/risk for surgery 
Isolated Ileal disease  16-24.7 0.84% resection AD. Significantly greater risk 
than colonic pathology of complicated disease * 
and ** 
Isolated Colonic disease 34.8–46.8 0.63% resection AD * 
Ileocolonic disease 37.2-40.5 6.9% resection AD * and ** 
25-91% reoperation risk after 15y *** 
Gastroduodenal 4-40 ** (for duodenal involvement) 
Oesophageal, gastric or duodenal 30 *** ** (for duodenal involvement) 
Stricturing >26 ** 28-44% recurrence after stricturoplasty (9y 
follow up) *** 
Upper GI Fistulating 0.08-0.6 ** 89% had surgery for this finding 
Pancreatitis 0.06-2.17  
Mouth (Aphthoid) ulcers 9  
Perianal disease 25-80 Ileal and perianal disease have RR of fistulation 
of 0.8-2.2. colonic and perianal disease have RR 
for fistulae of 3.4 
Cumulative incidence of fistulae 
in CD 
33 (10 years) 50 (20 years)  
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Table 1.2 Early onset CD phenotype (from (9)).  
 
 
 
 
 
 
Figure 1.1 Site of CD in children and adults, from (9). 
 
1.1.1.1 The Vienna classification of CD 
 
The Vienna classification of CD (16) was an attempt to put CD cases into 
more homogenous groups with prediction of disease behaviour based on the variables 
age of diagnosis and location of disease (see table 1.3). Cross table analysis of these 
cases shows association between age of diagnosis and location of disease as well as 
 6 
between location of disease and behaviour. Such a classification is useful as it can 
predict requirements for either medical, endoscopic or surgical assessment and 
treatment, and guide patient counselling. The Vienna classification (16) divides CD 
behaviour into penetrating, stricturing and inflammatory disease. Stricturing is 
narrowing of the bowel lumen which can lead to bowel obstruction, and penetrating 
disease implies fistulae between the skin and bowel or bowel and other organs or 
epithelia in the abdomen and pelvis. Inflammatory disease reflects absence of 
stricturing or fistulae. 
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Table 1.3 The Vienna classification of CD, modified from (16) 
 
1 = the age when the diagnosis of CD was first definitively established by endoscopy, 
radiology, surgery or pathology, 2 = the maximum extent of disease involvement at 
any time prior to the first resection, minimum involvement for a location is defined as 
any aphthous lesion or ulceration. Mucosal erythema and oedema are insufficient. For 
classification at least both a small bowel and a large bowel examination, are required. 
3 = Disease limited to the terminal ileum (the lower third of the small bowel) with or 
without spill over into cecum. 4 = Any colonic location between cecum and rectum 
with no small bowel or upper gastrointestinal (GI) involvement. 5 = Disease of the 
terminal ileum with or without spill over into cecum and any location between 
ascending colon and rectum. 6 = Any disease location proximal to the terminal ileum 
(excluding the mouth) regardless of additional involvement of the terminal ileum or 
colon. ’ 7 = Inflammatory disease which never has been complicated at any time in 
the course of disease. 8 = Stricturing (or stenosing) disease is defined as the 
occurrence of constant luminal narrowing demonstrated by radiologic, endoscopic or 
surgical-pathologic methods with prestenotic dilatation or obstructive signs/symptoms 
without presence of penetrating disease at any time in the course of disease. ’ 9 = 
Penetrating (or perforating) disease is defined as the occurrence of intra-abdominal or 
perianal fistulas, inflammatory masses andlor abscesses at any time in the course of 
disease. Perianal ulcers are also included. Excluded are postoperative intra-abdominal 
complications and perianal skintags.  
 
Age at diagnosis:
1
 A1, < 40 years  
A2, ≥ 40 years 
Location:
2
 L1, Terminal ileum
3
 
L2, Colon
4
 
L3, Ileocolon
5
 
L4, Upper GI
6
 
Behaviour: B1, Nonstricturing nonpenetrating
7
 
B2, Stricturing
8
 
B3, Penetrating
9
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Applying the Vienna Classification system retrospectively to some cohorts has 
produced varied results. In one cohort it has been shown that while CD location 
remains relatively unchanged over time following diagnosis, with only 16% changing 
location, behaviour can change dramatically (up to 46%), with another cohort 
showing 91% stability of location. Other factors, such as perianal disease can have a 
large effect on CD behaviour change. The most common change in behaviour was 
from non-stricturing and non-penetrating to stricturing (27%) and penetrating (29%) 
after 10 years, in ileal and colonic or ileocolonic CD respectively. In this cohort of 
125 patients examined, interestingly, and at some odds with the Vienna classification 
age at diagnosis had no impact on disease location or behaviour (17;18).  
The Montreal revision of this classification examined serological and 
molecular classification of CD (19), and separated upper gastro-intestinal disease and 
perianal disease as different CD entities with different natural histories.  
 
1.1.1.2 Factors affecting the progression rate of CD 
 
Factors that can affect progression rate of CD include smoking, peri-anal 
disease, prior steroids, and early onset of immunosuppression (14). Other studies 
identify weight loss and steroid requirement at first presentation (20) as prognostic 
risks. Perianal disease in colonic CD has significant risk of progressing to cause 
internal fistulisation (21) and small bowel location, ileo-colonic CD (20) and 
stricturing predict progression to complicated disease and surgery (17;22). 
Conversely, disease extension and severity can be modified by use of the 
immunomodulator, azathioprine (23;24). Early thiopurine use has been associated 
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with lower cumulative surgical resection rates in CD over time (25). Environmental 
factors affecting disease are discussed in more detail later. 
Independent of the classification system and treatments used, it is clear that 
CD is dynamic and can evolve, particularly from a non-stricturing, non-penetrating 
form into these more complicated disease forms, which is dependent on genotype and 
environmental exposures.  
In general most CD patients have a relapsing remitting course of illness, with 
13% having unremitting disease and 10% having more prolonged remission, and 
overall in an analysis of North American patients there was up to a 57% chance of at 
least one surgical resection during the course of the disease (26).  
 
1.1.2 Ulcerative Colitis 
  
Ulcerative colitis classification is much simpler than that of CD, with three 
groups identified: proctitis or proctosigmoiditis (affecting rectum and sigmoid colon), 
“left sided colitis” (up to the splenic flexure) and pancolitis (inflammation affecting 
the whole bowel).  
UC is largely limited to the colon, particularly the distal colon and rectum  and 
causes more superficial ulceration than CD (27). A large cohort of IBD patients were 
evaluated in London, and 63% of the South Asian population there had extensive 
colitis “pancolitis”, with the figure for North Europeans living in London at 42.5%. 
The prevalence of left sided UC was 27.1% and 31.4% respectively for the South 
Asian and North European communities, with cases having disease limited to the 
rectum “ulcerative proctitis”, at 9.9% and 26.1% respectively with higher prevalence 
of this localised disease seen in the North European group (10).  In a study of 1116 
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patients in Cleveland prevalence was 36.7% for pancolitis, 46.2% for 
proctosigmoiditis, and 17% for left sided colitis, which is comparable to the London 
based cohort for pancolitis prevalence. The mean follow up was 12.7 years, but within 
2 years 16.7% had colonic haemorrhage, with 12.7% having toxic colitis with a total 
surgical intervention rate of 37.6%  over the follow up period.  The chances of 
extension of disease are 70% in 5 years for left sided colitis, and 50% in 25 years for 
proctitis, with both initial and final disease location affecting colectomy and 
ileostomy rates. Factors which affected disease progression were younger age at 
diagnosis, extent of disease, toxic colitis, joint symptoms and severe haemorrhage 
(28). Age was independently associated with extent at diagnosis too, with younger age 
associated with a greater extent of mucosal damage (pancolitis), but not necessarily a 
worse disease course or increased rate of colectomy (29). 
 
Histological findings in UC include mucosal inflammation which is 
continuous and circumferential and extends proximally from the rectum to involve the 
colon and in severe cases the terminal ileum “backwash ileitis” may be involved, 
though this may be a misnomer and represent a discrete disease entity whose 
incidence is not comprehensively quantified. In a series of 100 patients who had 
restorative proctocolectomy for UC, 22% of these had ileitis and this was strongly 
associated with pancolitis, as well as associated with short duration to presentation, 
primary sclerosing cholangitis (PSC), but not with severity of colitis (30). 
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1.2 Extra-intestinal manifestations of IBD 
 
Both conditions can be associated with extra-intestinal manifestations (EIM) 
of disease (31), such as skin rashes, joint pain and eye inflammation. In a paediatric 
study of 1019 patients 28.2% were affected by at least one EIM, with 87% of these 
occurring in the first year of enrolment to the study, and 17% at baseline (see table 
1.4). Increased baseline clinical disease activity was associated with at least one of: 
arthralgia, erythema nodosum (EN), and aphthous stomatitis (AS) during the period of 
follow up (26.2 months) for both UC and CD, though there were statistically different 
rates of EN, AS, and Primary Sclerosing Cholangitis (PSC) between the conditions. 
PSC did not appear to be related to disease activity, but was more common in UC 
than CD, while the converse was true for EN and AS. Females with UC were more 
likely to experience arthralgia, and older patients were more likely to suffer PSC. PSC 
activity may be independent of IBD activity, and is not associated with underlying 
IBD activity in adults either (32;33), Extent of CD was not associated with EIM 
differences, whilst a pancolitis was associated with greater chance of EIM than 
limited disease (34).  Interestingly, patients treated with mesalamine, infliximab or 
immunomodulator therapy were less likely to have an EIM (IBD therapy discussed 
later).  
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Table 1.4 Extra-Intestinal Manifestations of IBD, and significant 
 differences between disease groups from (34). 
 
 
In 1976 a series of 700 patients explored EIM and their associations with different 
locations and levels of activity in IBD (35), identifying major EIM as mouth, skin, 
joint and eye related. These occurred with a total rate of 36% with skin disease in 
23%, joint problems in 15%, and eye and mouth EIM in 4%. Liver disease, gallstones, 
renal stones, peptic ulcer and amyloid were also documented. Pyoderma gangrenosum 
(PG) was observed more commonly in UC and EN more commonly in 
“granulomatous colitis”.  
 
1.2.1 Arthropathy 
  
One in four paediatric patients has an EIM and a similar rate is seen with adult IBD 
patients at 25-40% (34). Musculoskeletal, arthritic associations with IBD are in the 
form of spondylarthropathies, and include axial symptoms, peripheral arthritis and 
ankylosing spondylitis in 3-6%, but with sacro-iliitis more commonly in 14-20% 
making it the most common form of EIM, though the mechanism of arthropathy is 
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still unknown (36). Peripheral findings include sero-negative spondyloarthritis, 
arthropathies, enthesopathies, and dactylitis in 11-20% (37). These statistics are for 
both UC and CD.  The peripheral pauci-articular arthropathies are often associated 
with IBD intestinal activity, but axial back pain, sacro-ileitis  and ankylosing 
spondylitis are not. Sometimes arthropathy can be the presenting problem of an IBD 
exacerbation, and even though treating mucosal inflammation effectively does not 
always completely resolve arthralgia, the arthropathies associated with underlying 
IBD activity, mainly reactive non-erosive asymmetrical arthritis, usually resolve when 
the underlying disease is treated, whilst ankylosing spondylitis does not. Anti-tissue 
necrosis factor (anti-TNF) therapies have great promise in this area (see later) (36).  
 
1.2.2 Skin and Eye Involvement 
 
 In terms of skin manifestations, EN (4.0%) and PG (0.75%) are the most 
common skin complications in IBD. In a total cohort of 2402 patients with CD and 
UC,5.8% had at least one skin manifestation. PG is a neutrophilic dermatosis, causing 
necrosis and pigmented ulcers on the legs. EN is a panniculitis,with tender nodules 
present on the shins. In the cohort studied, EN was associated with CD, PG and joint 
involvement, as well as colonic involvement. PG was associated with uninterrupted 
pancolitis, eye involvement and EN, but neither was associated with a mixed surgical 
and medical severity assessment corresponding to disease activity in the IBD cohort 
studied. However the lesions can predict phenotype to some degree (38). 
 Eye involvement in IBD occurs in approximately 3-10% of patients, mainly as 
episcleritis and uveitis (38). Episcleritis runs a course parallel to that of the underlying 
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intestinal activity, whilst uveitis does not, and hence episcleritis may respond to IBD 
treatment better (39). 
 
1.3 Epidemiology of IBD 
 
IBD tends to be a disease of young adulthood, but diagnosis age has bimodal peaks 
(15-35, and to a lesser extent 50-70 years). The diagnosis of UC tends to be later than 
CD (40;41) CD is more common in women than men, with UC slightly more common 
in men than women in a study of hospitalised patients. (42)   
 
The incidence of IBD is rising rapidly in developed countries (43), with immigrants 
also seemingly acquiring increased risk. Developing countries disease rates are 
increasing with UC rate increases shortly followed by an increase in CD rate (44). 
These observations and the relative lack of concordance of disease in monozygotic 
twins (see later) are all suggestive of the role of environmental factors in 
pathogenesis.  
 
The prevalence of CD in North America ranges from 26.0 to 198.5 per 100,000 
persons with an incidence of  3.1-14.6 per 100,000 person-years. (26). Prevalence and 
incidence across the world varies with greater rates amongst whites and Ashkenazi 
Jews and in industrialised northern countries. (45) Originally, the incidence and 
prevalence of IBD was thought to be much higher in North America, northern Europe, 
and the United Kingdom with lower rates in Africa, Asia, Latin America, and 
southern Europe, but the differences are thought to be smaller now with changes in 
socio-economic status (46). 
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1.4 Prognosis 
 
Determining the extent and severity of disease helps in prediction of disease course  
(17) and risk of surgery (see table 1.1 and section 1.5) but the lifetime risk for surgery 
remains disappointingly constant at around 25% for UC and 80% for CD (47). 
Current treatments only target the consequences of the disease and not the underlying 
pathogenic mechanisms. Better understanding of pathogenesis should lead to 
different, safer, and more effective therapies. 
 
1.5 Genetic Factors in IBD – Familial Clustering and Twin Studies 
 
A large number of studies have shown familial clustering in IBD, with informative 
twin studies and aggregation seen of specific phenotypes of disease. Approximately 
25% of patients with IBD have another family member affected. Follow up of the first 
twin pair IBD register from 1988 showed remarkable concordance between twins for 
disease characteristics including phenotype using the Vienna classification. Age of 
diagnosis, progression of extent, location and behaviour  were the disease 
characteristics assessed. 80 twin pairs were identified with at least one twin affected 
by IBD, in 16 monozygotic (MZ) twin pairs with UC, only 1/16 were concordant 
compared to 8/18 MZ twins with CD. In 46 dizygotic (DZ) twin pairs with IBD, only 
1 pair was concordant (for CD) Pair concordance for MZ twins with CD was 50%, 
with a much lower rate for UC of 18.8%, and in a Danish cohort amongst Danish 
twins the concordance rate for CD and UC in MZ twins was 58.3% and 18.2% 
respectively with DZ twins correspondingly 0% and 4.5% (48) suggesting that CD 
has a stronger genetic component than UC, but also that an environmental component 
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is important in disease pathogenesis (49). IBD was also more common in the relatives 
of patients with UC or CD, with a general prevalence of 7.9%, and first degree 
relatives (FDR) of a UC sufferer had a 15 fold increased risk of UC than non 
relatives, and an increased chance of early onset of disease, as well as total colitis. 
Interestingly CD was 3.5 fold more likely in the FDR of a patient with UC too, 
supporting the view that these are not two completely discrete conditions, but perhaps 
a continuum (50). When familial clustering of CD was evaluated in 1048 patients, a 
similar pattern was seen with FDR of CD sufferers having a 13.4% prevalence of CD. 
In addition FDR had a 21 fold increased risk of CD, with a 6 fold increased risk of 
UC compared to unrelated patients (51). The same pattern was seen with a Danish 
cohort; FDR had 10 fold increased risk of UC or CD, with a particular association 
seen in those where the sufferer had a diagnosis before the age of 50 (52). As well as 
statistically increased IBD rates between relatives, the phenomenon of genetic 
anticipation is also seen in IBD, where the age at diagnosis is earlier in affected 
children than in their parents, with a greater effect seen in UC than CD (53). 
  
IBD rates also vary with ethnicity and the FDR of patients with IBD show differences 
between groups. The age specific rates for IBD in the FDR of sufferers who were 
non-Jews in California were 5.2 and 1.6% for CD and UC respectively, compared 
with the consistently higher rates seen in the FDR of the Jewish community with IBD 
in California who had rates of 7.8 and 4.5% respectively (54).  
 
 
  
 17 
1.5.1 Genetic associations with IBD – Genome Wide Association Scan (GWAS) 
studies 
 
Along with the above familial clustering and twin studies, other large studies  
in man show that UC and CD are polygenic disorders whose candidate predisposing 
genes have been clarified by a genome wide study (55). Ninety-nine gene associations 
with IBD have been identified. The NOD2/CARD 15 (nucleotide oligomerisation 
domain 2/ caspase recruitment domain 15) gene has been confirmed as an innate 
immune system gene polymorphism associated with ileal (56) and stricturing 
phenotypic variants of CD. It probably accounts for approximately 15% of CD 
causation in Western countries although is not associated with CD in Japan. NOD 
receptors along with Toll-like receptors (TLRs) are pattern recognition receptors 
(PRRs) for microbes (figure 1.2). NOD proteins are cytosolic whilst TLRs are 
membrane bound (57). 
Other bacterial handling genes identified in the genome-wide scan (58), 
include ATG16L1 (ATG16 autophagy related 16 like 1) gene, and IRGM (immunity 
related guanosine triphosphatase); a gene encoding a GTP binding protein which 
induces autophagy. Autophagy is involved in killing of intracellular bacteria including 
Mycobacterium tuberculosis (55). MST-1 (macrophage stimulating 1), also associated 
with CD, encodes a protein that influences motile activity and phagocytosis by 
peritoneal macrophages (55). 
Associations with mutations in the interleukin 23 receptor IL-23R, have also 
been reproducibly found (55). IL-23R encodes a subunit of the receptor for the pro-
inflammatory cytokine IL-23, which is pivotal in the differentiation of T helper 
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(Th17) cells. In animal models the Th17 T cell subset mediates chronic and 
autoimmune inflammatory conditions.
 
(59) 
Most of these associations, apart from NOD2/CARD15, although statistically 
significant, have modest odds ratios for CD but give useful clues to likely pathogenic 
mechanisms.  
The genetic contribution to UC causation is weaker than for CD, though recent 
work has also questioned the importance of the genetic influence in CD course (60). 
In UC initially it was thought that only about one in ten identical twins of UC patients 
became affected compared with about one in two for CD, though more recent work 
shows even weaker concordance in UC. In CD location in MZ twins was concordant 
in 65% at diagnosis and 69% at ten years, whilst with UC MZ twins showed no 
concordance in disease extent at diagnosis or after 10 years. The figures for age at 
diagnosis for MZ twins with UC showed some concordance at 67 %, with 
symptomatic onset also concordant in 44 % (61). HLA-DRB1*0103 is strongly 
associated with extensive UC in caucasians, as is the multi drug resistance 1 (MDR1) 
gene (59).
  
MDR1 expresses an apical epithelial efflux glycoprotein in distal small 
bowel and colonic epithelia. MDR1 gene-knockout mice have increased susceptibility 
to intestinal inflammation. TNF superfamily gene members have also been associated 
with IBD phenotypes, with both high and low risk haplotypes of the same gene 
(TNFSF15) identified.  
These genetic studies are providing increasing evidence to implicate defects in 
phagocyte function in CD and defects in barrier function in UC. The implications of 
some of these gene associations for interaction with the intestinal microbiota is 
discussed in chapter two. 
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1.6 Environmental factors in the pathogenesis of inflammatory bowel 
disease 
 
 
There are an abundance of hypotheses about the involvement of possible 
environmental factors in IBD and a number of risk factors have been identified: 
 
 
1.6.1 The effect of diet 
 
 
 
Diet can have both harmful and ameliorating effects in IBD, and this has been noted 
in both observational and interventional trials. A change in main dietary foodstuffs 
from rice to increased amounts of animal meat, fats and dairy products has been 
shown in a Japanese epidemiological study to precede increased incidence of IBD by 
approximately twenty years (62), other similar studies exist and a systematic review 
of the literature has demonstrated that high intake of total fats, omega-6 oils, 
polyunsaturated fatty acids and meat pre-disease are associated with an increased risk 
of both CD and UC. Obesity was associated independently with IBD disease activity 
(63), whilst high intake of fruit and vegetables was negatively associated with CD, 
with vegetables also negatively associated with risk of UC, but with omega-3 oils 
demonstrating no beneficial effect (63). The increasing incidence of IBD in areas 
previously thought to have low incidence like China, South Korea and Puerto Rica 
has been proposed to be due to the expansion of the ‘western diet’ (64). Diet can 
influence the microbiota colonising the intestines, and a comparison of fecal samples 
from European and African people, who eat a high fibre diet showed a preponderance 
of Bacteroidetes and low quantity of the Enterobacteraeciae and firmicutes seen in the 
European faecal samples (65). This dysbiosis has been associated with IBD (see 
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later), and it seems likely that diet plays a role in IBD, perhaps via this mechanism. 
CD patients have also been shown to have a higher than control or UC intake of 
sugar, though whether this is a primary or a secondary phenomena to CD is disputed 
(66;67) and intake of linoleic acid, an essential fatty acid found in many oils also 
seems to precede UC diagnosis (68). In areas of the world where soluble fibre, for 
example, in the form of plantains, are consumed in high quantity, such as the 
Caribbean and West Indies, incidence of CD is low and in vitro experiments have 
demonstrated an inhibitory effect of this plantain fibre on bacteria mucosal adhesion 
(69). The permitted food emulsifier polysorbate, a detergent contained in highly 
processed fatty foods, enhanced bacterial translocation through the bowel mucosa in 
vitro, and this suggests a mechanism by which highly processed food may worsen 
IBD or risk of developing IBD (69). Finally the importance of diet in IBD 
pathogenesis is confirmed by a meta-analysis demonstrating that specialised enteral 
feeds such as basic constituent (elemental) or polymeric diets, which have low residue 
and basic constituents excepting hydrolysed protein, can induce clinical remission in 
CD (70). 
 
1.6.2 Hygiene  
 
IBD has been reported to be commoner in people with reduced microbial exposure 
during childhood for a variety of reasons, the so called ‘hygiene hypothesis’, and 
factors important in this hypothesis may be H.Pylori, helminths, breast feeding and 
sibship (71). Most of these epidemiological studies are limited by methodology, with 
recall bias the most difficult problem. The hypothesis emerged when the observation 
was made that the incidence of IBD in developed and developing countries was rising 
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(72;73), and that this correlated with improved sanitation, hot water and less crowding 
and use of products like toothpaste. The basis of the hypothesis is that a reduced 
exposure to common infectious agents when young leads to a immune 
hypersensitivity response later on in life when challenged with the same bacteria that 
may be a component of, or cause the pathology seen in IBD (74). Larger family size is 
associated with lower rates of all atopic disorders, which may be a due to differing 
levels of microbial antigen exposure in small and large families (75).  
 Improved hygiene is associated with decreased microbial exposure (76), and 
the development of immunological tolerance to these microbes, and the subsequent 
balance point between pro-inflammatory T-cells and regulatory T-cells  may be 
impaired by this and be the cause of future hypersensitivity and diseases like IBD in 
patients (77).   
 A specific environmental microbe associated with reduced incidence, delayed 
presentation and a possible protective effect in IBD is Helicobacter pylori (78-80). In 
a study examining rates of relapse in IBD, amongst non-smokers, patients 
seropositive for Helicobacter Pylori were also less likely to relapse than in those 
seronegative for the bacteria, implying a possible protective role (81) which merits 
further evaluation. 
 With increasing urbanisation and modern hygiene practices there is also a 
lower exposure to soil borne helminths in infants, and helminths such as Trichomona 
suis induce a strong Th2 immune response, opposing the pro-inflammatory Th1 
response (82;83) and providing an important role in regulation of the intestinal 
microbiota and their absence has been associated with the development of IBD (84). 
Chronic infection with helminths also induces production of the anti-inflammatory 
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cytokine TGF β which is a component of the regulatory T cell effect (85) and clinical 
trials with helminths in IBD have also shown some efficacy (86).  
 The ‘cold chain’ phenomenon is the observation that the introduction of the 
refrigerator is often related in time to CD outbreak (87). This is thought to be because 
some bacteria which can survive at fridge temperatures are also seen in CD lesions 
(88), namely Listeria monocytogenes, Yersinia enterocolitica, Clostridium botulinum 
and Bacillus Cereus (89). In some older IBD patients matched with controls, it was 
noted that the IBD sufferer owned a fridge 4 years earlier than the matched control 
patients (90). Whether other confounders which co-existed with the introduction of 
fridges such as increased electricity are more important is debated.  
 The importance of childhood infections below the age of 6 months in later 
development of CD has proved equivocal (91;92), but the impact of measles in 
particular has been debated. Measles infection has some biological plausibility, as it 
can colonise with some chronicity in the mesenteric endothelium and potentially 
cause the immunological changes seen in IBD (83), but no association has been found 
between measles in-utero and CD in a large study (93), and this discordance argues 
against causation.  
 Another more controversial factor that forms part of the hygiene hypothesis is 
whether childhood vaccination plays a role in subsequent development of IBD. 
Vaccination affects immune maturation, including that of the gut and could 
hypothetically play a role in IBD pathogenesis. One study suggested that those who 
had childhood vaccinations were 2.5 – 3 fold more likely to get UC or CD, but on 
closer scrutiny differential follow up terms were used between groups, which 
weakened the work (94), and other cohort studies did not support a pathogenic role 
for vaccinations in IBD (95),(96). A large case-control study was performed in 
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response to some public concern about the Measles, Mumps, and Rubella (MMR) 
vaccine and a link with IBD, and the results were negative (97).    
 Though antibiotics have been used to treat IBD in clinical trials and for 
perianal disease and abscesses in CD (see later), they have also been associated with 
risk of CD in some observational studies and though it has not been clarified which 
specific antibiotics are important, tetracyclines have some correlation with disease. 
Unfortunately studies were often confounded by other drugs which were co-
administered and not accounted for which may have been more relevant (71;98).  
 Breast milk is a common environmental exposure for children which contains 
amongst other constituents immunoglobulins, and lactoferrin which has some 
antibiotic effect against particularly Escherichia coli (E.coli) and Staphylococci.  
Again some papers have cited a protective role for breast milk against future 
development of IBD (99;100) whilst others state that no difference was found (101). 
 Siblings may play a role in the development of IBD, with smaller family size 
associated with a decreased risk of IBD (102) and with an older sibling having an 
increased risk of developing UC with a younger sibling having a decreased risk of CD 
(103). The siblings of an older brother or sister are in general exposed to pathogens at 
an earlier age than they otherwise would be, though its not clear why the risks are in 
different directions in UC and CD, though immune repriming and repeated exposures 
to pathogens may have different effects in the different conditions.  
 The effect of living in an urban community versus a rural upbringing causing 
an increased incidence of IBD has its proponents (104), and opponents (105). The 
observation that attending day care centres in the first six months of life has an 
increased risk of adult CD also has positive and negative results (77;106), and living 
near a hot water tap in a household with a separate bathroom also has been observed 
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to be associated with a five fold increased risk of CD (107;108). Taken together, all 
these observations suggest that there is some plausibility to the hygiene hypothesis, 
and it may play some role in the greater than 50% environmental component 
responsible for IBD causation. 
 The studies involving the examination of the effect of siblings, breast milk, 
rural life and day care are all fundamentally limited by the effects of recall bias and 
prospective  cohort studies are needed to examine these effects with more confidence. 
 
1.6.3 Stress 
 
Stress has been associated with IBD (43) and IBD has been reported to be higher in 
association with ‘white collar’ occupations, city living and higher income (109). 
‘White collar’ occupations included instrument makers, electricians, sales 
representatives and office workers and their work may involve greater stress but 
interpretation may be confounded by higher physical exercise levels and open air 
exposure in the other jobs these were compared too, such as bricklayers and road 
construction workers. Stress can arise from external (exteroceptive) or internal 
(interoceptive) sources and intuitively for most patients and clinicians, stress would 
seem to worsen IBD. Though most longitudinal studies demonstrate that stress, 
adverse life events, or depression worsen the course of IBD, there is not yet good data 
to demonstrate that relaxation and stress reduction measures improve the clinical 
course (110).  Mechanistically stress has also been associated with reactivation but 
not initiation of IBD in mouse models (111), and psychoneuroimmunological studies 
have evaluated the effects of the ‘brain gut’ axis comprising the hypothalamic, 
pituitary and adrenal tissue and the autonomic and enteric neuronal complexes, and 
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have provided a feasible biological mechanism by which psychological stress can 
affect mucosal inflammation. These include inducing low grade inflammation, 
affecting epithelial ultrastructure and consequent paracellular and transcellular 
permeabilities, increased bacterial translocation, and allowing access of the bacterial 
antigens to the lamina propria and antigen presenting cells (see later for the 
importance of these mechanisms) as well as affecting signalling by corticotrophin 
releasing factors (CRF) from mast cells and a reduction in the visceral sensitivity to 
nociceptive stimuli (110;112-114). 
 Psychotherapy has not been shown to alter IBD disease activity, even if it 
improves general psychological state, and so cannot be generally advocated for all 
chronic IBD patients, though the therapy probably works best for those who have 
psychological problems related to their IBD (115). More recent studies showed 
reduced relapse rates in those given psychological counselling, and reduced outpatient 
attendance compared to the pre-counselling year (116).  In addition CD patients who 
use ‘unfavourable’ coping strategies least have lowest rates of relapse after one year 
follow up (117). The role of stress modification strategies such as hypnotherapy and 
antidepressants  in treatment of IBD also needs further delineation, and improvement 
of support networks, be they family based or the resources of the national IBD patient 
associations is intuitively related to better quality of life, with absence of these 
associated with worse outcomes (110;118). 
 
1.6.4 Smoking  
 
Smoking both increases the risk of developing CD, and worsens the course of the 
disease, with smokers experiencing increased relapse and surgical rates (119). 
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Conversely smoking has been associated with decreased UC risk with ex-smokers 
being at increased risk of relapse (63;120). In CD smoking has been associated with 
increased steroid and immunosuppressant requirement, and increased rate of 
reoperation (68) with increased ileal and decreased colonic incidence in most studies 
(121;122). It has correspondingly been associated with increased rates of penetrating 
disease (123).  
 
1.6.5 Microbiota and surgical factors in IBD pathogenesis 
 
Infectious agents may have a key role in IBD, and have been investigated extensively, 
particularly Mycobacterium avium paratuberculosis, or MAP, (124) and E. coli (125), 
and these bacteria amongst others are discussed in some detail in chapter two.  
Prior tonsillectomy and appendicectomy (126) appear to increase risk of CD, 
but appendicectomy reduces the risk of UC.  
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1.7 Treatment of IBD  
 
 
For many years the treatment for both conditions has been corticosteroids for acute 
attacks and oral 5-aminosalicylic acid (5-ASA) compounds for maintenance, with 
immunomodulation with azathioprine or mercaptopurine added for patients with 
chronic relapsing disease. Newer biological agents such as the tumour necrosis factor 
α (TNFα) binding antibody infliximab have helped substantially  (127) Recently there 
have been meta-analyses for most therapies used in IBD (128). 
 
 
1.7.1 Anti-inflammatories - 5 ASA compounds 
 
5-ASA compounds contain a salicyclate moiety, and they improve disease course in 
both rheumatoid arthritis, where their effects were first noticed, and IBD (128). 
Sulphasalazine induces dose related reduction in male fertility and rarely blood 
dyscrasia (129). It is the mesalamine component of 5-ASA compounds that accounts 
for their efficacy in IBD and different delivery formulations exist (128;130) with 
enema preparations also showing clinical efficacy and serious side effects are rare 
(131). Meta-analysis of 11 randomised controlled trials (RCT) confirms the ability of 
5-ASA compounds to both induce remission in active UC and prevent relapse in 
quiescent UC, with an optimum dose of 2.0 to 2.4g for induction of remission and 
relapse prevention with no greater response seen for induction of remission in UC 
with higher doses than 2.4g, though trials comparing relapse prevention in UC with 
higher doses were small in number (132). A previous Cochrane Database review 
examining  the  effect of  the 5-ASA compounds  use for treating CD  was  more 
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equivocal about the efficacy of 5-ASA drugs in CD (133), and this was supported by 
more recent meta-analyses of the effect of 5-ASA compounds in inducing remission 
in CD relapse – a very modest but statistically significant clinical effect was seen 
(128;134). 5-ASA drugs were not recommended as only one trial was deemed to have 
low bias (135). In terms of preventing relapse of quiescent CD there is also poor 
evidence (136;137). 
 
1.7.2 Steroids 
 
Steroids are used in a variety of conditions including respiratory and rheumatological 
problems and the first RCT evaluating the effect of cortisone in UC with placebo was 
performed in 1954 (138). Steroids have a multitude of effects on the immune system, 
including reducing immune cell migration to a site of damage, reducing cell adhesion 
molecule expression, inhibition of neutrophil migration to an area of damage and 
decreasing pro-inflammatory cytokine production as well as inducing apoptosis of 
lymphocytes. Most of these effects are mediated by increased transcription 
subsequent to agonist binding glucocorticoid receptors in the cell nucleus (139;140). 
They have significant side effects which include an increased risk of infection (141), 
reduction in bone density with prolonged courses of treatment, and Diabetes Mellitus 
(142), though budesonide (143) and beclomethasone have significantly fewer side 
effects. The effects of steroids on macrophage function are evaluated in this thesis in 
chapter 8.     
A meta-analysis of five trials demonstrated that steroids were effective in 
inducing remission in relapses of UC (144), with a single trial demonstrating efficacy 
of intravenous  (IV) hydocortisone (145), though quality of evidence overall was low 
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as only 445 patients were included (128). Two RCT indicated that steroids could also 
induce remission in CD relapse (135;146) with standard steroids inducing remission 
in 60 % of patients compared to the 31 % observed with placebo. There was no 
evidence for IV hydrocortisone use compared with oral steroid in CD relapse, and the 
oral steroid trials involved a relatively low total of 247 patients too, but statistically 
significant effects were seen in both trials. Similarly two trials of the efficacy of 
budesonide in CD relapse showed efficacy (147;148) in a small number of patients 
(458, with terminal ileal or right sided CD), with studies comparing standard steroids 
and budesonide showing a modest superiority of standard steroids over budesonide at 
the cost of an increase in side effects attributable to the standard steroids (144). Five 
trials assessed efficacy of budesonide in prevention of relapse in quiescent CD with 
no benefit seen, though it obviously can be considered to limit side effects in steroid 
dependent disease (128). 
 
1.7.3 Immunosuppression 
 
The immunosuppressants 6-mercaptopurine (6-MP) and its precursor azathioprine are 
used as maintenance therapy in IBD. Other drugs used as immunosuppressants are 
methotrexate, cyclosporin, and tacrolimus. Following success in rheumatological 
disease, initial reports of the utility of azathioprine and 6-MP (149;150), prompted 
further clinical trials of all these immunosuppressants, though weaknesses in study 
design and analysis have prompted a recent meta-analysis to clarify their most 
appropriate use in relapse and remission in IBD (151). Each drug has separate 
mechanisms and some of the potential subtleties of these are discussed in chapter 
eight. Side effects from this group of drugs can be significant and require monitoring 
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(152;153). They include nausea, infection, allergy, bone marrow suppression, acute 
pancreatitis, hepatitis, and cancer (azathioprine and 6-MP), with methotrexate 
potentially inducing hepatitis, pneumonitis, infection, malignancy, myelosuppression, 
alopecia and stomatitis. The main concern in the use of cyclosporin and tacrolimus is 
renal toxicity, which is closely monitored, but they can also be associated with 
neurological symptoms (152).  
 Both azathioprine and 6-MP were not found to be significantly useful for 
induction of remission in UC (154;155) with methotrexate similarly ineffective (156), 
but with all three drugs assessed on minimal RCT information (128). Only one RCT 
of cyclosporin was evaluated and this involved twenty patients treated with either 
4mg/kg IV cyclosporin for seven days followed by oral therapy versus placebo in 
patients admitted with steroid refractory acute UC, and ‘response’ was significantly 
greater in the cyclosporin group, with response defined as an improvement in a non 
standard clinical response score ranging from 0 – 21, for no symptoms ranging to 
severe symptoms (157). Two other clinical trials lacked a placebo arm and were not 
included in analysis (128) (158;159). Tacrolimus was also ineffective at inducing full 
remission in patients with mild to moderate UC (160), though some response was 
seen.  
 The meta-analysis (151) of the effect of azathioprine for maintaining 
remission in UC demonstrated benefit, based on annual relapse rates of 39% and 66% 
in the azathioprine and placebo groups respectively, with 3 RCT included and 
suggesting that the best time to instigate azathioprine treatment is during remission, 
rather than during relapse, and increased relapse rates were seen in the year following 
withdrawal of azathioprine therapy (161). Trials of methotrexate also found the drug 
equally unhelpful in maintenance of remission, certainly in oral form (151;162). 
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 In CD, azathioprine, 6-MP (156), and cyclosporin (163) were all ineffective 
for the induction of remission (151), but intra-muscular (I/M) methotrexate proved to 
be effective, even if only when co-prescribed with steroids at levels > 20mg/day 
(164). Tacrolimus proved of some utility in treating fistulae (165). 
 In the analysis of immunosuppressants (151) which could prevent relapse 
azathioprine (166;167), 6-MP and methotrexate were all considered capable of 
maintenance of remission with relapse rates higher when azathioprine was withdrawn 
(151) and the beneficial steroid sparing effects of azathioprine in corticosteroid 
dependent patients were also noted (168). Finally both azathioprine, and 6-MP (169) 
were better at preventing post-operative recurrence of CD. Methotrexate had a 
significant effect at preventing relapse in CD patients (170), but cyclosporin was as 
ineffective for maintaining remission as it was for preventing relapse (128).  
 
1.7.4 Biological Therapies  
 
Anti TNF α therapies  target the dominant common inflammatory cytokine signalling 
pathway in IBD to prevent mucosal inflammation. Adalimumab (Humira®) is an anti-
TNF-alpha recombinant human IgG1 monoclonal antibody (171), whilst certolizimab 
pegol (Cimzia ®) is a pegylated TNF α blocker – a recombinant humanised antibody 
fragment against TNF α (172). Infliximab (Remicaide®) is a chimeric anti-TNF-alpha 
monoclonal antibody (173). Other treatments  exist to modulate TNF signalling such 
as etanercept and thalidomide but are not in widespread use and not discussed here. 
 Antibody therapies against integrins such as the anti α4 integrins 
(natalizumab) block the adhesion and migration of leukocytes into the gut, and as this 
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has been associated with CD pathogenesis are potential therapeutic targets (174). RCT 
have been conducted in this group of drugs and their utility is evaluated too. 
Anti TNF α antibodies had initial impressive results in rheumatoid arthritis 
(175), and subsequently were tried in IBD, and now form an important part of recent 
American and European guidelines for the treatment of CD and UC (128;176;177). A 
meta-analysis of all current data on biological therapies which examines double blind 
RCT has been performed to assess both their efficacy and safety (178). The chief risks 
from these therapies are opportunistic infection and lymphoma (142;179), with risks 
increased when these drugs are used in combination with immunosuppressives. 
Congestive heart failure, demyelinating disease, lupus like syndromes and induction 
of autoantibodies are other potential sequelae (180). 
 Infliximab (IFX) is effective at inducing remission in moderate to severely 
active UC (181;182), as well as in improvement of the condition of hospitalised 
patients with severe disease, (183;184) though the recommendation was given without 
statistically significant results in clinical response. There were insufficient data to 
comment on the utility of IFX as a maintenance therapy for UC (128), as two trials 
evaluating this only really examined prolonged induction (182).   
 The efficacy of IFX, adalumimab (ADA), and certolizimab pegol (CTZ) for 
induction of remission in CD was evaluated in patients with difficult disease at 4 -12 
weeks, producing remission in 28% of patients in the treatment arm, compared to 
19% on placebo. These differences are smaller than those seen with other treatments 
analysed above, but represent a difficult ‘refractory’ group of patients (128;185-187).    
 Anti α4 integrins are effective at inducing remission (188;189) in CD patients, 
but have the serious risk of progressive multifocal leukoencephalopathy (190;191), 
and if used are reserved for patients refractory to anti – TNF α therapy. 
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 In a meta-analysis of 1390 patients the anti – TNF α therapies were found to 
be effective at prevention of relapse in CD (192-194). Relapse occurred in 56% of 
patients on IFX, ADA or CTZ therapy and in 78% of patients on placebo treatment. 
Further benefit is likely when anti – TNF α therapy is combined with 
immunosuppressives like azathioprine, though this benefit has so far been seen with 
IFX and azathioprine together (195), but not with methotrexate. Natalizumab in one 
RCT has also been demonstrated to prevent relapse in CD, but is used as second 
choice after anti – TNF α therapy (188). 
 
1.7.5 Antibiotics  
 
Immunosuppressant and biological therapies are clearly effective, and may modulate 
the gut immune response to triggering antigens or bacteria, but altering the gut 
microbiome using probiotics is in its infancy with little efficacy seen in either UC or 
CD with their use (196;197). Antibiotic use generally targets bacteria hypothesised to 
be causative or involved in CD such as Mycobacterium paratuberculosis, Listeria, or 
Escherichia coli (87;124;198-200). Antibiotics and meta-analyses of their efficacy are 
discussed in detail in chapter two, section 2.9. 
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1.8 Implications of IBD gene-associations for interactions with the 
gut microbiota – evidence for disordered innate immunity and 
mucosal barrier function 
  
Sections 1.5 and 1.5.1 explain the familial clustering seen in IBD as well as the gene 
defects identified so far. How some of these defects might affect mucosal barrier 
function and interaction with the microbiota is explained below. 
  
1.8.1 NOD2/CARD15  
 
The NOD2/CARD15 protein is expressed intracellularly in macrophages, 
epithelial cells and Paneth cells. The CD-related NOD2 mutations all affect the 
leucine rich region (LRR) which acts as the receptor for the bacterial cell wall 
proteoglycan component muramyl dipeptide (MDP). There has been uncertainty about 
whether these are loss-of-function or gain-of-function mutations, but the consensus is 
moving towards regarding them as loss of function. 
The NOD2 mutations produce different impairments in bacterial handling 
depending on the cell type involved. Defensin levels are noted to be low in the Paneth 
cells (present at the base of small intestinal crypts and some colonic crypts, 
particularly proximally) of individuals with mutant NOD2 (47). However recent work 
has shown defensin deficiency to be independent of NOD2 status, and perhaps 
secondary to mucosal inflammation (201), so this remains controversial.
 
NOD2 
mutant macrophages have diminished IL-8 response to MDP (47) and this reduced IL-
8 response correlates with reduced neutrophil recruitment and generally defective 
acute inflammatory processing of bacteria in CD (202). 
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NOD2 -mutant mice are particularly susceptible to challenge with oral Listeria 
monocytogenes (47), have decreased β defensin secretion and increased nuclear factor 
kappa B (NFκB) pro-inflammatory signalling in response to MDP(47). It seems 
possible that a point is reached in IBD where NFκB signalling becomes pathological 
rather than homeostatic, and the NOD2 mutation could lower the threshold at which 
this point is reached. 
There is considerable cross-talk between NOD and TLR signalling with 
Myeloid differentiation factor 88 (MyD88) as an essential core intermediary (203)   
(Figure 1.2). 
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 Figure 1.2 (from (125)) NOD/TLR signalling in a mammalian host cell. Sensing 
of molecular moieties produced by invading microbial pathogens (so-called pathogen-
associated molecular patterns or PAMPs) occurs both on the cell-surface and within 
the host cytoplasm, mediated by PRRs. These include TLRs triggered by bacterial 
moieties. MyD88 is an essential core intermediary for most TLRs leading to 
activation (increased nuclear localization) of transcription factor NF B the key cell 
signalling molecule for inflammation. Of note, TLR5 is sited basolaterally and 
stimulated by bacterial flagellin. Nod-like receptors also activate NF B via 
recruitment of RIP2 kinase, triggered by peptidoglycan moieties present within Gram-
negative and Gram-positive bacteria cell wall, e.g. L-Ala- -D-Glu-meso-
diaminopimelic acid (triDAP) and MDP MurNAc-L-Ala-D-isoGln. There is possible 
cross-talk between NODs and TLR signalling pathways (203).
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1.8.2 The role of Defensins in innate immunity (204) 
 
The strong expression of the Crohn’s-associated gene NOD2/CARD15 in Paneth 
cells, the main
 
source of bactericidal defensins, has led to great interest
 
in the role of 
defective defensin production/function in CD
 
pathogenesis. Paneth cells are 
particularly plentiful in the
 
distal small intestine and the typically low number of 
bacteria
 
in the small intestine may be partly due to the high abundance
 of α-defensins 
(cryptidins). Defensins can also act as a chemoattractant
 
for cells expressing 
chemokine receptor CCR6, such as dendritic
 
cells (a specialized antigen-presenting 
cell) and help to integrate
 
host innate and adaptive immune response (204).
 
 
There is increased mucosal expression of human β-defensin 2 in UC, which may 
reflect the type of epithelial interaction
 
involved in the pathogenesis. Mucosal 
peptides extracted from
 
patients with CD, UC and healthy individuals showed 
different
 
abilities to kill bacteria, as assessed by flow cytometry.
 
There is a decreased 
anti-microbial effect in CD, when compared
 
with UC, independent of inflammation 
status or concurrent steroid
 
treatment, and notably a decreased anti-microbial effect on
 
Escherichia coli (E. coli) – a key pathogenic suspect (204). In ileal CD, there is 
reduced expression of ‘wingless-type’ (Wnt) signalling, a regulatory pathway 
directing cell–cell interactions and transcription factors. This leads to reduced Paneth 
cell differentiation and reduced defensin release and
 
might be a primary problem in 
ileal CD (204).  
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1.8.3 Defective phagocyte clearance 
 
There are marked similarities between CD and the intestinal
 
lesions found in patients 
with inherited phagocyte disorders
 
such as chronic granulomatous disease and 
glycogen storage disease
 
type 1b in humans. Further support for the defective 
phagocyte
 
hypothesis comes from the identification of autophagy gene mutations
 
in 
association with CD.
 
 
There is also good evidence that macrophages in CD tissue contain
 
bacteria. 
Immunocytochemical searches for bacterial antigens
 
in mesenteric and lymph node 
specimens from patients with CD
 
show that macrophages and giant cells contain 
Listeria spp.,
 
E. coli and Streptococcal antigens. These were present near
 
ulcers, 
fissures, abscesses and in granulomata, as well as within
 
germinal centres of 
mesenteric lymph nodes (88). E. coli DNA has
 
also been identified by laser capture 
dissection of CD tissue
 
granulomas (205), and was found in 12/15 CD granulomas 
compared
 
with 1/10 from Controls.
 
 
An adherent invasive E. coli (AIEC), LF82, isolated from a patient
 
with ileal CD, has 
been shown to be endocytosed normally by
 
macrophage endomembrane organelles 
and then to replicate within
 
mature phagolysosomes without triggering host cell lysis 
(206).
 
There is also evidence that AIEC induce macrophages to form
 
granulomata 
(207). 
Bacteria can also suppress macrophage responses. Previous work by our group has 
shown that a mannose-containing
 
glycoconjugate that is expressed by Mycobacterium 
paratuberculosis
 
as well as by Candida albicans and other yeasts (but not E.
 
coli), is 
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able to inhibit the killing of E. coli by macrophages (208).
 
This effect is dependent on 
the MyD88 regulatory pathway and
 
TLR4. A circulating anti-mannan antibody is 
commonly found
 
in CD, the anti-Saccharomyces cerevisiae antibody (ASCA). Thus,
 
the pathogenesis of CD may be contributed to by primarily impaired
 
phagocyte 
function, secondary suppression of macrophage function
 
by bacteria, or both.
 
Bacteria 
and their interaction with macrophages are discussed in more detail in chapter two 
 
1.8.4 Neutrophils 
 
The neutrophil is the ‘professional killer’ of bacteria and it has been suggested that 
defective neutrophil recruitment
 
as a consequence of reduced IL-8 expression by 
mononuclear cells,
 
e.g. as a result of NOD2/CARD15 mutation, may result in 
macrophages
 
being left to clear bacteria which they are less competent to
 
kill (209). 
Repeat mucosal biopsy, hours apart, at the same site
 
of the rectum in CD, UC and 
Control patients, resulted
 
in lower expression of IL-8 and fewer neutrophils being 
recruited
 
into the biopsy site in CD intestinal tissue (202). Neutrophil migration
 
into 
skin blisters in CD patients was also reduced (210). This reduced migration of 
neutrophils exposes further the already ‘autophagy impaired’ macrophages ability to 
clear bacteria.  
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1.8.5 Mucosal barrier 
 
The integrity of the mucosal barrier in the intestine relies upon
 
the mucus layer 
(and associated secreted proteins), the underlying
 
glycocalyx and the epithelial cell 
membranes and tight junctions.
 
The mucus layer is continuous in the colon but 
discontinuous
 
in the small intestine. The mucosal barrier has been shown to
 
be 
compromised in IBD, and in unaffected relatives of CD patients (211)
 
where it may 
precede lesion development (212). 
The mucosal barrier weakness may be genetic or acquired. Absence
 
of the 
apical efflux glycoprotein gene MDR1, and also possibly
 
abnormalities of the trans-
membrane mucin MUC3 are associated
 
with UC (59). Acquired barrier defects can 
also occur, although
 
may be at least in part secondary to inflammation. In vitro
 
studies 
have demonstrated that pro-inflammatory cytokines such
 
as interferon-gamma and 
TNF alpha, which are increased in the intestinal
 
mucosa of patients with IBD as a 
result of bacterial NOD/TLR
 
stimulation or through hypersensitivity, can induce 
mucosal
 
permeability, mediated by internalization of junctional proteins (212).
  
The activation of NF kappa B in epithelial cells is an early event
 
in IBD that 
can be found in the surface epithelium of unaffected
 
identical twins of IBD patients, 
even in the absence of histological
 
inflammation. This seems likely to be a 
consequence of bacterial–epithelial interaction and may again reflect a barrier defect 
(213). Weakness
 
of the mucosal barrier allowing flagellin to pass through tight
 
epithelial junctions and thus have access to basolateral TLR5
 
with subsequent 
triggering of IL-8 release has been described
 
in mouse models (214), and represents a 
plausible model for UC,
 
perhaps with inflammation perpetuated by autoimmunity 
(215).  
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The above defects in innate immunity and mucosa barrier all support the hypothesis 
that CD results from an altered response to the gut microbiota which is now 
discussed. 
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CHAPTER TWO : THE ROLE OF THE INTESTINAL 
MICROBIOTA IN THE PATHOGENESIS OF 
INFLAMMATORY BOWEL DISEASE 
 
 
 
2.1 Diversity in the Gastrointestinal tract  
  
 
The human gastrointestinal tract is colonised by 500-1000 bacterial species 
with 80% of these yet to be cultured (216). In the average individual metagenomic 
sequencing studies have demonstrated that at least 160 species are harboured, and 
largely shared (217). The bacterial population increases distally along the small bowel 
with gram negative aerobes and some obligate anaerobes present, whilst the colon is 
heavily populated with anaerobes, approximately 10
14 
per gram of luminal content 
(47).The use of culture-independent techniques such as real time polymerase chain 
reaction (PCR) (218), FISH (127;219), ribosomal intergenic spacer analysis 
(RISA)(220;221) and 16S ribosomal DNA (rDNA) (218;221) sequencing can allow 
analysis of microbes involved in CD by their expressed genes and demonstrate their 
cellular location. It can provide additional insight into the microbiota changes in CD, 
particularly when a combination of techniques is used (218). 
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2.1.1 Loss of diversity in IBD 
 
 Automated ribosomal intergenic spacer analysis (ARISA), terminal restriction 
fragment length polymorphisms (T-RFLP) and denaturing gradient gel electrophoresis 
(DGGE) have shown reduced diversity in both faeces and mucosa-associated  
microbiota in IBD (222;223).  In one study, species richness increased from control to 
non inflamed UC and CD tissue but then declined in more inflamed tissue (223).
 
Firmicutes and Bacteroidetes diversity are particularly affected, though ARISA 
demonstrated an increase in diversity of less well characterised Firmicutes. 
 
2.2 Alterations in the faecal microbiota in IBD 
 
 There is clear evidence that up to 50% of relapses of UC and CD may be 
triggered by infection with conventional pathogens such as Salmonella spp and 
Campylobacter spp (47;224;225) or related to foreign travel. Generally though, the 
faecal microbiota in IBD lack any obvious conventional pathogens. The faecal 
microbiota do not reflect the mucosa-associated bacteria, which may be of much 
greater significance in IBD. FISH probes can be used to identify 11 bacterial groups 
in healthy patients and those with IBD and demonstrate distinct differences between 
faecal samples (219). Depletion of Faecalibacterium prausnitzii (F. prau) bacteria in 
CD, and conversely normal F. prau. in UC enabled recognition of active UC or CD 
with good sensitivity and specificity. More recent twin studies which examined 
biopsies from multiple sections of the intestinal tract within an individual from ileum 
to rectum, showed that F. prau. was consistently present (for colonic CD or healthy 
controls), or consistently absent throughout (for ileal CD) (226). In other work there 
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was also no association found between depletion of F. prau. and isolated colonic CD, 
though this was seen in ileal CD (227). In animal models there is a probiotic effect 
demonstrated by the supernatant of F. prau. (228) and also a negative association 
between F. prau. and recurrence of ileal CD after surgery (228;229). Differences in 
bacteria numbers and species in the colonic bacteria in the mucus layer have also been 
noted (219).
 
Other changes in IBD faecal microbiota included depletion of 
Clostridium coccoides in UC and Clostridium leptum in CD (47).  
Bacteroides fragilis has been shown to account for 60% of the biofilm 
(mucosa associated bacteria within the mucus layer) mass of IBD patients and 
Eubacterium rectale- C. coccoides  in 15% of the same biofilm (47). Culture-
independent analysis of ileal mucosa has also demonstrated relative depletion of 
Clostridiales but an increase in invasive E. coli in ileal CD (218). Listeria and 
streptococcal  antigens have also been found in CD tissue (88) , but further attempts 
to identify Listeria by PCR have been negative (47). 
Emerging evidence also suggests that genetics and/or environmental exposure 
during childhood, in part, may determine the gut microbial composition. Using T-
RFLP molecular fingerprinting, (230) recently demonstrated not only that that the 
faecal microbiota was more similar between healthy identical twins than between 
twins with CD, but that there were significant differences between identical twins 
concordant and discordant for CD.  
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2.3 Growing evidence for a pathogenic role of E. coli in CD 
 
The colon, unlike the small intestine, has a near continuous mucus coat, and 
the bacteria adherent to this may differ in type (eg anaerobic) and number to those 
under the mucus -a microaerophilic niche (231). Aerobic culture of colonoscopic 
biopsies after removal of mucus is often sterile in control colons, but in CD contains 
increased bacterial numbers. More than half of these are E. coli (232), even though 
they represent less than 1% of the faecal microbiota. A similar result has also been 
seen in ileal mucosa in CD (233). Adherent and invasive E. coli (AIEC) have been 
found in 21.7% of CD cases versus 6.2% in controls. At least eight groups have 
identified independently an increase in mucosa-associated E. coli in CD (215), and 
culture-independent molecular techniques have confirmed this (218;220). Two of 
these studies also demonstrated increased numbers of E coli in UC. 
 
E. coli DNA has also been identified by laser dissection of CD tissue 
granulomas (205), and was found in 12/15 CD granulomas compared with 1/10 from 
‘controls’. RISA has been used to identify DNA segments more commonly present in 
CD and UC mucosal biopsies than controls (220). Five segments specific for CD 
mucosa have been sequenced and all found to contain E. coli DNA. Poor correlation 
was noted between site of inflammation and E. coli, compatible with E. coli being a 
causative organism rather than simply colonising inflamed mucosa. The E. coli 
isolates identified by RISA were more likely to be from phylogenetic groups B2 and 
D (220), characteristically more likely to be pathogenic at extraintestinal sites and 
adherent to intestinal cells. Group B2 E. coli have virulence factors conferring strong 
colonising capacity (234), and this provides an explanation for their increased 
prevalence in CD mucosa and also for the tendency for abscess and fistula formation 
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in CD. E. coli isolated from ileal biopsies in patients with CD have been shown to be 
adherent and invasive in epithelial cell lines, and able to survive and replicate within 
macrophages (206) without causing cell death but inducing secretion of the 
proinflammatory cytokine tissue necrosis factorα (TNFα). A broad spectrum of faecal 
microbiota lacking these virulence factors may invade after a mucosal breach. 
 
2.3.1 Genetic basis for the A, B, and D phylogenetic classification of E. coli 
 
Phylogenetic analysis has shown that E. coli has four main groups, A, B1, B2 and D.  
These groups can be classified by multilocus enzyme electrophoresis or by ribotyping, 
but it is more expedient to perform a triplex PCR using the genes chuA (haem 
transport), yjaA (unknown function from K-12 bacteria), and an anonymous DNA 
fragment TSPE4.C2 (235) which gives excellent correlation with standard methods. 
Previous work has shown that phylogenetic groups B2 and to a lesser extent D contain 
virulent extra-intestinal strains (236-238). 
 
2.3.2 E coli virulence factors 
 
CD E. coli do not possess any known invasive determinants seen in other 
groups of E. coli but interact with epithelial cells via type 1 pili, flagellae, outer 
membrane vesicles, and outer membrane protein C (239). Mucinases are also 
produced by CD E. coli which more commonly possess serine protease 
autotransporters (SPATES)(220), perhaps explaining why they have been found 
within and beneath the mucus layer. Bacteria in the B2 phylogenetic group 
characteristic of CD patients (220) have enhanced persistence in the colon which is 
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dependent on P fimbriae (facilitating adherence) and aerobactin, an iron trapping 
compound (234). Group B2 seem to have accumulated virulence factor genes and it 
can be speculated that improved hygiene has possibly reduced expression of other E. 
coli groups in the West (234). 
Type 1 pili of E. coli mediate bacterial adherence to ileal epithelia, and mannose has 
been shown to diminish this adherence (240).
 
The Carcino-embryonic antigen-
associated  cell-adhesion molecule (CEACAM ) 5 (otherwise known as CEA) and 
CEACAM 6 glycoproteins have been shown to be overexpressed in ileal epithelial 
cells in CD and E. coli adherence is prevented in vitro by blockade of CEACAM 6 
(240). E. coli induces expression of CEACAM 6 on cultured intestinal cells directly, 
and also indirectly by induction of macrophages to secrete TNFα which increases 
CEACAM 6 levels (240).  
Receptor binding events can also now be analysed at the level of a single 
bacterial species via flow cytometry. CEACAM receptors can be solubilised as probes 
to identify CEACAM binding of single bacteria, which can be decorated with 
fluorescent markers. This advance may be used to explore host-bacterial interactions 
in future experiments (241). 
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2.4 M cells as portals of entry 
 
M cell
dendritic cell
lymphocyte
enterocyte
E. coli
mucus*
macrophage
‘fuzzy’ glycocalyx
(with associated CEACAMs)
Intra-macrophage 
replication of E. coli
 
Figure 2.1 M cell interactions in CD NB – not to scale: the mucus layer >100 µm, is 
considerably thicker than the glycocalyx at <1 µm. (figure from reference (125) 
  
An illustration of how adherent and invasive E. coli may gain access to the mucosa 
via M (microfold) cells in CD mucosa is shown in figure 2.1. It seems likely that 
AIEC found in CD, although lacking conventional pathogenicity genes, will also have 
to enter via specialized M cells within the FAE overlying Peyer's patches and isolated 
lymphoid follicles, and not through ordinary surface epithelial cells. M cells account 
for approximately 5% of the epithelial cells in the dome epithelium that 
overlies Peyer’s patches and lymphoid follicles. They arise as a result of 
differentiation from surface epithelial cells stimulated by as yet unknown factors 
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released by the underlying B lymphocytes. Antigen sampling by these M cells is 
thought to be an early step in the development of mucosal immunity. The lack of 
mucus and the ‘fuzzy’ glycocalyx (which has the associated CEACAMs) facilitates 
contact between bacteria and the M cell-surface, followed by microbial antigen 
presentation to lymphoid or antigen-processing cells in the sub-epithelial tissue. AIEC 
are shown replicating within macrophage vacuoles (242). Bacteria are also 
translocated from the lumen by dendritic cell processes extending between epithelial 
cells (243).  
 
2.5 Diarrhoeagenic E. coli epithelial interactions 
 
As well as the AIEC seen in CD there are a number of different pathotypes of E. coli 
whose pathogenicity and method of epithelial interaction varies according to their 
virulence factors including  EPEC (entero-pathogenic E. coli), and ETEC (entero- 
toxigenic E. coli). These bacteria interact with gastro-intestinal epithelia to colonise 
and invade tissue and cause pathology in diverse ways and to different degrees. 
Diarrhoeal illness is a common cause of illness and death worldwide, particularly in 
developing countries (244), and though worldwide incidence is falling, infantile 
diarrhoea cases are rising. (245) The various pathotypes of E. coli mean that different 
subtypes can induce diarrhoea without conferring group protection against other 
diarrhoeagenic E. coli pathotypes (DEP). In studies that have looked at a broad range 
of aetiological organisms causing diarrhoea, E. coli are pre-dominant. In some series 
E. coli was detected in 20% of cases where a bacterial cause was suspected (244;246).   
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 Research has shown five types of DEP unequivocally associated with 
diarrhoea, distinguishable from non pathogens by virulence genes. There are global 
variations in monitoring and epidemiology of the pathotypes but they represent a high 
disease burden, particularly in areas like sub-Saharan Africa. (244;247). Experiments 
in vitro with diarrhoeagenic E. coli are discussed in chapter nine. 
  
2.5.1 EPEC types and mode of epithelial interaction 
 
Bray identified an EPEC, 0111, in the 1940’s as a probable cause of infantile 
diarrhoea (Bacterium coli var neapolitanum) (244) and E. coli have been recognised 
as DEPs since then and the role of EPEC in infantile diarrhoea was verified by 
volunteer experiments (248). 
EPEC can be divided into ‘typical’ and ‘atypical’ types. They are distinguished from 
entero-haemorrhagic  E. coli (EHEC) by absence of the phage borne shiga toxins 
(244). Typical EPEC strains carry genes for the LEE (locus for enterocyte 
effacement) on a chromosomal pathogenicity island and virulence plasmids bearing 
genes encoding bfp (bundle-forming pili) and  EAF (EPEC-adherence factor) whilst 
atypical EPEC do not have the EAF-plasmid or EAF-associated virulence plasmid.  
(244;249). The LEE factors give the EPEC its unique interaction with epithelial tissue 
as shown in figs 2.2 and 2.3. and allows serotype independent identification of EPEC 
(250).  EPEC initially adheres to host epithelial cells utilising its bfp virulence factors, 
which co-ordinate bacterial aggregation (249). Subsequently, EPEC secretes several 
virulence factors by an LEE encoded type III-secretion system used also by other 
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organisms. The type III secretion system delivers proteins which promote diarrhoeal 
illness (251) but the bacterium adheres tightly to the host by secreting its Tir 
(translocated intimin receptor) receptor into the intestinal cell, and binding to this with 
its outer membrane ligand, intimin, another LEE factor,  which can also bind ß1-
integrins and invoke cytoskeletal re-arrangement. Actin, -actinin, talin, and ezrin 
proteins are recruited to the site of EPEC attachment following Tir-intimin binding, 
resulting in a unique pedestal-like structure where the pathogen resides, and this 
binding also causes microvillous effacement. This re-organisation is called an 
adherent-effacement lesion (A/E, see figure 2.2)(249;252). When the Tir is intimin 
bound it is tyrosine phosphorylated initiating signal transduction involving activation 
of phospholipase C (PLC), protein kinase C (PKC), inositol triphosphate (IP3) flow, 
and intracellular Ca
2+
 release ultimately producing the cytoskeletal re-arrangement 
seen (figure 2.3)(253).  
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Figure 2.2 Transmission electron micrograph of an A/E lesion formed by EPEC 
infection of intestinal epithelial cells. From (252), Trabulsi et al. mv = microvillous 
effacement. Star demonstrates pedestal formation.  
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Figure 2.3 Signal transduction following EPEC Tir –intimin binding, from (249). 
 
2.5.2 ETEC toxins and interaction with intestinal epithelium 
 
ETEC are amongst the most common causes of travellers diarrhoea (244;254), and 
also a common cause of infantile diarrhoea, spread by contaminated food and water 
sources (255). Following adhesion to intestinal mucosa by fimbriae, they utilise a heat 
labile (LT) and heat stable (ST) toxin which causes diarrhoea. LT toxin is very similar 
to the cholera toxin which ADP-ribosylates G proteins (256), and antibodies against 
the cholera toxin can provide some treatment for travellers diarrhoea caused by 
ETEC. The ST toxin has no homology to cholera toxin (257). Disease is caused by 
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toxins rather than mucosal invasion, though inhibition of bacterial proximity to the 
intestinal mucosa intuitively seems likely to lessen damage.  
 
 
Fig from – “Virulence factors of enterotoxigenic E. coli" from Epidemiology of 
Infectious Diseases. Available at: http://ocw.jhsph.edu. Copyright © Johns 
Hopkins Bloomberg School of Public Health. Creative Commons BY-NC-SA.  
Figure 2.4 Virulence Factors for ETEC.  
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2.6 Characteristics of AIEC 
 
The AIEC thought to be potentially causative in CD have the general colonisation 
factors, type 1 pili and mucinases described in section 2.4, but may also have 
increased numbers of specific virulence factors which determine their tropism. One  
such factor has been identified - long polar fimbriae (lpf) (258), which may facilitate 
the translocation of AIEC across m-cells overlying Peyer’s patches and lymphoid 
follicles, of key interest as the earliest lesions CD often occur at the ileum. The stress 
‘high temperature requirement’ protein (HtrA) (259), and the disulphide bond forming 
(DsbA) protein (260), which facilitates cytoskeletal change have been demonstrated 
to be important for the replication of one strain of AIEC within macrophages (strain 
LF-82), which follows translocation. In contrast some genes may be present in much 
smaller numbers in CD E.coli in comparison to control E. coli, such as the iron uptake 
chelate (iucD) gene, which is involved in the synthesis of the iron siderophore 
aerobactin. It is also possible that the differences between the virulence genes utilised 
by AIEC and ‘standard’ E. coli are small, and some studies have not identified a 
significant difference in virulence factors between AIEC and control E. coli. The 
bacterial genes encoding virulence in AIEC bacteria warrants further evaluation as 
they may provide utilisable therapeutic targets (261). 
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2.7 Mycobacterium avium subspecies paratuberculosis (MAP) 
 
MAP has been a putative causative organism for CD for almost a hundred 
years and is a continuing source of controversy (262). Johne’s disease in cattle, 
caused by Mycobacterium paratuberculosis and CD have similarities. Reported 
detection rates for paratuberculosis DNA in CD tissue range between 0 and 100% 
(47). Meta-analysis of published studies shows a pooled risk difference (‘risk’ of 
presence of MAP in control patients subtracted from ‘risk’ of presence of MAP in CD 
patients) of 0.23 (95% CI 0.14 – 0.32) (263). Laser dissection of CD tissue has 
identified MAP DNA within granulomas but not within distant non-granulomatous 
tissue which might explain some of the discrepancies (205).
 
MAP has been shown to 
release mannose-containing glycoconjugates that inhibit bacterial killing by 
macrophages in vitro (208) and an indirect role for MAP in CD pathogenesis is 
plausible. 
The link between MAP and IBD, assessed by presence of  IS 900 (a MAP 
DNA insertion element) in Crohn’s and control tissue PCR, and enzyme-linked 
immunosorbent assay (ELISA) of serum immunoglobulin reaction to MAP, have also 
been examined in another recent meta-analysis. This produced a pooled odds ratio of 
7.01 (95% CI 3.95-12.4) for PCR, and 1.72 (95% CI 1.02-2.90) for ELISA when 
comparing CD and controls (124), but proof of a causal role needs further work. A 
recent controlled trial of anti-MAP therapy in CD has been disappointingly negative 
(264). Moreover anti-TNF therapy can cause reactivation of Mycobacterium 
tuberculosis and its efficacy in CD is surprising if MAP is a significant pathogen.  
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2.8 The mechanism of interaction of AIEC with macrophages  
 
Macrophage function and response to commensal bacteria, particularly adherent 
invasive E. coli AIEC, may be pivotal in CD. Genome wide associations with CD 
include macrophage defects and are discussed in section 1.5.1, and the associations of 
E.coli with macrophage tissue in CD in section 1.8.3. The internalisation of bacteria 
into macrophages, and the enzymatic processes and autophagy machinery required to 
eliminate bacteria are key patho-physiological events, which may be orchestrated by 
signalling molecules. These molecules may represent novel therapeutic targets (265). 
Cell signalling events following internalisation of E.coli and their sequelae (206) 
result in the inflammation, structuring and  ulceration seen in CD tissue. Defects in 
the autophagy process within macrophages may be responsible for the pathology of 
CD, and in-vitro work has demonstrated that there is enhanced E.coli replication 
within the autophagolysosomes of cells which are deficient in the autophagy proteins 
IRGM and ATG16L1 (266).  
 One of the histological features of CD is the presence of a coalescence of 
macrophages or granulomata. Whilst the granuloma is not pathognomonic of CD, its 
presence within tissue is supportive of the diagnosis, and in one series granulomata 
were seen as frequently as 1/4 biopsies from CD tissue, with tight well defined 
appearance discriminating these from the granulomata seen in tuberculosis (267). The 
prevalence of these lesions microscopically is supportive evidence for their 
importance in CD. Macrophages utilise a number of mechanisms for killing bacteria 
including production of reactive oxygen species (259) and encapsulation of these 
bacteria within phago-lysosomal intra-cellular pockets (208;242;265) and the putative 
pathogenic AIEC in CD adopt a number of strategies to avoid this. The alkalinisation 
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of these subcellular phagolysosomal organelles is also known to enhance bacterial 
killing (268). The ability of bacteria, particularly E coli, to survive and replicate 
within these macrophages (206;242) may be what governs their pathogenicity.     
  
2.9 Antibiotics in IBD  
 
If CD results from inadequate clearance of mucosal bacteria then use of antibiotics 
would be predicted to have beneficial effects. The gut microbiome can be altered by 
antibiotics and these have been evaluated in a number of clinical trials (269). 
Choice and combination of antibiotics is key and should target the suspected 
bacterial pathogens in CD. Many studies are not blinded or placebo controlled and can 
involve other treatments making comparisons difficult. Rifabutin, clarithromycin and 
clofazimine (targeting M. paratuberculosis) have shown improvement over placebo at 
16 weeks, but this was not sustained (47). A meta-analysis of broad spectrum 
antibiotics, involving six randomised and blinded trials, in patients with active CD 
(270) demonstrated an advantage for antimicrobial therapy, particularly when 
ciprofloxacin was used, and recent meta-analysis studies looking at pooled outcomes 
for antibiotic therapy showed statistical significance, even if antibiotics were not 
advocated based on an inability to clearly specify which antibiotics were of most use 
(269). 
 The more recent meta-analysis of antibiotic trials in IBD divided the analysis 
into sections assessing their usefulness in CD and UC separately, as well as their use 
for both maintenance of remission as well as induction of remission. Analysis of 9 
pooled RCT showed that the use of antibiotics had statistical significance for the 
induction of remission in UC, though it was not clear which antibiotics were most 
 59 
important. Single antibiotics or combinations of ciprofloxacin, tobramycin, rifaximin, 
and vancomycin were used with pooled data showing significance (269;271-275). 
There is a real paucity of data evaluating antibiotic use in maintenance therapy for UC 
with one trial showing no effect (276). 
  Trials comparing the effect of antibiotics for the induction of remission in CD 
following relapse found a statistically significant effect for antibiotic therapy in 
induction of remission in CD. This was for the pooled analysis of 1160 patients, 
though again it was not clear which specific antibiotics were beneficial as a diverse 
number of antibiotics were used alone or in combination (264;269;277-282). 
Similarly there was some benefit in improvement of fistula drainage with use of 
ciprofloxacin or metronidazole (283). Similar improvements were seen in 
maintenance treatment of CD with antibiotics, in general targeting Mycobacteria 
(264;269;277), and it may well be that the selection of antibiotics targeting 
pathologically relevant micro-organisms in IBD, coupled with a favourable side effect 
and resistance profile for the antibiotics, may be a more useful clinical approach. 
 
The susceptibility of CD E. coli within macrophages to antibiotics has been 
evaluated in vitro (242). Ciprofloxacin, rifampicin, tetracycline, sulfamethoxazole, 
clarithromycin, and trimethoprim were all associated with kill rates greater than 50% 
at Cmax, the published peak serum concentration of antibiotic achievable in patients 
taking a conventional dosing regimen. A combination of ciprofloxacin, tetracycline, 
and trimethoprim resulted in a 97% kill rate versus 86% for ciprofloxacin alone when 
assessed at 10% Cmax. Further studies are required, with appropriately targeted 
antibiotic therapy, particularly in combination. 
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2.10 The use of immunomodulators in clinical practice and their 
possible effects on macrophages and bacteria in vitro 
 
It follows that if replication of E. coli within macrophages is central to disease 
activity then inhibition of this replication should result in clinical improvement. Drugs 
which are classically considered to be immunomodulators, such as azathioprine and 6-
mercaptopurine (6-MP), the metabolic intermediate of azathioprine (see figure 2.5), 
are often used as a therapy to maintain clinical remission in CD and UC, with steroids 
such as hydrocortisone and prednisolone commonly used to induce remission (284). 
 
2.10.1 Azathioprine, 6-MP and 6-thioguanine (6-TG) 
  
 
 
 The effects of azathioprine, 6-MP, and 6-TG, on replication of CD specific E. 
coli strains within macrophages are unknown. Effects of these drugs on the replication 
of other bacteria has been seen, with Azathioprine and 6-MP known to inhibit MAP 
replication, with some synergism seen with macrolide antibiotics (285;286). The 
different effects of azathioprine and 6-MP on the activity of the Nitric Oxide 
Synthetase (NOS) enzyme using in vitro macrophages has been previously examined 
(287) but effects on E. coli replication have remained unexplored. Similarly the 
effects of the main end metabolite of azathioprine, 6-TG, have not been evaluated in 
terms of its effects on modulation of E.coli replication within macrophage function, 
though it is known to have a direct bactericidal effect on E. coli. as well as other 
bacteria when used in nanoparticle treatments (288).  It is also known that the 
intercalation of 6-TG into macrophage cell DNA makes the cells more sensitive to 
reactive oxygen species (ROS) produced endogenously or in cocultures, so this 
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metabolite’s effects on intra-macrophage E.coli replication were also investigated in 
this work (chapter eight).  
 
 
 
Figure 2.5  Illustration of the Metabolism of thiopurines. 
 
 
Metabolism of thiopurines. The pro-drug azathioprine (AZA) is converted rapidly to 
6-mercaptopurine (6-MP), which is metabolised via three competing pathways, 
mediated by xanthine oxidase (XO), thiopurine S-methyltransferase (TPMT), and 
hypoxanthine guanine phosphoribosyl transferase (HPRT). The reaction mediated by 
XO produces the inactive metabolite 6-thiouric acid (6-TU). TPMT catalyses the 
production of an inactive metabolite (6-methymercaptopurine, 6-MMP). The HPRT 
reaction generates 6-thioinosine monophosphate (6-TIMP). 6-TIMP may itself be 
transformed into thioguanine nucleotides (6-TGN) by the rate limiting enzymes 
inosine-5-monophosphate dehydrogenase (IMPDH) and guanine monophosphate 
synthetase (GMPS), methylated into 6-methylmercaptopurine ribonucleotides (6-
MMPR) by TPMT or phosphorylated to become 6-thio-inosine triphosphate (6-thio-
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ITP). 6-MMPR, 6-TGNs, and 6-thio-ITP are all active metabolites. The accumulation 
of 6-thio-ITP to toxic levels is prevented by inosine triphosphatase (ITPase), which 
converts 6-thio-ITP back to 6-TIMP. AZA can act as an immunosuppressant via the 
random incorporation of 2'-deoxy-6-TGTP into DNA and RNA. Modified from (289). 
 
2.10.2 The effects of steroids on macrophage function  
 
Steroid therapy in CD and UC is frequently used in relapse to control symptoms, but 
does not affect the overall natural history of these diseases, and in fact their use can be 
associated with adverse prognosis over a patient’s lifetime (14;20). The effects of 
dexamethasone on macrophages have been previously investigated, and it has been 
shown to have a suppressive effect on both phagocytosis via inhibition of the 
phospholipase-A2 enzyme (290;291) and the level of activity of inducible nitric oxide 
synthetase (iNOS) (292), both of which would seem to inhibit intra-macrophage 
bacterial killing. However, work with human monocyte-macrophages has 
demonstrated a phagocytosis stimulating effect with dexamethasone (293), which 
needs clarification. Hydrocortisone has previously been shown to inhibit monocyte 
recruitment from peripheral blood, and peritoneal macrophage numbers in mice (294), 
but the drug’s effects on E. coli replication within macrophages have not been 
explored.  The effect of this steroid at a clinically relevant concentration was also 
investigated in this work in chapter eight.  
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2.11 Prebiotics, probiotics and soluble fibre 
 
Prebiotics are ‘food ingredients fermented by intestinal bacteria that 
selectively promote changes in the gut ecosystem’ (295). Inulin and oligofructose 
stimulate saccharolysis in the colon and enhance growth of lactobacilli and 
bifidobacteria. This effect has been associated with reduced mucosal inflammation in 
several animal models of IBD (295). Preliminary clinical trials have evaluated inulin 
in pouchitis (a condition in which the ileal pouch becomes inflamed after colectomy 
and reconstructive ileal pouch-anal anastomosis for UC) and oligofructose in UC and 
CD, generally involving patients with mild to moderate disease, and inulin improved 
endoscopic and histological appearance in pouchitis (295). The other trials suffered 
from low numbers or absence of a control arm (in the CD study) and were 
inconclusive. A recent adequately powered randomised double-blind RCT examining 
the effect of fructo-oligosaccharides on active CD was negative (296), but further 
studies examining other prebiotics, or combinations of prebiotics are required. 
Probiotics have been assessed in animal models and some clinical trials (297). 
However, there are few large randomised double blind clinical trials. The probiotic 
VSL#3 reduced pouchitis relapse rate by 85% in one study and there is some 
suggestion that it can have an effect in maintaining UC in remission. Some strains of 
E.coli may have a beneficial effect on intestinal health, and are utilised 
therapeutically. E. coli nissle 1917 has been shown to promote synthesis of inducible 
human beta-defensins in cell lines (298) and has a maintenance effect in UC 
(299;300). 
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 It may be that probiotics and  prebiotics can be used as co-therapies 
(synbiotics) in genetically bacteriologically susceptible patients if further evidence 
accumulates.  
Currently there are more studies showing beneficial effects of probiotics in 
prevention of inflammation rather than treatment of inflammation. Apical TLR9 
stimulation of intestinal epithelial cells delivers negative signals that attenuate pro-
inflammatory signalling induced by basolateral epithelial cell stimulation by TLRs 
(301) and ‘hyper-polarise’ the epithelial cell. Probiotics could work in this way. 
Basolateral TLR5 and TLR9 activation induce IL-8 and NFκB release respectively, 
and inflammatory models demonstrate that antigens may access basolateral sites 
(214;302), which may occur particularly when pro-inflammatory cytokines are 
present in the mucosa,  and junctional protein internalised (212). It may be that the 
contrasting effects of basolateral versus luminal stimulation of TLR9, and the 
potential for flagellin released from probiotics to access basolateral TLR 5 in inflamed 
mucosa might explain the differences seen with probiotic treatment used 
prophylactically versus post-inflammatory.  
 
Our group has been investigating the hypothesis that bacteria-epithelial 
interactions, many of which may be lectin-carbohydrate receptor-mediated, might be 
inhibited by soluble plant fibres. A number of  fibres, including particularly soluble 
plantain (banana) fibre, have been shown to inhibit adhesion of E. coli to the intestinal 
mucosa (232).
 
This has obvious potential therapeutic benefit in arresting the events 
that induce mucosal inflammation in CD. In areas of the world where plantain fibre is 
consumed in large amounts, (Africa, India and the West Indies), the prevalence of CD 
is rare. It is possible that other foodstuffs or fibres could inhibit or promote (western 
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diet) bacterial adherence, and this merits further evaluation. The interaction of 
fluorescently labelled bacteria with intestinal cells has been investigated by the FACS 
technique (303) and affords the possibility of testing novel therapeutic foodstuff 
interactions with bacteria and epithelial cells with this modality in vitro (see chapter 
nine).  
Figures 2.6 and 2.7 below show a current view of the possible pathogenesis of 
CD and UC respectively, with potential therapeutic targets identified in figure 2.6. 
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Figure 2.6 Gene–environment interactions in CD: defining new therapeutic 
targets. Defective phagocyte dysfunction could result from CD-associated genetic 
mutation, environmental factors and Mycobacterium paratuberculosis (MAP) wall 
components. Ingested microbiota, such as AIEC, may be presented to macrophages by 
M cells of the FAE overlying Peyer's patches of the small intestine and lymphoid 
follicles of the colon. The typical early lesions in CD arising at the FAE could result 
from inadequate clearance of ingested gut microbiota by dysfunctional intestinal 
macrophages. Each white arrow represents a possible target for therapy. Most current 
treatments target the final step in the pathway.  From (215) 
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Figure 2.7 A model for bacterial involvement in UC. Current evidence is 
compatible with UC being an autoimmune condition, perhaps triggered by an 
inflammatory response to mucosa-associated gut microbiota. Shed flagellin, that 
elicits epithelial pro-inflammatory IL-8 release, may gain access to the basolaterally 
located TLR5 by a pre-existing barrier defect in patients with UC. This inflammatory 
response could then be perpetuated by autoimmunity. A distinct subset of pANCAs, 
that cross-react with bacterial antigens and are present in about two-thirds of UC 
cases, could have a direct role in pathogenesis (47). From (215) 
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CHAPTER THREE : HYPOTHESES 
 
 
     1a) Mucosa-associated E. coli may have a role in the pathogenesis of CD. 
 
     1b) Mucosa-associated E. coli are therefore likely to be increased in association        
 with mucosal ulceration in CD. 
 
2) The quantified levels of E. coli in Crohn’s tissue may correlate directly with 
levels of mucosal inflammation seen macroscopically or microscopically, or 
even with clinical scores of disease activity. 
 
3) The aphthous ulcers of CD patients, which are likely to represent the earliest 
lesions, may be populated by bacteria (possibly E. coli) that have an important 
role in pathogenesis.   
  
4) Drugs may have efficacy in CD if they can kill E. coli within macrophages. 
These may include antibiotic combinations but also may include some of the 
drugs that are commonly used in CD maintenance therapy including 
immunosuppressives.  
 
5) The adherence of E. coli and other diarrhoea-causing bacteria to intestinal 
cells may be modified by dietary components, including soluble non starch 
polysaccharides (NSP) such as those present in plantains (Musa [banana] spp.) 
as well as oat NSP and apple pectin. 
 69 
CHAPTER FOUR : AIMS 
 
 
1) To develop culture-independent molecular methods of quantifying bacteria 
from biopsy tissue so that these can be (a) correlated with the clinical and 
histological status of a patient with CD (b) used to assess response to therapy 
with soluble fibre supplements. 
 
2) To assess the quantity of E. coli and other bacteria within aphthous ulcers of 
CD patients.   
 
 
3) To evaluate the effect of antibiotics and immunomodulators used at clinically 
relevant concentrations on in vitro replication of CD E. coli within 
macrophages.  
 
4) To assess, using several in vitro modalities, whether dietary soluble fibre 
(Non-starch polysaccharide, NSP) and other dietary components affect the         
adherence of  diarrhoea-causing bacteria and E. coli to intestinal cell lines. 
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CHAPTER FIVE : GENERAL MATERIALS AND 
METHODS  
 
 
5.1 Mammalian Cell culture   
 
5.1.1 Caco2 cells 
 
To study bacteria-host intestinal epithelium adherence and invasion, the human 
colorectal adenocarcinoma cell-line Caco2 (#86010202) was obtained from the 
European Collection of Animal Cell Culture (Public Health Laboratory Service, 
Wiltshire, UK). Caco2 cells were grown and maintained in supplemented Dulbecco’s 
modified Eagle’s medium (DMEM), see appendix six 
 Caco2 cells were used when they were at a maximum of  80% confluent, and 
were passaged at a ratio of one in four twice weekly, using either a 10% (v/v) solution 
of  (0.5 mg/ml) trypsin in sterile phosphate-buffered saline (PBS). For experiments 
(see chapter nine), Caco2 cells were initially seeded into 24-well tissue culture plates 
(Corning/Costar, High Wycombe, UK) at 1x10
5 
cells per well and grown overnight in 
Dulbecco’s modified Eagle medium (without antibiotics). The monolayers were then 
washed twice with sterile PBS before the addition of bacteria (see chapter nine). 
 For FACS experiments Caco2 cells were maintained until 80% confluent in 
flasks. 24 h before adherence assays, DMEM medium was removed, cells were 
washed three times in cold PBS, and cells were incubated with antibiotic-free 
medium. Cells were then washed three times again with PBS and removed from 
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tissue-culture flasks with a trypsin-PBS dilution (10% v/v), counted using a 
haemocytometer and adjusted to 1x10
5 
cells/ml using antibiotic free DMEM (see 
chapter nine). The non-starch polysaccharides (NSP) used in adherence and FACS 
experiments in chapter nine with Caco2 cells, were extracted from plantain, the 
banana family (Musa spp.) and oats. These were provided as water soluble freeze 
dried powders by Provexis Plc (Windsor). Apple pectin used in the adherence 
experiments was supplied as a viscous solution by Sigma-Aldrich (Dorset, UK). 
FACS measurements were performed using a FACScan flow cytometer (Becton 
Dickinson, Oxford), and the data were analysed with the Cell Quest software 
programme (Becton Dickinson).  
 . 
5.1.2 J774-A1 macrophages 
 
To study the effect of antibiotics and immunomodulators on intra-macrophage 
replication, the murine macrophage-like cell-line J774-A1 (#85011428) was also 
purchased from the European Collection of Animal Cell Culture (Public Health 
Laboratory Service). This is a BALB/c monocyte macrophage cell line from the 
ascites of a female mouse. Human cells were not used due to previous difficulties in 
their extraction and maintenance at the laboratory. Cells were maintained in 
supplemented Roswell Park Memorial Institute RPMI-1640 medium, see appendix 
six. All mammalian cells were maintained at 37° C in a humidified atmosphere of 
95% air, 5% (v/v) CO2. Culture medium and supplements were supplied by Sigma-
Aldrich excepting FBS (Invitrogen; Paisley, Scotland).  
J774-A1 cells were grown until 80% confluent and passaged following gentle 
physical removal using cell scrapers (Corning® Chorges, France. Product number 
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#3011). Both Caco2 and J774-A1 cells were used at passage numbers less than 10 in 
experiments. J774-A1 macrophages were seeded into 24 well plates at the same 
concentration 1x10
5
/ml with 1 ml added, and used for experiments after 24 or 48 h 
(see chapter eight). When macrophages were treated with drugs, antibiotics were 
solubilised in dimethyl sulfoxide (DMSO) followed by dilution in RPMI and then 
sterile filtration. Immunomodulators were also solubilised in RPMI media before 
sterile filtration and all drugs were then prepared at the experimental concentrations 
specified in chapter eight using RPMI as diluent. Gentamicin was an exception as it 
was supplied as a liquid. All drugs were supplied by Sigma-Aldrich. 
 
5.1.2.1 Assessment of possible cytotoxic effects of pharmacological agents on 
macrophage cells 
 
Potential cytotoxic effects of pharmacological agents used in this thesis on 
macrophage cells were assessed. This involved both cell counting using a 
haemocytometer and the use of the Toxilight™ adenylate kinase assay kit (Cambrex, 
Lockland USA). Cell supernatants were evaluated as per manufacturer’s instructions 
(protocol 2, of kit LT07 – 217 ). Techniques used are described in chapter eight. 
 
5.2 Bacterial strains 
 
5.2.1 Adherent-invasive E.coli 
 
 Bacterial strains examined for the presence of the uidA gene included 
mucosally-associated Escherichia coli (E. coli) isolated from colonoscopic biopsies of 
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patients with Crohn’s disease (CD) attending the Royal Liverpool University Hospital 
by Helen Martin (232). These were designated ‘HM’ and specifically were HM95, 
HM154 (non adherent, nonhaemagglutinating strains), HM580, HM605, HM615, 
HM670 (adherent haemagglutinating strains). Two further E. coli isolates were kindly 
donated by the research group of Professor Arlette Darfeuille-Michaud, (Clermont 
Ferrand): LF10, an adherent, invasive haemagglutinating strain, and LF82 an 
adherent, invasive non-haemagglutinating strain, both isolated from patients with ileal 
CD (200;206). The majority of these E.coli studied possess ability to adhere to, and 
invade Caco2 cells (200;232) and to survive and replicate within phagolysosomes of 
macrophages (206;242) and meet the phenotypic criteria of the pathotype designated 
as Adherent-Invasive E.coli (AIEC) (207). 
 
Further processing of the HM605 strain for quantification standards is discussed in 
section 5.2.4 
 
5.2.2 Control bacterial strains 
 
Given that uidA is a gene unique to E. coli or Shigella species and not found in 
other bacteria a negative control for uidA was included:  Klebsiella pneumonia (304). 
(HM534) was obtained and characterised from a patient in (232) and PCR negativity 
for the bacterium was also confirmed using the NCBI database. 
 
Two further bacteria Enterococcus faecalis (HM65) and Citrobacter rodentium 
(HM481) also isolated in (232) from colonic samples were also used to provide 
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negative genomic DNA controls for uidA qPCR in (Standardisation method 3) with 
DNA extracted as per section 5.3.1. 
Two probiotic bacteria Lactobacillus paracasei and Bifidobacterium longus 
were used as negative control template in standardisation method four. Each was 
cultured as per E. coli strains on Luria Bertani (LB), agar (see appendix six) overnight 
to stationary phase and genomic DNA extracted as per section 5.3.1. 
 
K12, an indolent laboratory strain of E. coli with limited in vitro adherence 
was used as a reference negative control as per (242) in the experiments evaluating 
diarrhoeal pathogens in chapter nine.  
 
All bacterial isolates were stored on Protect beads (Scientific Laboratory Supplies, 
Yorkshire, England) in glycerol broth at -80°C. Each was grown overnight on LB 
agar at 37°C.  
 
5.2.3 Diarrhoeagenic bacterial strains 
 
Diarrhoegenic E. coli used for studies to examine the inhibitory effects of foodstuffs 
on bacterial adhesion included enteropathogenic (EPEC) strains D55 and E2348/69 
which were obtained from stocks held within the Department of Clinical Infection, 
Microbiology and Immunology, University of Liverpool. Enterotoxigenic E. coli 
ETEC C410 (serotype O160, ST+ and LT+) was kindly supplied by Dr Godfrey 
Smith (Medical Microbiology, Royal Liverpool & Broadgreen University Hospitals 
NHS Trust, UK). All enteropathogenic E.coli were cultured on LB agar plates with 
overnight incubation in air, at 37ºC. C. difficile Type 027 (strain 080042), also 
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supplied by Dr. Godfrey Smith, was grown on Fastidious Anaerobe Agar (Lab M Ltd, 
Bury, UK) under anaerobic conditions. Campylobacter jejuni (strain 11168H (305)) 
had also been prepared within the Department of Clinical Infection, Microbiology and 
Immunology, University of Liverpool. They were cultured in a micro-aerophillic 
environment for 48 hours before use on the day of experimentation. 
 
5.2.4 Use of the E. coli strain HM605 in standardisation methods 1-3. 
 
After overnight growth on LB agar, E. coli HM605 cells were diluted in PBS to an 
absorbance (550 nm) of 0.825 (1x10
9 
E. coli/ml). 
 
When standardisation required quantification of colony forming units (CFU), after 
each dilution of the initial bacterial suspensions, seven further serial 1:10 dilutions 
were performed in a 96 well plate. 
 Based on standard curves for E. coli HM605 established within our 
laboratory, up to four dilutions were selected to provide countable colonies after 
plating. 50μl of bacterial suspension were plated out on LB agar in triplicate and 
incubated at 37°C for 24 h before colonies were counted and standardised per ml. 
CFU numbers were calculated using the mean of triplicate measures at two dilutions 
(except for the most dilute initial suspension, where only one dilution was useful). As 
a control, sterile PBS alone was plated out neat in triplicate.  
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5.3 Human and Bacterial DNA Extraction 
 
Bacterial and human cell DNA was extracted in a number of ways, which included 
both a crude technique involving boiling, vortexing and centrifugation, as well as 
commercial DNA extraction kits: 
 
5.3.1 Crude DNA extraction 
 
Crude genomic DNA template extracted from bacterial suspensions was used for 
endpoint PCR, primer optimisation experiments in the development of a qPCR 
bacterial quantification method and in the preparation of control bacterial DNA for 
qPCR quantification methods three and four (all chapter six). Briefly, following 
overnight growth on LB agar (see appendix six) in the 37°C incubator, two colonies 
of each bacterial strain were selected and removed with an inoculating loop to 100μl 
sterile-filtered PCR grade water in nuclease-free tubes. DNA template was prepared 
by boiling (100ºC for 10 min), vortexing for 1 min and centrifugation (13,000 rpm, 
13,200 g for 10 min) of these suspensions. DNA template was diluted as required for 
each standardisation assay.  
 
5.3.2 Qiagen mini-prep purification of  bacterial and human DNA  
 
This kit was used for extraction of bacterial DNA, human DNA, and the combination 
of both in human biopsies. 
One ml of a suspension of E. coli was prepared to an absorbance (550 nm) of 0.825,  
equivalent to  1x10
9
 organisms/ml, and used for Qiagen DNA mini-kit (51304) 
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extraction (306). The extraction was performed using the Qiagen tissue kit protocol 
for bacterial DNA extraction (appendix D of manufacturers protocol). After overnight 
growth bacterial pellets were resuspended, homogenised with buffer ATL, treated 
with proteinase K, 4 µl of 100 mg/ml RNase A ( Sigma-Aldrich) buffer AL, 100 % 
ethanol, AW1 and AW2  (see appendix six for buffer composition), before elution of 
DNA from QIAamp mini-spin columns with  PCR grade water (Roche). Recovery 
was with only one elution volume (50 µl) for all extractions.  
 
 When human biopsies were processed from the clinical studies the Qiagen 
DNA kit was also used. The human samples (see section 5.11 and chapter six) were 
thawed. Initially the biopsies and the bacterial pellets were treated differently. Whilst 
bacterial pellets were resuspended in 180 μl buffer ATL as before in a 1.5 ml 
microcentrifuge tube, the biopsies were also mechanically homogenised. Each biopsy 
was placed in 80 μl PBS in a 1.5 ml tube and then homogenised, using the laboratory 
nucleic acid homogeniser probe (Fisher, Loughborough, UK) until complete 
homogenisation. In between samples the homogeniser probe was washed with 70% 
(v/v) ethanol and PBS. 100 μl of buffer ATL was then added to the sample. Both the 
bacterial pellet and biopsy were processed identically from this point.  
The DNA extraction was completed as above from the proteinase K step,   
again with recovery by a single elution These DNA elution samples were stored at -
80ºC. 
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5.3.3 Use of the Promega kit to extract and optimise bacterial DNA 
 
The Promega kit gives a high yield of bacterial DNA from usual starting materials, 
100 µg from 5 ml of bacterial suspension (page 4 of the Promega Wizard® Genomic 
DNA Purification Kit (A1125) protocol). This was therefore used to enhance E.coli 
bacterial DNA template prior to qPCR quantification methods three and four in 
chapter six.  
The E. coli strain HM605, a typical AIEC with uidA PCR positivity was used 
to generate E.coli DNA, and was grown overnight in standard LB broth at 37˚C  
before use. Six ml cultures were harvested by centrifugation (13,000 g for 2 min), 
then processed according to the Promega Kit instructions (section G - isolating 
genomic DNA from Gram negative bacteria). Briefly, bacteria were lysed in nuclei 
lysis solution at 80˚C then RNase I-treated. Protein was removed with protein 
precipitation solution and finally DNA was precipitated using 70% ethanol, and  
rehydrated with DNA rehydration solution respectively. DNA was stored at -80˚C.     
 
5.4 Endpoint PCR amplification reactions 
  
Two µl aliquots of supernatant from the centrifugation of crude genomic DNA 
preparations of AIEC bacteria from CD patients were used in 50 µl PCR reactions 
which contained 45 μl of 1.1X ABgene PCR mastermix (Advanced Biotechnologies 
Limited; Surrey, UK) and 1.5 μl each of forward and reverse uidA gene primers (1.0 
M final concentration, uidA F1 and uid R1 (pair one)) – see table 5.1). Reactions 
were carried out on the Techne Genius Thermal Cycler (Rhys Scientific; Chorley, 
UK). An initial denaturing step at 95ºC for 15 min was performed, then 35 cycles of : 
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94ºC for 15 s, annealing temperature of 55ºC for 1 min, 72ºC for 1 min, with an 
additional extension time of 72ºC for 10 min.  
 
 
5.4.1 Endpoint PCR DNA electrophoresis 
 
The products of PCR reactions were electrophoresed on 2% (w/v) agarose gels 
(Sigma), containing 10 µl per 500 ml agarose of 10 mg/ml ethidium bromide, for 50 
min at 100 V. Gel images were acquired using the ‘Quantity one’ software package 
(BioRad, Hemel Hempstead, UK), on the Flu- imager (BioRad). Hyperladder IV 
(100-1000 bp) (Bioline, London, UK) was used to define product size. 
 
5.5 The use of spectrophotometry to quantify DNA 
 
DNA was quantified by standard spectrophotometry. Absorbance at wavelength 260 
nm was multiplied by 50 to quantify DNA in µg/ml. The ratio of absorbances at 
wavelength 260 nm/280 nm was used to assess DNA purity (with a target range for 
this ratio between 1.7-1.9) using samples in standard semi-micro UV cuvettes (10 mm 
path length); (CM scientific, Silsden UK). 
 
Samples were also quantified using the Nanodrop ™ spectrophotometer 
(Thermoscientific, Loughborough, UK) for comparison. The Nanodrop™ has 
advantage that only 1-1.5 µl sample is required for quatification (as opposed to 50 µl 
in standard UV cuvettes), and has increased sensitivity for measuring DNA 
concentration  with stated precision of 1.5 ng/µl. 
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5.6 Oligonucleotide primers used in the PCR reactions performed in 
this study 
 
Primers and probes used are listed in Table 5.1. Supplied by Eurogentec (Belgium). 
  
Table 5.1 Primers used in PCR assays, all sequences specified in 5’-3’ direction 
 
Primer Name Sequence (5’ to 3’) Amplicon 
size/bp 
Annealing 
temp/ºC 
Reference Target 
uidA F1 Forward: 
TATGAACTGTGCGTCACAGCC 
186 55 (205) uidA gene 
uidA R1  Reverse: 
CATCAGCACGTTATCGAATCC 
    
 
uidA F2 TGTGATATCTACCCGCTTCGC 61 60  (218) uidA gene 
uidA R2 CAGGAACTGTTCGCCCTTCA     
uidA TaqMan® 
probe 2 
FAM/TCGGCATCCGGTCAGTGGCA-
BHQ-1 
    
 
uidA F3 GCCAGACAGAGTGTGATATCTACCC
GT 
135 55 (205) uidA gene 
uidA R3 CCACGCAAGTCCGCATCTTC     
 
16S F  ACTCCTACGGGAGGCAGCAGT 200 49 (307) 16S rRNA gene 
common sequence 
16S   R  GTATTACCGCGGCTGCTGGCAC     
 
18S F Eurogentec (RT-CKFT-18S control kit) 121 60 (218) 18S rRNA gene 
18S R      
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5.6.1  Optimisation of uidA qPCR  
 
The primer sequences used for uidA qPCR were different to those used in endpoint 
PCR as a shorter amplicon size improves efficiency of qPCR. Primer pairs uidA F2 
and uidA R2 together with uidA TaqMan® probe 2 (see Table 5.1) were used to 
quantify E. coli uidA genes as previously described (218). For optimisation assays of 
primers, aliquots of a  genomic DNA  sample extracted from a bacterial suspension 
(the equivalent of DNA crudely extracted from 1x10
7
 E. coli/ml) were used as a 
‘constant’ template, with TaqMan® probe  final concentration constant at 200 nM, 
while primer final concentrations were varied in combinations of 50 nM, 300 nM and 
900 nM to see which produced the lowest threshold cycle number ‘Cp’ and highest 
fluorescence in unit time. qPCR composition and reaction conditions are described in 
5.7.1-5.7.2 
 
5.7 qPCR Reaction Conditions and a summary of primers used in 
quantification  processes  
 
Throughout qPCR assays, pipettes were treated for two hours pre- and post assay with 
UV light. This was to minimise contamination and qPCR amplification crossover. 
Table 5.2 summarises which of the primer pairs from table 5.1 were used in endpoint 
PCR, primer optimisation and which specific quantification assays, which are 
discussed in chapter six. 
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Table 5.2 Summary of primers (from table 5.1) used in specific assays and 
quantification methods in this thesis 
 
 PRIMER PAIR USED 
ASSAY uidA F1 R1 uidA F2 R2 uidA F3 R3 16S  
Endpoint PCR YES NO NO NO 
Optimization of 
qPCR primer 
concentrations 
NO YES NO NO 
qPCR 
quantification 
method 1 
NO YES NO NO 
qPCR 
quantification 
method 2 
NO YES NO NO 
qPCR 
quantification 
method 3 
YES NO NO NO 
qPCR 
quantification 
method 4 (non-
linear plasmid 
DNA) 
YES  YES NO YES 
qPCR 
quantification 
method 4 
(linear plasmid 
DNA) 
YES YES YES YES 
 
 
Sections 5.7.1 onwards detail the reaction composition and conditions used for each 
primer pair in Table 5.1. uidA primer pairs F2 and R2 were used initially in 
optimisation assays with crudely extracted genomic DNA as described in the section 
above to ascertain their optimal concentrations.  
 
 
 
 83 
5.7.1 qPCR reaction composition for uidA F2 and R2  primers  and probe 
 
PCR reactions, typically in 20 μl volumes, were performed in triplicate for each crude 
DNA template in a LightCycler 480® (Roche, West Sussex, UK), contained 5 μl 
template, 10 μl LightCycler 480® probes mastermix (Roche), 1 μl of probe (200 nM 
final concentration) and each primer (50-900 nM final concentration), and 2 μl PCR 
grade water (Roche). The non-template control was 5 μl of PCR grade water (Roche). 
Where primers or probe were not added (as controls), equivalent volumes of PCR 
water were added instead. 
Following optimisation uidA F2 and R2 primers were used at 900 nM 
concentration, as were the other primers used and the uidA probe was used at a 200 
nM concentration. 
 
5.7.2 Thermocycler conditions for uidA gene amplification with primers F2 and 
R2 
 
Reactions were carried out in the LightCycler 480®, on the first occasion with pre-
incubation temperatures of 50ºC for 2 min followed by 94°C for 10 min, then 40 
cycles of 94°C for 20 s, 55°C for 20 s,  then 72°C for 30 s, as described previously 
(218) but with a short cooling step added (40°C for 30 s). Fluorescence was measured 
at each 72°C step. 
This was modified on advice from the manufacturer of the LightCycler 480® 
machine, with fluorescence acquisition at 60°C (probe annealing step), a single pre-
incubation step (95°C for 10 min) and 40 amplification cycles- 95°C for 10 s, 60°C 
for 30 s and 72°C for 1 s, with a final cooling step 40°C for 30 s. These changes did 
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not affect fluorescence signal adversely, and were used as standard conditions for 
primers uidA F2 and R2 subsequently. 
 
5.7.3 qPCR reaction composition and reaction conditions for uidA primers F1 R1 
and F3 R3 (incorporating SYBR green technology) 
 
qPCR reaction compositions for these primer pairs were as the standard mix (5.7.1), 
but instead contained 10 μl LightCycler 480® SYBR green probes mastermix (Roche) 
and  3 μl PCR grade water (Roche) as the 1 μl uidA probe was not used. 
The reaction conditions (modified from (205) were 95°C for 10 min, followed 
by 40 cycles of 95°C for 10 s, 55°C for 20 s, 72°C for 30 s (with fluorescence 
acquisition), followed by a melt curve analysis (95°C for 5s, 65°C for 1 min and then 
continuous acquisition from 97°C). 
 
5.7.4 qPCR of non-linearised uidA plasmid DNA for standard curves. 
 
After initial experiments using crudely extracted, and commercial kit extracted 
genomic DNA (quantification method 1) as template, development of the 
quantification assay meant that modified plasmid DNA, generated using amplicons 
produced by the primers uidA F1 R1 and F2 R2 (see chapter six) were  evaluated with 
the uidA primers.  
Non-linearised uidA amplicon 1 and 2 plasmid DNA was  serially diluted ten fold and 
used to produce standard curves using the standard conditions for uidA primers F1 R1  
2 (5.7.3), and uidA primers F2 R2 (5.7.2). The  non-linearised plasmid-uidA amplicon 
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1 DNA samples were assessed alongside negative control probiotic bacteria 
(Bifidobacterium and Lactobacillus)  to confirm specificity.  
  
5.7.5 16S rRNA qPCR assay 
 
The reaction composition was as 5.7.3 but used 16S primers, and an additional  2 μl 
PCR grade water when only 3 μl of DNA template was used in the assay. The 
temperature conditions and timings were as 5.7.3, but with a primer specific  
annealing temperature of  49°C used. 
 
5.7.6 qPCR of human 18S rRNA genomes, the denominator assay 
 
Serial ten-fold dilutions of the human chromosomal DNA provided at 30 ng/µl (which 
corresponds to 10,000 genome copies of 18S), with the Eurogentec control kit (RT-
CKFT-18S) were prepared. There are two hundred 18S rRNA genes per human 
genome (see Eurogentec technical data sheet – RT-CKFT-18S). The control used was 
PCR grade water (Roche). \The composition of the 18S rRNA qPCR reactions was 
entirely different to previous qPCR apart from the template volume used, as were 
reaction conditions. Each 20 µl qPCR reaction (in triplicate) contained 5 µl of 
chromosomal DNA template (5 - 50,000 genome range,  or 15 pg – 150 ng DNA), 3.4 
μl PCR grade water, 0.4 μl of 18S rRNA TaqMan® probe (125 nM final 
concentration), 1.2 μl 18S rRNA primer mix (600 nM final concentration), and 10 μl 
of the LightCycler480® probes mastermix (Roche). This control kit has been used 
previously as a denominator (218). Amplifications were carried out in the 
LightCycler480® with a pre-incubation temp of 95°C for 10 min, followed by 40 
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cycles at 95°C for 15 s, then 60°C for 1 min, and 72°C for 1 s, with fluorescence 
measured at each 60°C step, with a final cooling step 40°C for 30 s. These conditions 
are as per 18S rRNA kit instructions, with slight modification to suit the LC480® 
machine and the amplicon size generated using these primers is 121bp. 
 
5.7.7 qPCR of plasmid DNA (all forms) 
 
5µl of plasmid DNA were used as template in qPCR amplification reactions to 
confirm successful insertion of the uidA, and 16S rRNA amplicons. Primers and 
reaction conditions are detailed in table 5.1 and sections 5.7.1 – 5.7.5 with a primer 
pair used for its corresponding amplicon (or nested amplicon) 
 
 
5.8 Generation of non-linearised uidA and 16S plasmid DNA for 
quantification : Plasmid and amplicon preparation including 
confirmation of suitable product, ligation reactions, and 
transformation of cells to accept cloned plasmid-gene amplicon DNA 
 
The generation of non-linearised plasmid DNA involved four main steps; generation 
of an appropriate amplicon, ligation of this amplicon into plasmid DNA, 
transformation of cell lines to accept these cloned plasmids, and extraction of plasmid 
DNA from these cells. 
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5.8.1 Plasmid and amplicon preparation, ligation reactions and confirmation of 
amplicon insertion into plasmids 
 
pGEM® -T vector was  supplied as a 3000 bp linearised plasmid (Cat.# 
A3600, Promega, Southampton, UK), convenient for the cloning of PCR products. 
The vector was prepared by cutting with a blunt-ended restriction endonuclease and 
adding a 3´terminal thymidine to both ends. These 3´ T overhangs at the insertion site 
greatly improve the efficiency of ligation of a PCR product into the plasmids by 
preventing recircularization of the vector and providing a compatible overhang for 
PCR products with 5′ A overhangs.  This was ready  to accept PCR products produced 
by thermostable polymerases in the presence of the ligase enzyme. uidA or 16S 
amplicons were generated from genomic E.coli DNA using primers F1 R1 and F2 R2 
or 16S primers and reaction conditions described in sections 5.7.1, 5.7.2 and 5.7.5. 
The amplicons were 186, 61, and 200 bp in size respectively, and were used directly 
from the reaction mix in ligation reactions, forming a recircularised plasmid for the 
non-linearised uidA plasmid assays. 
Using the Promega ligation kit (A3600) a PCR product-plasmid ligation 
reaction was set up, pipette mixed and incubated overnight at 4˚C comprising: 
10 µl 2x ligation buffer, 1 µl pGEM®-T (50 ng), 7 µl amplified PCR  product, and 2 
µl of T4 DNA ligase (3 Weiss units/µl activity). As a control, 1 µl of control DNA 
supplied with the kit combined with 6 µl PCR water were used in place of amplified 
PCR product to confirm that the ligation process was successful. 
Confirmation that the correct amplicon had been inserted into the plasmid 
vector was achieved primarily by amplifying the ligated plasmid DNA using qPCR 
and, in one  case (the uidA amplicon), performing a restriction enzyme digest of the 
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extracted plasmid-amplicon DNA products.  This was followed by DNA gel 
electrophoresis to confirm size. 
 
5.8.1.1 Restriction enzyme digest of the uidA amplicon-plasmid DNA  
 
The sequence of the pGEM®-T (A3600) plasmid, along with a restriction 
enzyme map was published in the Promega product guidance, and the sequence of the 
uidA gene was acquired from Genbank (NCBI Reference Sequence: NC_010473.1). 
Webcutter 2 internet software was then used to check for restriction enzymes that did 
not cut within the uidA gene sequence but did cut either side of the amplicon insert on 
the pGEM-T plasmid. Subsequently a restriction enzyme digest was performed with 
enzyme, temperature, and incubation time selected as guided by the New England 
Biolab catalogue. The enzymes used were SacII and SpeI (Roche), requiring a double 
digest and using buffer no. 4 (Roche). These enzymes were incubated together at 
37˚C for 1 h with the plasmid DNA:uidA amplicon product, followed by heat 
inactivation at 80˚C for 20 min (SpeI requires 80˚C to be inactivated even if SacII is 
inactivated at 65˚C). Bovine serum albumin (BSA) was needed for the action of the 
SpeI restriction enzyme and was ten fold diluted from the original concentration of 10 
mg/ml, (with buffer 4 which was itself ten fold diluted in sterile distilled water to 
produce 1x buffer 4), to prevent any inhibitory effect on the digest reaction.  The 
reaction components were : 2 µl reaction buffer 4, 10 µl plasmid DNA, 1 µl of each 
restriction enzyme 2 µl of the diluted BSA and 4 µl of sterile distilled water. Control 
restriction enzyme digests were set up which were either lacking the SpeI enzyme, the 
SacII enzyme, or both and these were run on the same DNA electrophoresis gel. 
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When a restriction enzyme was omitted, an equivalent volume of sterile distilled 
water was used instead. 
 
 When SYBR green mastermix was used in qPCR assays, a melt curve analysis 
was performed as an additional means of confirming specificity of product. 
  
5.8.2 Transformation of cell lines 
 
The uidA gene amplicons, once ligated into plasmid DNA, were used to transform 
XL10 Gold Ultracompetent cells (Stratagene), C4040-03 (Invitrogen ™) cells, and 
JM107 electrocompetent cells (supplied by Dr Joanne Fothergill and Dr Chloe James 
(Department of Clinical Infection, Microbiology and Immunology, University of 
Liverpool). 
  
The plasmid containing the 16S rRNA amplicon was used to transform XL10 Gold 
Ultracompetent cells, for use as a denominator for total bacteria.  The specific 
transformation of each cell line is described in sections 5.8.2.1 – 5.8.2.3. 
 
5.8.2.1 Transformation of XL10 Gold® Kan
r  
Ultracompetent Cells using the 
modified  plasmids, and overnight incubation of these cells 
 
The experimental plasmids with amplicons ligated, and control DNA, was 
incorporated into XL10 Gold® Kan
r  
Ultracompetent Cells (Stratagene 200317) using 
the XL10 Gold® Kan
r  
Ultracompetent Cells transformation protocol (Revision 
#074003, Stratagene). Briefly, ultracompetent cells were thawed from -80˚C on ice, 
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and 100 µl of cells were mixed with 4 µl B-mercaptoethanol on ice for 10 min. 5 µl of 
ligation mix (PCR amplicon product or control DNA) were added to this, mixed, and 
then further incubated on ice for 30 min. These tubes were then heat pulsed in a 42˚C 
water bath for precisely 30 s before being re-incubated on ice for 2 min. 0.9 ml of pre-
heated (42˚C for 2 h) Nyzatidium Bromide (NZY+) broth was then added to each tube 
which were then incubated at 37˚C for 1 h with shaking. Finally, 200 µl from each 
tube were added to pre-prepared Amp X-Gal agar plates (see appendix six) and 
incubated at 37˚C overnight to screen for transformants. 
 
5.8.2.2 Transformation of One Shot® TOP 10 Competent cells, C4040-03 
(Invitrogen™) with modified plasmid DNA, and overnight screening incubation 
 
Briefly, Amp X-Gal agar plates were prepared, and pre-warmed in a 37ºC incubator 
for 30 min. The ligation reactions were centrifuged briefly and placed on ice while 
vials of chemocompetent cells were thawed out on ice. 5 µl of each ligation reaction 
was added to each 50 µl vial of cells and mixed by gentle tapping. These were 
incubated on ice for 30 min followed by a precise 30 s incubation in a 42ºC water bath 
followed by placing immediately on ice. Then 250 µl of pre-warmed S.O.C. (super 
optimal broth with catabolite repression or enriched bacterial growth medium) was 
added to each vial before vials were shaken at 220 rpm or 8.5 g for 1 h at 37ºC. 200 µl 
from each vial were then spread on prepared Amp X-gal agar plates and stored at 
37ºC overnight with colonies examined for blue/white screening the following day. 
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5.8.2.3 Transformation of JM107 electrocompetent cells with modified plasmid 
DNA by electoporation of cells. 
 
Briefly a fresh overnight culture of E. coli JM107 cells was grown  in 5 ml of LB and 
then inoculated into 500 ml (or 1% dilution) of LB, and these cultures were grown 
with shaking at 37ºC to an OD600 of 0.35-0.5. The cells were centrifuged at 10,000 
rpm or 17,000 g for 10 min in a pre-cooled centrifuge, resuspended in 500 ml of ice-
cold sterile distilled water, followed by three further centrifugations, and resuspension 
in decreasing amounts of ice-cold sterile 10% (v/v) glycerol (500 ml, 250 ml, 2.5 ml). 
The volumes were then transferred to cold 1.5 ml tubes and recentrifuged at 13,000 
rpm (17,000 g) before resuspension and aliquoting (150 µl volumes) prior to flash 
freezing in liquid nitrogen. These aliquots were stored at -80ºC when not used 
immediately. 
 
On the day of electroporation, 1 mm electroporation cuvettes were cooled on ice. 10 
µl of ligation reaction were added to 40 µl of electrocompetent cells in the cuvette. 
The cells were electroporated at 25 µF, 200 Ohm, 2.5 kV (Gene-Pulser II 
Electroporater, Bio-Rad), followed by immediate suspension in 1 ml S.O.C and 
shaking incubation at 37ºC for 1 h. They were then plated on amp X-gal agar to 
screen for successful transformants. 
 
 5.8.2.4 Blue-white colour screening of plasmid-transformed bacterial cells  
 
The Amp X-gal agar plates with the transformed cells added were checked after 
overnight culture and white colonies (which had successfully incorporated plasmid 
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DNA) were used for further subculture, and stored as useful bacterial clones for 
extracting plasmid DNA. This plasmid DNA was used to produce standard curves, for 
bacterial gene quantification as required. Control DNA was used alongside the 
ligation reactions with cells to confirm that they could be transformed effectively.  
 
5.8.3 Plasmid DNA extraction  
 
The successfully transformed ultracompetent bacteria were used to harvest plasmid 
DNA. This plasmid DNA extraction was performed using the QIAprep Spin miniprep 
kit (Qiagen, 27104) and the associated protocol from the QIAprep Miniprep 
handbook. In brief, one colony of transformed cells was placed in LB broth (see 
appendix six) with ampicillin added at 100 mg/ml, (2 x 1.5 ml) and incubated 
overnight at 37˚C. This 3 ml of transformed bacterial cells was centrifuged at 13,000 
rpm (13,225 g) for 4 min to pellet the bacteria the next day. These were resuspended 
in 250 µl of buffer P1 (which had had RNase A pre-added), followed by 250 µl buffer 
P2, and finally 350 µl of buffer N3 (see appendix six). This was centrifuged for 10 
min and the supernatant from this was added to a QIAprep column and centrifuged for 
60 s.The spin column was washed with 0.75 ml of buffer PE (see appendix six) and 
centrifuged for 60 s x2. Finally plasmid DNA was eluted by addition of 50 µl of PCR 
grade water to the QIAprep column in a clean 1.5 ml microfuge tube, which was 
allowed to stand for 1 min before centrifugation for 1 min.  
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5.9 Linearisation of plasmids containing the uidA/16S rRNA 
amplicons 
 
 During method development for quantification of uidA and 16S rRNA genes 
(E.coli), re- linearization of the modified circular plasmids containing the gene 
amplicons was performed as an additional step, in order to see if assay sensitivity 
could be improved (see chapter six).    
To linearise the pGEM-T plasmids, the restriction enzyme RsaI was used. The 
sequence of the uidA and 16S rRNA gene were acquired from Genbank and Webcutter 
2 internet software used to check that the restriction enzyme did not cut within the 
gene sequences but did cut once at the side of the amplicon insert within the plasmid. 
 The reaction mix comprised 2 µl RsaI and 2 µl buffer A (Roche) with 5 µl of 
the plasmid DNA and 11 µl of PCR grade water. The reaction mix was incubated at 
37ºC for 2 h followed by 65ºC for 30 min to inactivate the restriction enzyme. The 
gene copy number from previous calculations was divided by 4 to reflect the 1:4 
dilution of the plasmid DNA in the reaction mix, successful linearisation was 
confirmed by 1% (w/v) agarose DNA gel electrophoresis and the linearised template 
was subsequently used in qPCR. 
 
5.10 DNA gel electrophoresis to confirm the size of amplicons, 
restriction enzyme products, or to demonstrate plasmid linearisation  
 
Amplicons, restriction enzyme digests of plasmid, non-linear plasmid or ‘single-cut’ 
linearised plasmid DNA were electrophoresed on 1-2, and also 3.5% (w/v) agarose 
gels (Sigma), as appropriate for product size, intercalated with ethidium bromide or 
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‘gel-red’, for 50 min at 100 V. The gel images were acquired using the ‘Quantity one’ 
(BioRad) or ‘Genesnap’(Syngene) software packages. Hyperladders I (200 – 10,000 
bp), IV (100 – 1000 bp), and V (25 – 500 bp), were used to define product size 
(Bioline).  
 
5.11 Small and large intestinal biopsy handling procedure used in the 
plantain clinical trial and aphthous ulcer study  
 
Intestinal samples were taken in both the aphthous ulcer study and plantain clinical 
trial in this work, and local ethics approval was granted for both. For the aphthous 
ulcer study local ethics approval was from Northwest 2- Liverpool Central, reference 
10/H1005/25, with the same committee separately approving the plantain clinical trial 
EudraCT number: 2006-005526-23, Ethics committee reference : 07/H1002/105, 
ISRCTN number 62819212.  
 Five patients were recruited to the aphthous ulcer study, in which twelve small 
and large intestinal biopsies in total were collected in addition to routine samples. In 
the plantain trial twelve patients were recruited to the biopsy arm of the RCT in which 
four sigmoid colon biopsies were taken in addition to routine samples. 
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5.11.1 Processing of samples within the endoscopy unit 
 
An individual sample identity number was used for each intestinal sample taken from 
a patient, and was the only identifying number stored at the laboratory. Clinical 
details were kept separately at the RLBUHT NHS hospital site.   
 
In addition to histological samples taken for routine patient care, up to twelve small 
and large bowel biopsies were taken, with informed written consent, from each patient 
recruited to the aphthous ulcer trial, with standard single use sterile endoscopic 
forceps used. Biopsies were taken from areas of aphthoid ulceration, lymphoid 
follicles, Peyer’s patches, and ileal tissue, as well as colonic samples including  
normal mucosa.  Patients had standard bowel preparation with Moviprep (Norgine). 
The biopsies were put individually into 1.5 ml tubes containing 500 μl of sterile 
saline, and these samples were placed on ice and taken back to the laboratory for 
qPCR analysis.  
 In the plantain trial patients did not receive bowel preparation and the four 
sigmoid colon samples, taken at between 15 and 25 cm from the anal margin, were 
similarly placed in sterile saline on ice, and taken for DNA extraction and qPCR (see 
chapter seven). 
  
5.11.2 Removal of the adherent mucus layer to evaluate mucus associated 
bacteria 
 
Samples used for qPCR from each patient were placed in 500 μl 0.016% (w/v) 
dithiothreitol (DTT) made up in sterile saline in 1.5 ml tubes (as per (232)). These 
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were rotated for 15 min to remove the mucus layer. The supernatant was removed for 
each sample separately and then these biopsy samples were then washed three times 
by transferring them into consecutive 1.5 ml tubes containing 500 μl of sterile saline, 
by pipette suction. Each of these washings was pooled with the original supernatant 
from each biopsy and these were then centrifuged at 10,000 rpm (7830 g) for 10 min 
to produce a bacterial pellet, for assessment of the mucus-associated bacteria by 
qPCR.  
 
The residual DTT-treated biopsies and bacterial pellets were placed directly in the       
-80ºC freezer for storage prior to genomic DNA extraction. 
 
5.11.3 DNA extraction from human biopsies and bacterial pellets 
 
Human biopsies and their associated pellets had human and bacterial DNA extracted 
from them as described in section 5.3.2. 
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CHAPTER SIX : THE DEVELOPMENT OF A Q-PCR 
ASSAY FOR QUANTIFICATION OF BACTERIA IN 
ENDOSCOPIC INTESTINAL MUCOSAL SAMPLES 
 
 
6.1 Aim:  
 
To develop a quantitative polymerase chain reaction (qPCR) assay for quantification 
of mucosal bacteria with sufficient sensitivity and reproducibility for use on 
endoscopic biopsy samples obtained in clinical trials in CD. 
 
6.2 Introduction 
 
6.2.1 Direct quantification of bacteria by PCR amplification 
 
To develop a method for direct quantification of bacteria by PCR meant a number of 
issues had to be addressed. These issues were sensitivity, use of an appropriate 
denominator, choice of an appropriate candidate gene for bacterial quantification and 
choice of an appropriate quantification method. 
  
 
 
 
 98 
6.2.1.1 Determining the required sensitivity 
 
It was anticipated that quantifying bacterial numbers from endoscopic biopsies by 
qPCR might be difficult. Even when DNA is optimally extracted from biopsy tissue, 
it is known that bacterial DNA template numbers from intestinal biopsy tissue can be 
expected to be low; one might expect in the order of 10
6 
total bacteria/mg intestinal 
tissue, and from work in this thesis, for DTT-treated samples, average biopsy wet 
mass was found to be between 8-115 mg  at the extremes of  sampling for both CD 
and control samples (n=54, mean mass 48.4 ± 3.8 mg SEM (308), meaning an 
expectation of  4.84 x10
7 
aerobic bacteria per biopsy. Previous work from our own 
laboratory in Liverpool yielded results in the order of mucosa-associated bacteria (0-
1000 CFU per biopsy, median >100), mucus-associated  (0-3000 CFU per biopsy, 
median >10), and  intracellular (0-500 CFU per biopsy, median >1). These figures 
include all aerobic bacterial species cultured and not simply E. coli. These E. coli 
accounted for about 50 % of cultures of mucosa-associated bacteria after mucus 
removal (232).   
 
6.2.1.2 Standardisation and choice of appropriate denominator 
 
Standard curves can be generated by taking serial bacterial suspension dilutions and in 
parallel (i) plating the bacteria out on standard LB agar and (ii) extracting DNA from 
the same suspensions and then analysing them in a qPCR reaction. The results may be 
compared by correlating colony forming units (CFU) against PCR crossing point 
(Cp). Crossing point  refers to the earliest cycle number at which the accumulation of 
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fluorescence from a qPCR reaction rises above background fluorescence level. It is 
inversely correlated with the gene or DNA template quantity in the qPCR reaction.  
 Alternative approaches to producing a standard curve include expressing 
bacterial numbers per tissue cells following DNA extraction, or using tissue DNA as 
denominator, with qPCR used for both bacterial and epithelial cell quantification  
(218), or as number of bacterial genomes per wet weight of biopsy tissue (306).  
In order to produce standard curves relating gene copies to bacterial numbers, 
either ‘bulk’ quantities of candidate bacterial chromosomal DNA can be extracted and 
quantified spectrophotometrically (306), or the gene of interest can first be amplified 
and cloned into a plasmid vector. These plasmid-amplicon products can then be 
incorporated into chemically or electrocompetent cells and used for generation of a 
large amount of plasmid-amplicon DNA, quantified by sophisticated 
spectrophotometry such as use of the Nanodrop. Using this DNA, the target 
sequences (genes) of interest can be quantified in terms of copy number and used to 
generate a calibration curve  (309;310). This approach allows precise calculation of 
the number of target genes present in standard plasmid DNA template quantities and 
it was ultimately used in this work.   
 
Each method makes certain assumptions and has limits of sensitivity and 
precision. Semi-quantitative assessment of bacterial numbers may also be achieved 
using fluorescence in situ hybridization (FISH) (218;311), but this method is perhaps 
better used to show distribution of bacteria in tissue and was not used here. 
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6.2.1.3 Use of appropriate candidate genes and the relevance of viability in 
quantification of  bacterial numbers 
 
 The uidA gene has been used previously in studies for quantification of E. coli 
(218;226).  It is specific for E.coli  (304) and was used here. The uidA gene, encoding 
the β-glucuronidase enzyme,  is assumed to be present as a single copy per E. coli 
genome (218),(312)  and is certainly known to be present in a single copy in the E. 
coli K-12 genome (NCBI database).  The possibility of more than one copy in 
different E. coli strains has been suggested, though no definitive evidence has been 
presented (313). 
A direct correlation between CFU and PCR products is not always found, as 
an amplified piece of DNA does not necessarily correspond to a viable micro-
organism upon agar plating. In some studies this has produced an over-estimate by a 
log factor of 1.5  (312). Separation of live from dead bacteria quantified by PCR can 
be achieved staining with ethidium monoazide. This reagent will not pass through the 
cell wall of live bacteria (312) but intercalates into dead bacterial cells, and inhibits 
dead cell DNA amplification. This technique was not employed in this work, as 
presence of bacteria, alive or dead, was of interest in this research, as we were 
interested in the quantification of bacteria, and if E.coli were found attached to 
mucosa or in the associated mucus, they can be assumed to be alive at some point to 
get to these locations. 
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6.2.2 Minimum statistical requirements required by the qPCR assay 
 
There is considerable variation in the quality of statistical analysis and presentation of 
qPCR data in the literature, and consequently ideal minimum standards have been 
proposed (see table 6.1 below). These criteria are addressed throughout this work in 
chapters five, six, and seven. It is necessary to produce sufficient experimental detail 
of qPCR setup to allow replication of assays, these standards are discussed in detail in 
(314). In addition, to these standards, a further specification of sensitivity for the 
assays was stipulated in this work, namely that quantifying bacteria in the order of 
1000 would be the lower limit of detection for the assay. Good reproducibility (low 
coefficient of variability) is also desirable.  I will now define and discuss the relevant 
terms: 
 
6.2.2.1 Efficiency of a PCR reaction  
 
 The slope of a standard curve (Cp plotted against log10 gene copy number) describes 
the kinetics of a PCR reaction and is the efficiency of the amplification reaction. It 
indicates how much the target nucleic acid can be expected to increase with each 
cycle. A perfect amplification reaction has an efficiency of 2 (which is the 
LightCycler® machine equivalent of 100%), when the target nucleic acid is doubled 
in every amplification cycle. 
 
Tn = T0 x 2
n
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Where Tn is the number of target molecules at cycle n, n is the cycle number, and T0 
is the number of target molecules present at the start of the reaction.  This relationship 
is true for a perfect amplification reaction during the log-linear phase.  
However, since real life PCR reactions are not perfect, non-specific 
amplification of other nucleic acid sequences can make the efficiency above or below 
100%, and therefore the efficiency (E) is calculated by: 
 
E = 10
-1/slope 
 
where slope is the standard curve gradient. In essence therefore the amplification 
efficiency is related to the linear regression line calculated from the calibration curves 
for standard DNA templates (315). The ‘acceptable minimum efficiency’ range for an 
assay is within 90-110% (expressed as 1.8-2.2 on the LightCycler® machine) The 
source for these equations is the following web address (Roche): 
 
http://icob.sinica.edu.tw/pubweb/Core%20Facilities/Data/R401-
core/LightCycler480%20II_Manual_V1.5.pdf : section 4.2.2, p162-163. 
 
6.2.2.2 Correlation coefficient (r
2 
) for quantification assays 
 
This is a measure of association between the dependent and independent variables 
(316). In these experiments the dependent variable is the PCR Cp (defined in section 
6.2.1.2  - inversely correlated with quantity of template) and the independent variable 
is log10 quantity of template, be that CFU, genomes, or genes. In other words, r
2 
defines  the proportion of sum squared points which are accounted for by the linear 
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regression of the dependent and independent variables. The acceptable minimum 
requirements for correlation coefficient is a calculated value >0.95.  
 
6.2.2.3 Error of a PCR reaction 
 
The Error rate is similar to correlation coefficient but is a more accurate calculation of 
“variance”; the Error value (mean squared error of the single data points fit to the 
regression line), is a measure of the accuracy of the quantification result based on the 
standard curve (an acceptable value should be < 0.2)" (from the LC480® user manual, 
weblink as above, 6.2.2.1). In essence it is an averaged measure of how far the 
standard points are off the regression line. 
 
6.2.2.4 Sensitivity or limit of detection in PCR 
 
In real-time PCR, sensitivity refers to the minimum number of copies in a sample that 
can be measured accurately within an assay. It is usually expressed as the limit of 
detection (LOD), which is the concentration that can be detected within a ‘reasonable 
certainty’ (95% usually). 3 copies per PCR is the minimum theoretically possible 
LOD, assuming a Poisson distribution, a 95% chance of including at least one copy in 
the PCR, and single copy detection. Results which specify ‘zero’ for quantities are 
also meaningless; firstly it is more appropriate to state ‘not detectable’, and secondly, 
PCR results are usually expressed as a logarithm of a quantity (due to the nature of the 
PCR reaction), and a logarithm of zero is unquantifiable (314). When template 
concentration is zero the crossing point is also undefined (due to the logarithmic 
nature of qPCR) which also makes LOD estimates complicated. Appropriate 
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determination and expression of LOD as an issue in qPCR is being explored 
(314;317), due to these ambiguities. For these experiments in view of the known 
difficulties of detection of low copy numbers, (314;317), and the estimated 
requirement for the assay based on CFU seen in previous work (3000, see (232)), 
attempts were made to try and match this magnitude with an LOD of 1000 bacteria. 
 
6.2.2.5 Reproducibility of PCR assays or coefficient of variability 
 
This describes long term precision or inter-assay variance in the results between runs 
and is typically expressed as the coefficient of variability (CV); this is the SD for 
aliquot data expressed as percent of mean (314). My target for this reproducibility, in 
line with a recent PCR publication, was <20%, and ideally <10% (318).  
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Table 6.1 Ideal minimum qPCR standards checklist.  Checklist for authors' of 
MIQE précis (from (319)), detailing information about individual parameters 
associated with each step of the RT-qPCR workflow. 
 
NAC = non amplification controls, NTC = non template control, RT = real time. 
 
Sample/Template Details 
Source If cancer, was biopsy screened for adjacent normal tissue? 
Method of preservation Liquid N2/RNAlater/formalin 
Storage time (if appropriate) If using samples >6 months old 
Handling fresh/frozen/formalin 
Extraction method TriZol/columns 
 RNA: DNA-free Intron-spanning primers/no RT control 
Concentration Nanodrop/ribogreen/microfluidics 
RNA: integrity Microfluidics/3':5' assay 
Inhibition-free Method of testing 
Assay optimisation/validation   
Accession number RefSeq XX_1234567 
Amplicon details exon location, amplicon size 
Primer sequence even if previously published 
Probe sequence* identify LNA or other substitutions 
In silico BLAST/Primer-BLAST/m-fold 
Empirical primer concentration/annealing temperature 
Priming conditions oligo-dT/random/combination/target-specific 
PCR efficiency Dilution curve 
Linear dynamic range spanning unknown targets 
Limits of detection LOD detection/accurate quantification 
Intra-assay variation copy numbers not Cq 
RT/PCR   
Protocols  detailed description, concentrations, volumes 
Reagents supplier, Lot number 
Duplicate RT ▲Cq 
NTC Cq & melt curves 
NAC ▲Cq beginning:end of qPCR 
Positive control inter-run calibrators  
Data analysis   
Specialist software e.g., QBAsePlus 
Statistical justification e.g.,  biological replicates 
Transparent, validated normalization e.g., GeNorm summary 
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6.3 Detailed aims 
 
 1) To develop suitable qPCR assays for the detection of mucosa-associated 
bacteria in human biopsies with a sensitivity of approximately 1000 bacteria per 5μl 
of template DNA extracted from human intestinal biopsies. Reviewing the literature 
expected E. coli quantities in intestinal biopsy tissue vary depending on the method 
used for quantification, sometimes quite widely if PCR techniques and those 
involving CFU are compared. There is a paucity of studies directly comparing E.coli 
numbers using a single standardised PCR method, and therefore the quantity of 
bacteria expected in different tissues quantified using this method was unpredictable. 
In one study E.coli were quantified by qPCR (218) and results were expressed as uidA 
genes per million (18S rRNA genomes) human cells. Assuming one copy of the uidA 
gene per E.coli bacterium, and extrapolating this study’s figures for an average sized 
biopsy found in our work (18S rRNA results in chapter seven), to correct for size 
differences, one could expect 469–4690 E.coli from DNA extracted from ileal tissue, 
with only 12 E.coli per biopsy of colonic tissue, and 7 E.coli  per normal biopsy, but 
these figures were only based on one study expressing results in one way, and had to 
be regarded circumspectively (218).  
From previous work at this laboratory which examined all (aerobically) 
cultured microbiota from colonic biopsy tissue, using plated colony counts of control 
and CD samples, quantities expected per biopsy could be anywhere between 0 and 
3000 total aerobic bacteria per biopsy, with the higher figures seen in CD colonic 
tissue (232). Clearly, the technique used for quantification by CFU assessment is 
different from quantification by qPCR of DNA extracted from microbiota. The huge 
difference between techniques is emphasised by the disparity seen in E.coli numbers 
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found in each study in colonic tissue. This may reflect technique, patient disease or  
inherent variability. It does emphasise the need for a clear denominator in 
quantification studies. 
 
In an additional refinement of the main chapter aim, the bacterial 
quantification assay should have PCR efficiency between 90-110% and a correlation 
coefficient of at least 0.95,  with reproducibility demonstrating a coefficient of 
variation between assays of <20%.  
 
2) To construct a standard curve for qPCR of human 18S rRNA genomes to 
utilise as a denominator for standardisation of bacterial quantity per mucosal biopsy 
size for use in CD clinical trials. The qPCR technique used would have to satisfy the 
same minimum statistical requirements as specified above (aim 1) for the bacterial 
assay.  
 
6.4 Methods and results 
 
Detailed methods are in chapter five, the relevant sections are specified throughout 
the text below.  
 
6.4.1 Screening with endpoint PCR to detect uidA genes  
 
Previous authors had used the uidA gene in quantification assays for E. coli 
(218;312;313) on the assumption, proven for some UPEC and E. coli K-12, that there 
is a single copy of the gene per bacterium. It was important to demonstrate the 
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presence of this candidate gene in our library of CD E. coli isolates as a starting point, 
as well as to show a negative PCR in non-E. coli bacteria. Searches of the NCBI 
nucleotide database using uidA primers F1 R1 (see table 5.1, chapter 5) confirmed 
their presence in E. coli strains and Shigella spp. but not in any other species. Shigella 
are considered by some to belong to the same species as E. coli (244).  
DNA was extracted from a selection of six colonic and two ileal CD E. coli 
‘library’ strains (origin of strains discussed in section 5.2.1).  Endpoint PCR for the 
uidA gene was then carried out as described in 5.4.   
 
PCR amplification and DNA agarose gel electrophoresis (as described in section 
5.4.1) demonstrated the presence of the uidA gene in a representative sample of the 
DNA of our colonic CD E. coli isolates from Liverpool patients, as well as ileal 
strains LF-10 and LF-82 from French patients, whereas the negative bacterial control 
Klebsiella pneumonia was PCR-negative (shown in figures 6.1 and 6.2). 
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                       Colonic E. coli                   NTC         Colonic       Ileal E. coli 
 
 
Figure 6.1 Screening of the ileo-colonic CD isolates for presence of the uidA gene. 
The Appearance after CD E. coli isolates have undergone DNA extraction, endpoint 
PCR, and electrophoresis using a 2% (w/v) DNA agarose gel in TAE. 
Lane 1-4, and 6-7 : Colonic isolates HM670, HM615, HM605, HM580, HM154, and 
HM95 
Lane 5: PCR water (NTC). Lane 8 and 9: ileal isolates LF-82 and LF-10 
M: Marker lane, DNA Hyperladder IV 100-1000bp. 
This image demonstrates that the uidA gene is present in representative E. coli isolates 
from our CD library (232), as well as some ileal isolates (233).  
186 bp 
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Figure 6.2 The bacterial control Klebsiella pneumonia (HM534) is PCR-negative 
for the uidA gene. Amplicons were analysed using a 2% (w/v) agarose gel in TAE. 
Lane 1: E. coli HM605, Lane 2: PCR water, and Lane 3: Klebsiella pneumonia 
HM534. M: Marker lane, DNA Hyperladder IV 100-1000bp. 
 
As the specificity of the uidA gene for quantifying E.coli in CD patients had been 
supported, the optimum standardisation method was then evaluated. 
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6.4.2 Methods for generating a standard curve for E .coli 
quantification 
 
Four approaches were compared for quantification of bacteria, reflecting previously 
attempted strategies in the literature. 
 
Method 1: Crude extraction of genomic DNA from serial dilutions of bacteria with 
this DNA used in qPCR.  
 
Method 2: Extraction of DNA from an initial bacterial suspension using a commercial 
DNA extraction kit, with the extracted DNA and initial bacterial suspension diluted in 
parallel. For both methods one and two the bacterial suspensions were also agar plated 
and CFU enumerated by overnight culture. Method 2 involves higher purity DNA 
extraction compared to method 1. 
 
Method 3: Extraction of genomic DNA from an initial bacterial suspension as for 
method two but with dilution of this DNA, coupled with the use of spectrophotometry 
and published bacterial genome sizes to calculate the bacterial numbers present in 
DNA dilutions used.  
 
Method 4: Insertion of an amplicon from the uidA gene of interest in single copy into 
a plasmid vector. This was then followed by plasmid transformation of competent 
cells, extraction of plasmid DNA from these cells and subsequent quantification of 
plasmid copies with spectrophotometry. Methods 3 and 4 do not involve agar plating.  
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6.4.2.1 Method One. Production of a standard curve for E. coli 
quantification using bacterial CFU and PCR Cp 
 
The representative CD isolate E. coli HM605, which is an adhesive/invasive 
haemagglutinin-positive isolate that has been used for in-vitro work previously (242), 
was used for standardisation purposes. An E. coli suspension (see section 5.2.4) was 
serially diluted 4 times with PBS, each one in ten. The most dilute suspension was 
then further diluted 6 times, each one in two.  Volumes were removed from each 
subsequent suspension and used for both qPCR (100l) and agar plating (200l) in 
parallel (see sections 5.2.4, 5.7.1, and 5.7.2). This technique was based on previous 
work (218) and included the expected CFU range from CD and control tissue. Optical 
density (OD) was found to be an unhelpful measure in this range and was not utilised.  
 
6.4.2.1.1 uidA qPCR primer optimisation experiments 
 
Conditions for the uidA primers F2 R2 were optimised (5.6.1) before they were used 
to define the qPCR Cp of DNA extracted from bacterial suspensions. Primer 
concentrations of 300 and 900 nM were effective, but with a lower signal seen with 
both forward and reverse primer concentrations of 300 nM (figures 6.3 and 6.4). 
Forward and reverse primer concentrations of 900 nM, allowing the best signal and 
easy co-dilution, with a probe concentration of 200 nM were chosen as the optimal 
concentration for use in further experiments evaluating E. coli DNA templates. The 
final optimised annealing temperature was 60°C.  
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6.4.2.1.2 Determining qPCR crossing point for the E. coli suspensions 
 
DNA was extracted from E. coli bacterial suspensions and qPCR was performed as 
per sections 5.3.1 and 5.7.1 - 5.7.2 using the optimised uidA primers F2 R2 (see 
chapter 5, table 5.1 and results figure 6.5). The LC480® software enabled each qPCR 
reaction to be ascribed its corresponding CFU value from the parallel agar plating (see 
section 5.2.4), and generation of a standard curve (figure 6.6). None of the qPCR 
fluorescence curves reached the plateau phase, suggesting that a process increasing 
purity and yield of E. coli DNA extracted was required to improve qPCR, and 
standardisation. 
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Figure 6.3 Primer optimisation experiment using an acquisition temperature of 
60°C showing poor signal from 50nM primers and optimal signal with 300 and 
900nM concentration primers. Template was E. coli HM605, 10
7
 CFU/ml.  
 
 
 
PCR reactions containing uidA 
primers at 300,900nM F/R 
PCR reactions containing 
uidA  primers at 50nM 
F/R 
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Figure 6.4 Final primer optimisation experiment. Forward and reverse primer 
concentrations of 300 and 900nM were evaluated in the following combinations: 300-
300,300-900,900-300 and 900-900). A suspension of 10
7
 CFU/ml HM605 E .coli was 
used as template. qPCR of uidA genes shows similar signals for all primer 
concentrations used, with a lower signal for forward-reverse primer concentrations of 
300-300 nM (blue curves). The primer-less controls show background signal only    
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Figure 6.5 qPCR evaluation of DNA extracted crudely from bacterial 
suspensions. qPCR primer concentrations were 900 nM, with probe 200 nM. DNA 
was extracted by boiling and centrifugation from E. coli bacterial suspensions that on 
agar plating were equivalent to between 790 and 3.3x10
5
 CFU/ml. The fluorescence 
curves obtained by qPCR are shown. NTC (red curve) has a positive signal and most 
of these curves have Cp > 35. 
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Figure 6.6  The standard curve obtained using method one. The standard curve is 
generated by uidA qPCR of DNA extracted from E. coli bacterial suspensions. The y-
axis shows Cp, (the average of triplicates), for the DNA template from each bacterial 
suspension plotted against the log of the average corresponding CFU numbers (x-
axis) derived from each suspension by agar plating (efficiency 59.1% with error 
0.383).  
 
6.4.2.1.3 Conclusion for method one  
 
The standard curve produced had an efficiency of 59.1% with an error of 0.383. The 
LOD of the assay was at least 3.3 x10
5 
CFU. These were clearly not within the 
defined acceptable parameters for the assay.  
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6.4.2.2 Standardisation method two: use of the Qiagen DNA 
extraction kit prior to qPCR quantification of E.coli 
  
The two differences in method two compared to method one were, firstly, that the 
initial bacterial suspension of E. coli HM605 prepared at 1x10
9
 CFU/ml had DNA 
extraction performed using the DNA minikit, (section 5.3.2) to increase yield and 
purity. This had been used in previous standardisation work to extract DNA from H. 
pylori (306).  
Secondly, the DNA extracted from the initial suspension was diluted, rather 
than extracting DNA after each serial dilution of the bacterial suspension. Bacterial 
CFU were again assessed by agar plating as described in 5.2.4, with CFU standardised 
per ml. DNA was used in qPCR reactions as described in 5.7.1 – 5.7.2. 
 
6.4.2.2.1 Results for PCR quantification of mucosal bacteria - method two  
 
 Using method 2, excellent correlation was seen between crossing point and 
CFU (see figures 6.7 and 6.9). The coefficient of variation for the CFU enumeration 
process was similar and acceptable for both intra- and inter-experimental comparisons 
(Table 6.2). The fluorescence curves generated by qPCR of the DNA extracted and 
diluted from the initial E. coli HM605 suspension (1x10
9
 CFU/ml) are shown in 
figure 6.8 and the corresponding Cp in figure 6.9.  The fluorescence curves 
representing a range from 7.9 x 10
2
 to 2.2 x 10
5 
CFU/ml are very close together and 
do not reach the plateau phase, but do show increasing Cp value with increasing 
dilution. The black fluorescence curve, which represents signal in NTC (0 CFU/ml) 
 119 
has approximately the same signal as qPCR of DNA template extracted from a 
suspension of 2.2x10
5
 CFU/ml. 
 The implication from these curves was that more concentrated DNA 
extraction or template availability from the bacterial suspensions in the range of 
interest would be required to achieve adequate sensitivity as the dilution 
corresponding to the highest bacterial CFU numbers seen in previous CD biopsy 
studies (in the order of 3000 CFU per biopsy (232)) did not reach plateau.     
 
 
 
 
Figure 6.7  Demonstration of a linear relationship between CFU and dilution of 
bacterial suspension. Both axes are plotted logarithmically. Standardised CFU/ml 
versus bacterial suspension dilution, where each dilution is expressed as a value 
relative to the original (1) with 1/2 dilution = 0.5, 1/10 dilution = 0.1 etc) This gives a 
straight line (equation y=21851x
0.878
)  with correlation coefficient R
2
 = 0.983.  
 CFU/ml 
Dilution 
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Table 6.2  Coefficients of variation for the CFU plating component of 
standardisation methods 1 and 2. Co-efficients of variation (CV) for the colony 
counting technique used in methods 1 and 2. CV is equal to the standard deviation of 
a set of readings divided by the mean of that set of readings multiplied by 100.  
 
Analysis CV (%) 
Intra-method 1 (n 12) 18.28 
Intra- method 2 (n 12) 18.12 
Inter-experiment (N 2 series) 18.2 
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Figure 6.8  Fluorescence curves generated by qPCR of DNA extracted from E. 
coli bacterial suspensions using the Qiagen tissue minikit (method 2). The blue, 
red, and green curves represent standard dilutions of E. coli DNA corresponding to 
bacterial suspensions of approximately 10
9
,10
8
,10
7
 CFU/ml, (not plated) respectively. 
The other fluorescence curves moving from left to right are in the area of interest 
2.2x10
5 
to 790 CFU/ml, (or purple to orange). The black fluorescence curve 
represents signal in the NTC. 
NTC 
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Figure 6.9  Standard curve generated by method 2 - A standard curve was 
produced using the bacterial CFU suspensions 2.2x10
5 
to 790 CFU/ml, which had an 
efficiency of 2.814 (141%), and error of 0.298. The standard curve is generated by fit 
points analysis (all settings automated) using the LC480® software. Cp for each 
corresponding DNA template is plotted against log of standardised CFU/ml for 
bacterial suspensions. 
 
6.4.2.2.2 Conclusions regarding PCR bacterial quantification method two 
  
 Although the standard curve generated by this method was greatly improved 
relative to method one, with a PCR efficiency of 2.814 (141%), and an error of 0.298, 
and LOD of at least 2.2 x 10
5
 (figure 6.9), an alternative, more sensitive method for 
bacterial DNA quantification was needed.    
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6.4.2.3 Bacterial quantification method three – production of a 
standard curve following calculation of bacterial quantities using 
published genome size and spectrophotometry of bacterial DNA  
 
In order to improve assay sensitivity and precision, another technique for absolute 
quantification of bacterial numbers, which had been used previously in the literature, 
was attempted. This method utilises absolute genome numbers for bacteria (306), 
calculated from published bacterial genome size and accurate quantification of 
extracted genomic bacterial DNA quantity using the Nanodrop™ machine. Agar 
plating was not involved with this method and a DNA kit optimised for extracting 
bacterial DNA was used to enhance initial DNA template quantity. This was the 
Promega Wizard ® Genomic DNA Purification Kit (A1125) described in section 
5.3.3. This addressed the previous problems with sensitivity of the standardisation 
methods, as well as improving DNA extraction from bacteria and explored the effect 
of removing CFU quantification from the standardisation process.   
 
6.4.2.3.1 Quantification of bacterial genome copy numbers  
 
After DNA was extracted from multiple E. coli suspensions, these were quantified, 
and the sample with the highest purity and greatest concentration was used as 
template for the standard curve (385 ng/µl and Absorbance at 260 nm/280 nm ratio 
1.84). 
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E. coli genome numbers were calculated based on first principles: 
 
1) E. coli genome size = 4.7-5.1 Mbp, assumed to be 5.0 Mbp, and relative molecular 
mass (R.M.M.) of a DNA bp = 660 relative mass units 
Therefore E. coli genome RMM = 660 x 5x10
6 
= 3.3x10
9 
 
2) From formula for mass, RMM, and moles: 
Mass (g)/ RMM = number of moles 
Moles = 3.85 x10
-7 
g (the best DNA extraction quantity per µl found above) /3.3 x10
9 
= 1.17 x10
-16
 moles 
 
3) Avogadro’s number NA = number of molecules in a mole = 6.022x10
23 
Therefore molecules of E. coli genome present per µl DNA = 6.022x10
23
x 1.17x10
-16 
moles = 7.05 x 10
7
 genomes per µl. 
Therefore in the 5µl templates used in the PCRs this DNA concentration gives 
3.53x10
8
 genomes. 
 
 
 
6.4.2.3.2 Production of a standard curve for E. coli quantification by qPCR of E. 
coli linear genomic DNA vs PCR Cp 
 
The genomic E. coli DNA was serially one in ten diluted using PCR grade sterile 
water to produce a range of E. coli genome numbers between 3.53 and 3.53x10
8
, or 
DNA quantities between 3.85 fg l-1.  and 385 ng l-1. DNA template was used at 5µl 
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volumes in qPCR assays with PCR water (Roche) used as NTC. qPCR was performed 
on these E. coli DNA samples using SYBR green technology and uidA primers F1 R1 
(see table 5.1, chapter 5 and section 5.7.3). In addition to the E. coli genomic DNA, 
crudely extracted DNA (section 5.3.1) from bacteria which do not contain the uidA 
gene were also used as negative controls, namely Enterococcus faecalis, Citrobacter 
Rodentium, and Klebsiella pneumonia.   
Melt curve analysis was used with SYBR green qPCR to confirm the specificity of 
products.  
 
6.4.2.3.3 Results for bacterial quantification method three 
 
qPCR fluorescence curve results are shown in figure 6.10 with the resultant standard 
curve in figure 6.11 and melt curve analysis shown in figure 6.12. 
        Use of the uidA primers F1 R1 for qPCR of genomic DNA allowed clear 
differentiation of E.coli numbers from NTC, with a LOD of 3530 genomes or a DNA 
concentration of 3.85 pg l-1 (figure 6.10A). Enterococcus faecalis (HM65), 
Citrobacter Rodentium (HM481),  and Klebsiella pneumonia (HM 510) species had 
similar fluorescence signal to NTC (included in B), confirming that these species do 
not contain the uidA gene. Figure 6.10B shows that PCR templates containing 3.53 - 
3530 E. coli bacterial genome equivalents produced the same signal as NTC, 
suggesting that using uidA qPCR and genomic bacterial DNA, the limits of bacterial 
detection, or sensitivity, were being reached. Figure 6.11 demonstrates the standard 
curve produced by these genome standards used in qPCR. 
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The melt curve (figure 6.12) demonstrates a prominent peak for a unique product with 
a small secondary peak which encompasses a melt curve product produced by 
templates with Cp greater than or equal to NTC when used in qPCR. This may 
represent small amounts of E. coli, or non-specific PCR products, but quantitatively it 
is unlikely to have any significance. 
 
 
A 
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B 
 
Figure 6.10 qPCR fluorescence curves produced by E. coli genomes and negative 
bacterial controls used in quantification method three. 
 
uidA qPCR of E.coli genomes (red curves represent dilutions of E. coli genomic 
DNA, not all templates are shown for clarity). The LOD indicated represents 3530 
genomes or a DNA quantity of 3.85 pg l-1 A, with Enterococcus faecalis, (HM65) 
Citrobacter Rodentium,(HM481)  and Klebsiella pneumonia (HM 510) species having 
similar fluorescence signal to NTC (green curves included in B). Blue represents NTC 
(PCR water) in both A and B. 
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Figure 6.11  The standard curve generated using genomic E. coli DNA and the 
nanodrop to quantify bacterial numbers. PCR efficiency is 2.207 (110.35%) with 
an error of 0.896. 
 
Figure 6.12 Melt Curve demonstrating uniqueness of uidA amplicon product 
from genomic E. coli DNA. The second peak represents NTC and non E. coli 
bacterial species.  
 
 
 
 
 
Log 10 E. coli genomes 
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6.4.2.3.4 Conclusion for quantification method three  
 
Method three produced a standard curve with efficiency of 110.3%, with a LOD of 
3530 genomes and an error of 0.896. Therefore this method improved the sensitivity 
and efficiency of the assay, but the error value needed further improvement. 
  
6.4.2.4 Bacterial quantification method four – qPCR of the E. coli 
uidA gene amplicon cloned into pGEM®-T plasmid vectors 
 
As there was a large error value for the standard curve produced when genomic E. 
coli DNA was extracted and used in qPCR, despite acceptable efficiency, an 
alternative assay was used to improve performance using plasmid vectors which were 
beginning to become accepted as ‘gold standard’ for bacterial gene, and consequently 
bacterial quantification. 
            Method four involved insertion of a bacterial gene of interest in single copy 
into a plasmid vector, before using this ligated plasmid to transform cells. These cells 
were then incubated, with subsequent plasmid-amplicon DNA extraction and 
quantification of plasmid copies.  
 
5µl of genomic DNA, extracted using the Promega Wizard® Genomic DNA 
Purification Kit (A1125), was used as template to generate a high concentration of 
uidA amplicons (size 61 bp and 186 bp) using uidA primer pairs F2 R2 and F1 R1 
respectively (see chapter 5 table 5.1)  with standard conditions (see sections 5.7.3 and 
5.7.1 – 5.7.2).  
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6.4.2.4.1 Cloning of PCR products using pGEM®-T Promega vector systems 
 
PCR products were ligated into pGEM® -T vectors using the Promega ligation kit 
(A3600, see section 5.8.1), followed by transformation of chemocompetent or 
electrocompetent cells as described in sections 5.8.2.1 – 5.8.2.3.  Confirmation of 
successful transformation was by blue-white screen (5.8.2.4), qPCR, and restriction 
enzyme digestion (5.8.1 and 5.8.1.1 and figure 6.14), as a definitive way of 
demonstrating that the uidA amplicon was present in the plasmid. Successfully 
transformed bacterial cells were frozen down as clones for use as a long term source 
of plasmid DNA for standard curves. Plasmid DNA was extracted (5.8.3) and its 
concentration was measured, in order to perform the calculation to quantify uidA (and 
also 16S rRNA) amplicon-plasmid copy number.  
 
6.4.2.4.2 Electrophoretic confirmation of uidA amplicon insertion in plasmid 
DNA 
 
Following plasmid DNA extraction from cells, repeat qPCR was performed and the 
size of the amplicon was confirmed on an agarose gel (see sections 5.10). The results 
for uidA amplicons generated using uidA primers F2 R2 and uidA primers F1 R1 are 
shown in figure 6.13. This demonstrates that uidA amplicons of expected size were 
inserted into transformed cells  
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Figure 6.13 DNA electrophoresis following PCR amplification of plasmid DNA to 
confirm uidA amplicon insertion. 3.5% DNA agarose gel in TAE. Lane 1,2, and 5: 
Plasmid -amplicon 2 DNA. Lanes 3 and 4: Plasmid – amplicon 1 DNA. M: Marker 
lane, Hyperladder V, 25-500bp. Primers used to generate and confirm amplicon 
insertion were uidA primer pair F2 R2, with amplicon size 61 bp, and uidA primer 
pair F1 R1, with amplicon size 186 bp. See chapter 5 Table 5.1. 
 
 
6.4.2.4.3 Restriction enzyme digestion to confirm uidA amplicon insertion in 
plasmid DNA  
 
The method for restriction digestion is described in section 5.8.1.1, and this was 
followed by electrophoresis. The result is shown in figure 6.14. This technique was 
used with the plasmid into which uidA amplicon 2 DNA was cloned (figure 6.13). The 
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restriction enzymes cut on either side of the uidA amplicon within the circular pGEM-
T plasmid. A single cut is produced by both enzymes, so that when a single enzyme is 
used a linear piece of DNA (3061 bp size) is produced, with two enzymes producing 
two fragments of DNA (3000, and 61 bp approximately, the sizes of the plasmid 
vector and the inserted amplicon). Control lanes include ‘no restriction enzymes’ and 
each enzyme used in isolation.  
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Figure 6.14  Restriction enzyme digest of plasmid uidA amplicon 2 DNA 
extracted from transformed electrocompetent cells. 2% DNA agarose gel in TBE, 
showing plasmid DNA digested using restriction enzymes  (SpeI and SacII). Lane 1 
and 3: Double restriction enzyme digest using both SpeI and SacII enzymes. Lanes 2 
and 6: Plasmid DNA only, no restriction enzymes. Lane 4: SpeI enzyme alone, Lane 
5: SacII enzyme alone. M: Marker lane, Hyperladder I, 200 - 10000bp. 
 
6.4.2.4.4 uidA amplicon-plasmid copy quantification (examples) 
 
Using this method, it was important to precisely calculate the amplicon-plasmid copy 
numbers in each DNA simple, and this was acheived by firstly calculating the molar 
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mass of the plasmid with the additional amplicon inserted (whichever amplicon this 
was), based on the known molar mass of a base pair and known amplicon and plasmid 
size. Amplicon-plasmid copies were then calculated using the expressions relating 
DNA mass (quantified with Nanodrop™), moles, molar mass, and Avogrado’s 
number below. 
 
A) Calculation based on the use of uidA primers F2 R2 to generate an amplicon. 
 
The quantified DNA concentration for the uidA amplicon-plasmid was 122 ng/µl. The 
pGEM®T plasmid is 3000 DNA bp in size and when the uidA amplicon is inserted 
after ligation becomes 3061 bp in size.  
1) Therefore RMM of the plasmid is 660 (Mr of a DNA bp) x 3061= 2.02 x10
6
 
RMU 
2)  As moles = mass/RMM then 1.22 x10-7 /2.02 x106 = 6.06x10-14 moles per µl 
3) Using Avogrado’s no: molecules of plasmid-uidA insert = 6.022x1023 x 
6.06x10
-14 
=  3.65x10
10
 copies plasmid-uidA/µl  
4) Hence in 5µl of plasmid DNA there are 5x 3.65x1010 copies plasmid = 
1.83x10
11
 copies plasmid-uidA gene 
 
All of the plasmid calculations are based on the reasonable assumption that the 
pGEM-T plasmid only accepts one amplicon into its ligation site. 
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(B) Calculation based on the use of uidA primers F1 R1 to generate an amplicon.  
 
When the uidA primers F1 R1 were used to generate an amplicon, two plasmid DNA 
extractions were performed on the bacterial clones formed using the amplicon 
generated. The same principles as the above calculation were used with the important 
difference that the uidA amplicon-plasmid size was now 3186 bp. 
 
6.4.2.4.5 qPCR of non linearised uidA plasmids 
 
Plasmid DNA exists in multiple forms including supercoiled, nicked circular, and 
linear, which have different migration rates under electrophoresis, and can easily be 
purified separately from genomic DNA. Once the insertion of the uidA amplicons in 
plasmid DNA was confirmed, the extracted plasmid DNA was first evaluated in 
circular form. qPCR was performed as described in section 5.7.4.   
 When uidA primers F1 R1 were used to generate an amplicon (the uidA 
amplicon-plasmid size was now 3186 bp, 3000 bp plasmid + 186 bp amplicon) and 
transform cells, ultimately the plasmid DNA extraction produced a DNA 
concentration of 358.8 ng µl
-1
. This resulted in uidA gene copy numbers of
 
5.14x10
11
 
genes, when 5µl of undiluted plasmid-amplicon DNA was used as template in qPCR. 
 The results for the fluorescence and standard curves produced by qPCR of 
non-linear plasmid DNA are shown in figures 6.15- 6.18.  Results differed depending 
on the amplicon used. For amplicon 1, the assay gave a lower limit of discrimination 
from NTC samples of 5.14x10
8
 genes, (figure 6.15) and the fluorescence signals from 
the probiotic bacterial controls were equivalent to those seen with NTC, or PCR 
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negative. The melt curve obtained from the qPCR of the plasmid uidA amplicon 1 
DNA shows a unique product confirming the specificity of the reaction (figure 6.16).  
 When DNA containing the uidA amplicon 2 was quantified, the concentration 
for the uidA amplicon-plasmid was 122.37 ng/µl. The pGEM®T plasmid is 3000 bp 
in size and when the uidA amplicon is inserted after ligation becomes 3061 bp in size. 
Using the calculation described in section 6.4.2.4.4, 5µl of plasmid DNA has 5x 
3.65x10
10
 copies of plasmid = 1.83x10
11
 copies plasmid-uidA gene. When used in 
qPCR (figure 6.17) the lower limit at which non linear plasmid DNA template can be 
distinguished from NTC is 1.83x10
4
 gene copies, or a DNA quantity of 61 fg l-1. The 
standard curve for this series is shown in figure 6.18. 
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Figure 6.15 Comparison of the fluorescence curve genrerated by non-linearised 
plasmid uidA amplicon 1, NTC, and probiotic bacteria. 
The pink fluorescent curve shows the lowest concentration of non-linearised plasmid 
uidA amplicon 1 template that could be visibly discriminated from NTC, i.e. 5.14 x10
8
 
gene copies, or 1.79 ng DNA in 5l. The fluorescence signals from the probiotic 
bacterial controls are equivalent to those seen in NTC, or PCR negative. 
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Figure 6.16  Melt curve obtained using uidA amplicon 1 plasmid DNA. Melt curve 
analysis of the uidA amplicon 1 plasmids shows the specificity of the qPCR product 
(i.e. a single peak). 
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Figure 6.17 Fluorescence curves generated using plasmid uidA amplicon 2 DNA 
in qPCR. When plasmid uidA amplicon 2 DNA was assessed with uidA primers F2 
R2, a lower LOD of 1.83x10
4
 gene copies (or bacteria), or DNA concentration of 61 
fg l-1 was seen.  
 
 
 
Figure 6.18 The standard curve generated from non linear plasmid uidA 
amplicon 2 DNA. Error 0.448, efficiency 2.158 (108%).  
 
 
Log10  uidA  genes 
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6.4.2.4.6 Conclusion for the use of method four with non linearised plasmid DNA 
 
For plasmid DNA containing amplicon 1, the efficiency of the reaction could not be 
calculated for these templates, and the LOD was unacceptable for the assay at 
5.14x10
8
 gene copies. For plasmid DNA containing amplicon 2 the qPCR produced 
an error of 0.448, an LOD 1.83x10
4
 gene copies, and an efficiency of 2.158 (108%), 
so despite improvements in efficiency and LOD, both the error and sensitivity needed 
further optimisation. 
 
6.4.3 Linearisation of uidA amplicon containing plasmids. The definitive assay 
for E. coli quantification  
 
The sensitivity of the assay was improved to the required level by linearization of the 
DNA template. When supercoiled plasmid DNA is linearized, the multiple plasmid 
DNA forms become identical in their linear structure. DNA physical template 
accessibility is greater and theoretically similar, and efficiency is improved compared 
to amplification from supercoiled plasmid forms (320), which may also therefore 
theoretically improve sensitivity. Figure 6.19 illustrates a representative example of 
linearization of plasmid DNA, in this case two separate samples of the same plasmid 
uidA amplicon 1 construct, one of which is successfully linearised. 
 The uidA amplicon 1 and uidA amplicon 2 plasmids were linearised with 
restriction enzymes (see section 5.9). Non-linearised plasmid DNA was 
electrophoresed alongside the linearised plasmid DNA in the gel electrophoresis as a 
control. When DNA ladders were used, their sizes were only applicable to linearised 
DNA, as the multiple forms of circular plasmid DNA migrate through agarose gel at 
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different rates which are not identical to their linearised sizes.  Linearisation was a 
logical step as linearisation of plasmid DNA potentially increases template 
availability to qPCR reagents. Importantly, when plasmid DNA was linearised, the 
uidA gene quantity was diluted to one quarter of the pre-linearised amount (explained 
in section 5.9). 
 The linearised amplicon 1 plasmid was used for qPCR, and the same plasmid 
DNA was also assessed with the nested uidA primers F3 R3 (see table 5.1, chapter 5, 
and methods section  5.7.3. Similarly, the linearised uidA-amplicon 2 plasmid DNA 
was used in qPCR using uidA primers F2 R2 (section 5.7.1 and 5.7.2), and the results 
are shown in figure 6.20. The results were promising, so the qPCR was repeated to 
assess reproducibility of the uidA quantification assay and to allow assessment of 
coefficient of variation.  
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Figure 6.19 Figure showing representative examples of linearised uidA amplicon 
containing plasmid DNA. 1% DNA agarose gel in TAE.  
Lane 1: Successfully linearised plasmid-amplicon 1 DNA. Lanes 2-4: appearance of 
non-linearised plasmid-amplicon 1 DNA. M: Marker lane, Hyperladder I, 200-
10000bp. 
Successfully linearised plasmid DNA is demonstrated as a single band, with a single 
restriction enzyme cut of plasmid DNA at 3186 bp as expected. Non-linear plasmid 
DNA exists in multiple forms and also cannot be directly ‘sized’ according to the 
hyperladder marker bands, which are linear. Single rather than the double band 
appearance is seen after a successful linearisation.  
  
qPCR of the successfully linearised plasmid uidA amplicon 1 DNA produced 
increased sensitivity with a lower LOD of 2.11x10
5
 uidA gene copies. The PCR 
efficiency value was extremely unacceptable though, at 29.87 (1494%) with an error 
of 0.841 (results not shown). The same plasmid DNA was assessed with the nested 
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uidA primers F3 R3 in an attempt to increase efficiency using this smaller amplicon. 
This gave the same lower limit of detection with unacceptable efficiency (338.2) with 
an error of 0.668 (results not shown). This assay was therefore also not useable. 
 
6.4.3.1 Use of the linearised plasmid uidA amplicon 2 DNA in qPCR to quantify 
E. coli, the definitive assay 
 
The successfully linearised uidA amplicon 2 plasmid was used as template in the final 
standardisation experiment, to prepare suitable DNA standards by which E. coli 
bacteria could be accurately quantified from CD and control patient ileocolonic 
biopsies, in clinical trials (see chapter 7). This was a key experiment as it established 
an effective assay. Figure 6.20A shows the results obtained when the linearised 
plasmid uidA amplicon 2 DNA templates were used, and figure 6.20B shows the 
correlation coefficient between mean Cp and log10 uidA gene number. Figure 6.20A 
demonstrates that 1140 uidA gene copies, and by inference 1140 E. coli bacteria, or a 
DNA quantity of 1.52 pg per 5 l template, could easily be distinguished from NTC 
using these qPCR fluorescence signals. PCR efficiency (104%), error (0.130), and 
correlation coefficient (0.995) were all within acceptable limits. 
 On a second occasion the experiment was performed with the same templates 
the PCR efficiency was 2.132 (106%), error 0.096, and correlation coefficient 0.997, 
again within acceptable limits (not shown). Overall co-efficient of variability for Cp 
and log uidA gene numbers for the standard curve assay performed twice, n=6, was 
3.72%. 
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A 
  
B 
 
Figure 6.20 Linearised plasmid uidA amplicon 2 fluorescence curves (A), and  
correlation co-efficient (B). The linearised plasmid uidA amplicon 2 DNA LOD was 
1140 uidA genes with PCR efficiency of 2.07 (103.7%), error of 0.130 and correlation 
co-efficient (R
2
) of 0.995. The 5l plasmid DNA uidA templates shown represent 1.52 
pg to 15 ng of DNA, or 1.14 x10
3
 to 1.14 x10
8 
gene copies. The blue line represents 
NTC PCR water. 1140 uidA gene copies = 1140 E. coli bacteria present, assuming 1 
copy of uidA per genome in bacteria and one copy per plasmid DNA molecule.  
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A schema for the overall process used as ‘gold standard’ to absolutely quantify 
uidA and/or other future candidate genes is shown below 
 
Figure 6.21 Schema of method for absolute quantification of bacterial gene 
numbers using plasmid-amplicon DNA to generate standard curves 
 
6.4.3.2 Conclusion for the use of quantification method four with linearised 
plasmid DNA  
 
qPCR of the linearised plasmid uidA amplicon 1 DNA produced a lower LOD of 
2.11x10
5
 uidA gene copies but with a PCR efficiency value of 29.87 (1494%) with an 
error of 0.841. The same plasmid assessed with the uidA primers F3 R3  gave the 
same LOD with unacceptable efficiency (338.2) with an error of 0.668.  
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Finally, qPCR of the linearised uidA amplicon 2 DNA demonstrated an LOD 
of 1140 uidA gene copies, PCR efficiency 104%, error 0.130, and a correlation 
coefficient of 0.995. with reproducibility (CV) <20%. When the standards were used 
to quantify bacteria in human biopsies, (see chapter 7), the same reproducibility in 
standard templates was seen between runs, so the main aim of the assay development 
described in this chapter was achieved. Thus the assay has been shown to have a 
sensitivity of 1140 uidA genes, or the lowest quantity of E.coli bacteria detectable in a 
human biopsy using this assay is 1140.  
 
6.4.4 Application of method four to quantify total bacteria (16S 
rRNA genes) 
 
As quantification method four was the most successful method for quantification of 
bacteria, this method was applied to quantify total bacterial numbers as a denominator 
for E. coli using the 16S rRNA gene primers and the pGEM®-T plasmid technology. 
 
The same techniques as were used to generate the E. coli DNA standard curves were 
used to generate standard curves intended to be used to quantify eubacterial (total 
gastro-intestinal bacterial) numbers. A region of the 16S rRNA gene was used as a 
target for quantification as it is common to all bacteria. The 16S rRNA F/R primers 
(table 1, chapter 5) were used with the reaction conditions described in section 5.7.5 
to produce the amplicon of interest which was ligated into the pGEM®-T plasmid. 
Any gastro-intestinal bacteria could be used to generate this curve, (as all have the 
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16S rRNA gene sequence used), but for convenience E.coli genomic DNA was used 
(as 5.3.3). 
 The ligated plasmid-amplicon DNA was used to transform ultra-competent 
cells (as per section 5.8.2.1) before plasmid DNA was extracted from these bacterial 
clones (as 5.8.3) and quantified.   The 16S rRNA-plasmid DNA was then serially ten 
fold diluted for use in a standard curve. Once the 16S rRNA amplicon was generated 
from the plasmid DNA by qPCR, its size was confirmed by gel electrophoresis 
(section 5.10).The 16S rRNA gene copy number was calculated as per uidA using the 
equation in 6.4.2.4.4. 
 
6.4.4.1 The effect of using different template volumes in the 16S rRNA qPCR 
quantification assay 
 
Two different template volumes were used for this assay. The same template DNA 
dilutions were used, but in one assay 3µl volume template was used, and in the second 
5µl.  This was an attempt to see if DNA could be preserved. This could eventually be 
valuable when DNA was extracted from human biopsy samples. When 3µl of 
template was used, 2µl of PCR water was added as a volume control. It was expected 
that a high abundance of 16S rRNA genes would be present in colonic biopsies 
making this a feasible assay to attempt with lower template volume. In addition, the 
plasmid was also linearised, (see method section 5.9) and results (figure 6.22), to 
improve sensitivity.   
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6.4.4.2 Results for the quantification of total eubacteria (16S rRNA genes) 
 
The 16S rRNA amplicon was successfully ligated into pGEM-T plasmid DNA and 
used to transform ultracompetent cells. The quantity of plasmid DNA extracted from 
these transformed cells at the initial attempt was 17.4 ng/µl and with a plasmid-
amplicon size of 3200 bp, 4.961x10
9 
plasmid-16S rRNA gene copies were present per 
µl of plasmid DNA in neat template.  
When the diluted 16S rRNA plasmid DNA was used in qPCR to generate 
standard curves, the PCR quantification parameters were unacceptable, with the best 
result (see figure 6.23 for fluorescence and melt curves, the standard curve is not 
shown) seen with a 5 µl non-linearised plasmid DNA template.  5µl templates 
represented 2.48 x 10
10
 16S rRNA genes or a DNA concentration of 87 ng in the most 
concentrated dilution.   
 
In this case linearisation did not improve the assay sensitivity and the best result had a 
sensitivity of 2.48 x10
6
 bacteria or DNA quantity of 8.7 pg per 5 l template. The 
efficiency was 1.831 (91.6%), with an error of 0.57. The results for 3 µl 16S rRNA-
plasmid DNA and linearisation templates used in qPCR are not shown.  
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Figure 6.22 Linearisation of the 16S rRNA gene containing plasmid.  
1% DNA agarose gel in TAE. Lane 1: successfully linearised 16S rRNA Plasmid-
amplicon DNA. Lane 2: non-linearised 16S rRNA plasmid DNA. M: Marker lane, 
Hyperladder I 200-10000bp. Plasmid DNA containing the 16S rRNA amplicon exists 
in multiple forms (hence two bands) and does not equate to bp sizes in the linear 
hyperladder marker, but when linearised by restriction enzyme, exists as a single 
appropriately (3200 bp) sized product. 
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Figure 6.23 Best result for 16S rRNA gene eubacterial assay fluorescence curves 
(A). The 5 l templates shown represent a range between 2.48 x 105 and 2.48 x1010 
16S rRNA genes, or DNA quantities between 0.87 pg and 87ng. The lower LOD was 
2.48 x10
6 
, with error of 0.57 and an efficiency of 1.831 (91.6%). The melt curve 
below (B), shows a unique product is formed when plasmid DNA is amplified by 
PCR. 
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6.4.4.3 Conclusion for the 16S rRNA total bacterial assay 
 
The best result for the 16S rRNA assay had a sensitivity of 2.48 x10
6
 bacteria, which 
would probably have been utilisable for the expected total bacterial numbers in human 
biopsies (see section 6.2.1.1, an average magnitude of 4.84 x 10
7
 bacteria would be 
expected per biopsy). The efficiency was acceptable at 1.831 (91.6%), but the error 
(defined in section 6.2.2.3) of 0.57 was not. This assay would require further 
optimisation before use with human biopsy tissue, for example optimising primer 
concentrations or amending Lightcycler® thermocycling conditions. 
 
6.4.5 Method for the human cell denominator assay – quantification 
of 18S rRNA genes (human ribosomal genes) for biopsy 
standardisation 
 
To standardise for biopsy size in the clinical trial, alongside mass measurement (after 
mucus removal), the 18S rRNA ‘housekeeping’ gene was used. It has been used 
previously for ileal biopsy standardisation (218), in order to express E. coli numbers 
per million 18S rRNA genes (or human cells). There is some question as to whether 
the 18S rRNA gene copy number would be increased in inflamed tissue independent 
of biopsy size as increased levels of inflammation are associated with increased 
numbers of non-epithelial human inflammatory cells, and for this reason standard 
biopsy wet weight was also measured. The 18S rRNA Eurogentec control kit (RT-
CKFT-18S) was used as per kit instructions (see section 5.7.6).  
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6.4.5.1 Results for the human cell denominator (18S rRNA gene) assay 
 
The commercial kit worked well, and was straightforward in comparison to the 
bacterial assays. The fluorescence curves generated by serial dilution of the human 
genome DNA on the first occasion are shown in figure 6.24, with the corresponding 
standard curve assessed by qPCR Cp curve fit points in figure 6.25A, and the 
correlation coefficient illustrated in 6.25B. A second run confirmed reproducibility, as 
did the templates’ use in clinical trials (see chapter seven); the CV after the second 
run was 2.84%.   
 
 
 
Figure 6.24 Fluorescence curves produced by the 18S rRNA genome standards. 
Human genomic DNA (Increasingly dilute left to right, with template quantities of 5 
to 50000 genomes or 1x10
3
 to 1x10
7 
18S rRNA gene copies shown). Blue curves 
show NTC (PCR grade water). The lower limit of detection is 5 genomes (200 copies 
of gene per genome)   
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A 
 
 
B 
 
Figure 6.25 standard curve derived from Cp’s of fluorescence curves from 18S 
rRNA qPCR. Cp is plotted against log10 of 18S rRNA gene number in these graphs.  
 (A) The standard curve produced has an efficiency of 2.074  (104%), and an error of 
0.185. The calculated correlation coefficient is 0.992 (B) 
 
. 
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6.4.5.2 Conclusion for the human 18S rRNA quantification assay 
 
With a sensitivity of 5 human genome copies, efficiency 104%, error 0.185, 
correlation coefficient 0.992, coefficient of variability 2.84% and reproducibility 
<20%, the human 18S rRNA assay met all requirements for use in the clinical trials 
(see chapter 7). 
 
6.5 Summary of qPCR assay performance 
 
The statistical performance of all of the assays used in this chapter to quantify E.coli 
bacteria, whether based on CFU counting as a component, calculation of quantities 
using published genome sizes, or the use of modified plasmid techniques for 
quantification, are summarised in table 6.3. These statistical parameters are defined in 
section 6.2.2. The optimum statistical performance  of the 16S rRNA and human 18S 
rRNA assays are summarised in table 6.4. 
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Summary Table 6.3  Performance of assays for uidA genes  
 
The assays were initially assessed on the criteria of sensitivity, efficiency, and qPCR 
error, and where these were inadequate, the correlation coefficient, and CV (or  
reproducibility) of the assay were not assessed. Inter-assay CFU CV was assessed as 
it was informative at an early stage. 
*** means that the assay was used for tissue biopsies in clinical trials. 
 
Method  Sensitivity Efficiency 
% 
Error Correlation 
coefficient 
Coefficient of variability 
% 
Crude extraction DNA, 
Method 1 
?3.3x10
5 
CFU 
59.1 0.383  18 for CFU plating 
Qiagen kit DNA 
extraction, Method 2 
?2.2x10
5 
CFU 
141 0.298  18 for CFU plating 
Use of bacterial  
genomes, Method 3 
3530 
genomes 
110.35 0.896   
Method 4 – non linear 
plasmid uidA amplicon 1 
5.14x10
8
 
genes 
    
Method 4 – non linear 
plasmid uidA amplicon 2  
1.83x10
4
 
genes 
108 0.45   
Method 4 -Linearised 
plasmid uidA amplicon 1 
2.11x10
5
 
genes 
1494 0.841   
Method 4 – Linearised 
plasmid uidA amplicon 
1, nested primers 
2.11x10
5
 
genes 
16910 0.668   
Method 4 – Linearised 
plasmid uidA amplicon 2 
*** 
1140 
genes 
104 0.130 0.995 3.72 
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Summary Table 6.4  Performance from the 16S rRNA gene and 18S rRNA gene 
assays 
 
The assays were initially assessed on the criteria of sensitivity, efficiency, and qPCR 
error, and where these were inadequate, the correlation coefficient, and 
reproducibility (CV), of the assay were not assessed.  
*** means that the assay was used for tissue biopsies in clinical trials. 
  
Method  Sensitivity Efficiency 
% 
Error Correlation 
coefficient 
Coefficient 
of variability 
% 
16S rRNA 
genes 
(plasmid 
amplicon)    
2.48x10
6
 
genes 
91.6 0.57   
18S rRNA 
genes 
control kit 
*** 
5 genomes 
(1000 gene 
copies) 
104 0.185 0.992 2.84 
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6.6 Discussion 
 
 This qPCR assay was developed to examine the quantities of E. coli in colonic 
tissue from areas of inflamed and uninflamed intestinal biopsy tissue from patients 
participating in clinical trials which would include periods of relapse and remission. 
This would also afford the opportunity to quantify change in E. coli numbers with 
histological findings and clinical state (see chapter 7).    
 The development of an assay for absolute quantification of E. coli uidA genes 
(and hence E. coli bacteria) using qPCR, involved a lengthy process of evaluation of 
multiple techniques. The crucial issues were assay sensitivity and accurate DNA and 
gene copy quantification. 
 
6.6.1  Sensitivity and absolute quantification   
 
In a previous study molecular quantification (218) of uidA genes in CD ileal 
and colonic tissue generated 0.5-5x10
6
 uidA genes per million human cells in ileal 
biopsies and approximately 1.25x10
4
 cells in colonic tissue, with 0.75x10
4
 uidA genes 
in healthy tissue. The biopsies used in this work, which also involved mucus removal, 
unlike the previous study (218), overall produced an average of 187000 18S rRNA 
genes per biopsy, or 937 human genomes (cells) per biopsy (as there are 200 18S 
rRNA genes per human genome). Basing calculations on the results of (218) which 
they expressed as uidA genes /million human cells, one would expect 469–4690 uidA 
genes from DNA extracted from ileal tissue and 11.7 uidA genes per biopsy of colonic 
tissue, with 7 uidA genes in control tissue for average biopsy size. When human 
biopsy tissue had been analysed,  standard biopsy mass (wet weight) was found to be 
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between 8-115 mg at the extremes of  sampling in clinical trials evaluating CD and 
control tissue biopsies (n=54, mean mass 48.4 ± 3.8 mg SEM (Chapter 7).  
In terms of quantifying bacteria using CFU, the numbers likely to be of 
interest in CD, identified from previous laboratory work were  0 – 3000 CFU per 
biopsy (232) but these figures include all aerobic bacterial species cultured and not 
simply the E. coli identified specifically by the uidA gene. 
In one study looking at uidA genes in twins (226), the uidA gene numbers are 
expressed per 10
6 
16S rRNA genes, at levels of log 1.3-4.5 (or 20-31600), but the 
authors state that this is when E. coli was detectable, and that levels of  E. coli were 
significantly higher in patients with ileal CD than colonic CD.  In support of this work 
however, the authors also conclude that when E.coli was detectable for either colonic 
or ileal disease it was present at all areas of the gastrointestinal tract (ileum, ascending 
colon, transverse colon, descending colon and rectum). This serves to illustrate that 
often different studies use a different denominator, which makes direct comparison 
difficult for microbial ecology and absolute quantification, and also suggests that the 
uidA genes were sometimes undetectable. Without knowing the average 16S rRNA 
gene numbers present in a biopsy in CD tissue, it was difficult to know what E. coli 
numbers to expect and plan assays for. In healthy control tissue in the same (226) 
study uidA genes were detected but only, where detected, at levels of log 1.2 -2.5 (or 
15.8- 316) per 10
6 
16S rRNA genes. Significant variance was clearly seen as in one 
twin pair with ileal CD, one individual did not have uidA genes identified at all. 16S 
rRNA gene copies were also expressed in the twin study per β-globin gene present. 
Whilst it is valid to use a housekeeping gene, the differing denominators for each 
gene quantity expressed make direct comparison difficult, and ultimately one of the 
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improvements of the assay in this work is that it could be directly compared with most 
studies as each component examined was independently absolutely quantified.  
 Utilising FISH gives at best semiquantitative answers. One study (311) 
produced FISH images for various categories of mucosal bacterial concentrations, but 
in the results the authors remarked that accurate quantification could not be achieved, 
particularly in the tissues with high bacterial concentration. In the same study 16S 
rRNA genes were looked for with 10
3
-10
6
 CFU/l found, but not in all patient groups 
and generally in less than 83% of patients. Analysis of the spatial arrangement of 
bacteria and a visual representation of their abundance is certainly possible (218), but 
the data in the Swidsinski study are not obtained using absolute quantification, and are 
categorical data. This data gives only a broad indication of potential bacteria present 
(<1000, 1000-10000, and >10000 CFU/µl). Other authors have attempted to quantify 
E. coli and other bacterial numbers by specifying the % of biopsies examined with the 
specified bacterial species present within the tissue, without quantifying the actual 
quantity within each biopsy (200). This is also therefore a categorical measure. 
Eventually it was decided that the best solution was to aim for the maximum 
sensitivity possible for an absolute quantification assay (three bacteria), but that 
acceptable figures would be those approximating 1000 bacteria with acceptable 
reproducibility or CV (aim <20%). In terms of PCR performance targets were 
efficiency between 90-110%, error <0.2 and correlation coefficient >0.95, which were 
all eventually achieved. This was very difficult and pushed the limit of detection for 
qPCR to the extreme. 
 The first quantification method resulted in a very poor standard curve. This 
may have been due to the crude method of DNA extraction used, which would have 
given even lower yield when each bacterial suspension was diluted. The fact that CFU 
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counting can be inherently variable did not help this attempt at the assay. The assay 
was clearly improved using method two when an efficient commercial kit for DNA 
extraction was used, but this still resulted in an unacceptable assay that was not 
sensitive enough, with poor efficiency and error, key factors in PCR. 
 With a switch to purely molecular techniques there was removal of some of 
the variability seen when using methods involving CFU counting. The published 
genome size of E. coli, along with accurate quantification of extracted DNA using the 
Nanodrop ™, allowed good approximation of bacterial quantities, with a technique 
similar to (306). Unfortunately, this ultimately produced an assay with unacceptable 
error despite good efficiency and lower limits of detection (3530 copies). 
 
6.6.2 The successful development of a PCR method for bacterial quantification in 
human intestinal biopsy tissue 
 
 Finally, the use of plasmid technology produced the definitive solution. The 
multi-step process of producing a suitable amplicon, splicing it into DNA, 
transforming cells to accept plasmid DNA and ultimately extracting the plasmid DNA 
from these clones and confirming the presence of the amplicon by qPCR with or 
without restriction enzyme digest was complicated, but meant that bacterial numbers 
could be quantified with great precision using these standards for our template DNA. 
This was rewarded when an assay was produced with appropriate sensitivity, 
efficiency, reproducibility, and correlation coefficient. The linearisation of the 
plasmid template proved important for the uidA assay, but irrelevant to the attempted 
16S rRNA gene assay. This technique is regarded as the gold standard currently 
(309;310) and it is in general vital to linearise plasmid DNA, as plasmid secondary 
 161 
and tertiary structure can preclude against sensitive target sequence annealing. The 
‘gold standard’ technique of inserting a gene of interest into a plasmid and using this 
to construct a standard curve for target sequence copy number can also produce an 
over-estimation of gene numbers if the plasmid DNA is left in the supercoiled circular 
non-linear form, because PCR amplification is less efficient when DNA is in this form 
(320) in the early stages of PCR amplification. 
 
6.6.3 Definition of the lower limit of detection 
 
It became clear that it was important to define a lower limit of detection for 
the assay and this was simply defined as the limit where a fluorescence curve for a 
given template could be clearly and repeatedly differentiated from a PCR non-
template water control and also form part of a set of repeatedly useable templates that 
satisfied the statistical requirements for the PCR assay. The difficulties involved in 
looking at the lower limit of detection in qPCR are discussed in the literature. The use 
of low copy number template (317) problems with NTC, its non normal distribution 
and the artificial assignment of an end cycle number are subjects of current review 
(321). qPCR data is ‘non-normal’, censored and heteroscedatic (314) and its limit for 
magnitude of low copy detection is 1000 fold lower than standard endpoint PCR 
which argues against running gel electrophoresis to delineate LOD after qPCR has 
been performed. All appropriate statistics and methods are provided so that these 
assays  can be reproduced, consistent with good qPCR practice and MIQE standards.   
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6.6.4 Utilisation of plasmid technology for 16S rRNA gene quantification  
 
 Given its successful application to uidA quantification, it was appropriate to 
use the plasmid technology for other assays. The 16S rRNA gene assay reached the 
stage of development where a suitable clone had been produced for plasmid DNA and 
linearised, but when the plasmid DNA templates were used the qPCR did not reach 
acceptable performance statistics. Primer selection (as seen when different 
concentrations of primers were used with the uidA assays) and alteration of qPCR 
reaction conditions could improve this, though template quantity did not prove a 
crucial factor. Optimisation of this assay would provide useful denominator 
quantification of all bacteria present in biopsy DNA, and allow assessment of 
bacterial subset percentage changes in CD human tissue at different longitudinal 
timepoints and at different levels of disease activity. 
  
6.6.5 The use of the 18S rRNA assay for standardisation of human cell numbers 
  
In contrast to the other assays the human 18S ribosomal RNA assay, which had been 
used in a previous study (218), was straightforward. Its use as a housekeeping gene to 
standardise human tissue amounts was combined with standard biopsy mass 
measurement when CD biopsies were processed. The inflammatory cells involved in 
active CD lesions may produce an increase in 18S rRNA gene numbers which may be 
disproportionate to actual biopsy mass, so it was important to make both these 
measurements to allow for assessment of any disparity.  
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6.7 Conclusion 
 
After a long, difficult process of development, the use of linearised plasmid vectors to 
quantify E. coli bacteria proved the most sensitive, accurate and reproducible method 
used. Selection of appropriate primers to amplify a segment of the uidA gene, and 
accurate DNA quantification, also proved key. Molecular based techniques that did 
not include CFU enumeration proved more useful than those which did. Both the E. 
coli, and human 18S rRNA gene assay used as a denominator, fulfilled the statistical 
requirements specified for these assays, and were therefore used to perform absolute 
quantification on CD and control intestinal biopsy tissue in the plantain clinical trial 
and aphthous ulcer study (chapter 7).    
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CHAPTER SEVEN : QUANTIFICATION OF MUCOSA-
ASSOCIATED BACTERIA IN CROHN’S DISEASE  
DURING RELAPSE AND REMISSION 
  
7.1 Hypotheses:  
 
As aphthoid ulcers are probably the earliest lesions seen in active CD, the putative 
causative agent of CD, adherent, invasive E. coli, will be increased in number in these 
lesions in both human ileal and colonic tissue compared with control tissue.  
 
As any invading bacteria, including E. coli, are likely to invade through the 
specialised M cells in the epithelium overlying Peyer’s patches and lymphoid 
follicles, the aphthoid ulcers containing bacteria are most likely to be found overlying 
Peyer’s patches or lymphoid follicles. 
 
Greater quantities of E. coli can be expected to be present in tissue where patients 
show increased disease activity and when they have macroscopic or microscopic 
intestinal inflammation.  
 
Ingestion of soluble plantain fibre, by blocking recruitment of bacteria to the gut 
epithelium may be associated with a reduction in mucosa-associated E. coli.  
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7.2 Aim:  
 
To utilise qPCR to evaluate the number and distribution of bacteria within CD and 
control tissue, at different stages of disease activity. 
 
7.3 Section A. Effect of  dietary Soluble Plantain fibre on mucosal 
bacteria in Crohn’s disease 
 
The hypothesis that bacterial-epithelial interactions may be lectin-carbohydrate 
mediated, and may be inhibitable by soluble plant fibres is currently under ongoing 
investigation by our group. A number of soluble plant fibres, including particularly 
soluble plantain (banana) fibre, have been shown to inhibit adhesion of E. coli to the 
intestinal mucosa (232) as well as the translocation of CD E. coli
 
across M cells and 
follicle-associated epithelium, the likely portal of entry for AIEC in CD intestinal 
tissue (322). This has obvious potential therapeutic benefit in arresting the events that 
induce mucosal inflammation in CD. In areas of the world where plantain fibre is 
consumed in large amounts, such as Africa, India and the West Indies, CD is rare. 
These in-vitro and epidemiological observations have led to the development of a 
randomised double blind placebo controlled clinical trial of plantain fibre 
supplementation to CD patients at this institution (University of Liverpool and the 
RLBUHT NHS Trust). This allowed investigation by analysis of clinical trial biopsies 
using the qPCR methods developed in chapter 6, correlated with endoscopic, 
histological, and clinical assessment.  
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7.3.2 Methods 
 
7.3.2.1 Randomised double blind controlled trial of soluble plantain fibre in 
maintenance of CD remission  
 
This trial had full ethics approval (EudraCT number: 2006-005526-23, REC reference 
: 07/H1002/105, ISRCTN number 62819212. Ethics committee Northwest 2 
(Liverpool Central) Protocol code number NSP/0002/07 and RLBUHT NHS Trust 
approval).  
 
Patients with CD were recruited based on the inclusion and exclusion criteria in 
7.3.2.2. They were randomised independently to receive either 5g plantain fibre, or 
maltodextrin placebo twice daily over twelve months, with an option to be included in 
the biopsy arm of the study which involved sigmoid biopsy collection at 0 and 3 
months, or at a point earlier than 3 months if a relapse or decision to withdraw from 
treatment occurred (withdrawals and relapses are documented in appendix five). 
Patients were also stratified into groups receiving immunomodulators (azathioprine, 
mercaptopurine or methotrexate) and those receiving none, and by location of CD; i.e 
patients with colonic disease and those with ileal tissue involvement. Three to four 
additional biopsies were collected from the sigmoid alongside those taken for 
standard histology, and were analysed by the qPCR techniques developed in chapter 
six to quantify E.coli numbers standardised against human cell numbers present in the 
biopsies. The patients recruited to the trial had assessments of disease activity, 
assessed with the Crohn’s Disease Activity Index (323) or CDAI at 0,1,2,3,6, 9 and 
12 months, or if there were any symptomatic concerns. Relapse was defined as CDAI 
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> 220, and remission as CDAI < 150. Macroscopic sigmoid appearance and standard 
histology were assessed alongside CDAI and qPCR quantification. 12 patients in total 
were recruited to the biopsy arm of the clinical trial of which 2 withdrew, and one 
relapsed; one of the withdrawal patients was clinically relapsing also. qPCR 
assessment of large intestinal biopsies was performed blind of any clinical 
information, see results section 7.3.3.3 – 7.3.3.5 
  
7.3.2.2 Inclusion and exclusion criteria for the plantain trial 
 
The inclusion criteria were as follows: 
 
  
1) Patients with CD as diagnosed by conventional clinical, radiological and 
histological criteria. 
2) CD involving small bowel, colon or both. 
3) CD that is in remission: Crohn’s Disease Activity Index (CDAI)  
< 150 
4) Patients who have had a relapse of disease within the previous 12 months (Harvey 
Bradshaw Index modified for retrospective use >4, and/or a symptomatic relapse 
requiring a change in CD treatment. 
  
The exclusion criteria were as follows:  
 
1) Patients under 18 years or unable to give informed consent. 
2) Patients who have had surgery for CD within the previous 12 months. 
3) Any change to medication for CD within the previous 3 months. 
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4) Patients receiving corticosteroids or infliximab within the previous 3 months.  
5) CDAI >150 
6) Patients currently receiving enteral nutrition as part of their treatment for Crohn’s 
disease. 
7) Participation in other trials in the last 3 months. 
8) Women intending to become pregnant in the next 12 months 
9) Patients with a known allergy to bananas 
 
7.3.2.3 Biopsy sampling, macroscopic assessment of tissue, laboratory processing 
and analysis of qPCR data in the plantain trial 
 
Biopsies were taken from the sigmoid colon up to 15-25 cm (rectosigmoid) from 
the anus, and patients did not receive bowel preparation for this. These samples were 
in addition to any that were clinically indicated.  
The macroscopic appearance at endoscopy was documented (see table 7.1), for 
later comparison with microscopic appearance and uidA gene quantification from 
biopsies at the same region of the gastro-intestinal tract. A standard Olympus 
endoscope was used and biopsies were taken with standard disposable endoscopic 
forceps.  
 
7.3.2.4 Routine histological assessment of tissues 
 
The microscopic appearance of biopsies taken as part of routine clinical care were 
routinely examined by pathologists from the pathology department at the RLBUHT 
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hospital following standard formalin fixation, embedding and sectioning with routine 
haematoxylin and eosin (H and E) staining, and reported (see table 7.1). 
 
7.3.2.5 Laboratory processing of biopsies  
 
Samples were processed as described in Methods section 5.11, and DNA was 
extracted using the techniques described in 5.3.2. Once DNA was extracted from 
colonic tissue samples and their mucus washings, the number of uidA gene copies, 
and therefore E. coli bacteria, in each sample could be quantified using the qPCR 
assay developed in Chapter six. Aliquots of DNA (5 µl) were used as template in 
triplicate qPCR reactions to detect average uidA quantity as a marker of E. coli 
numbers in tissue. qPCR for human 18S rRNA was used (as described in section 
5.7.6) to quantify human cell numbers, and uidA gene copies were expressed relative 
to one million 18S rRNA genome copies. Biopsy samples were weighed prior to 
qPCR so that uidA gene copies could also be expressed per mg of biopsy tissue (wet 
mass). 
 
7.3.2.6  Reproducibility of the qPCR assays  
 
In each qPCR assay, for every sample analysed, whether for uidA gene or 18S rRNA 
gene quantification, one of the standard templates from the uidA or 18S rRNA gene 
standard curves developed in Chapter six (sections 6.4.3.1 and 6.4.5) was included in 
triplicate in the run, with the same automated LightCycler® settings applied as were 
used in the original standardisation runs. The quantified standard template amount 
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was compared to its original value in the standard curves to assess reproducibility of 
measurements, and the range of variation is explained in the results (section 7.3.3.2). 
  
qPCR quantification was initially performed separately for biopsy tissues and 
the mucus washings from these, and then quantities were combined. Analysis 
comparing remission and relapse biopsies was performed on all groups using 
Wilcoxon’s two sided signed ranks test, with data considered significant for p < 0.05.   
 
7.3.3 Results   
 
7.3.3.1 Clinical, Endoscopic, Histological, and Physical data 
 
There was a large amount of clinical, histological and quantitative data produced in 
the clinical trial of plantain therapy, which is summarised in table 7.1. Of note, three 
patients  withdrew or had clinical relapse at the time of preparation of this thesis (see 
figure 7.1, code numbers 502, and 603, with patient 101 withdrawing at the point of 
near clinical relapse) had macroscopically normal endoscopies, with histology also 
unremarkable. Similarly, patient 604 had mild proctitis on endoscopy but normal 
histology and CDAI scores (table and figure 7.1). Conversely, there was a patient 
(201) who had histological features of inflammation within the sigmoid including 
crypt abscesses and granulomata in the lamina propria, but who had normal 
endoscopies on two occasions and indeed remained clinically well throughout the 
trial. Also patient 504, the only patient to test positive for Clostridium Difficile Toxin, 
or in fact any bacterial agent, remained clinically (see figure 7.1), macroscopically, 
and microscopically quiescent. 
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 From the physical parameters measured, of note the extracted DNA quantities 
were always much lower in biopsy samples from patients who had relapsed (see table 
7.1), which may reflect changes in human or bacterial DNA quantities in the sigmoid 
colon in CD relapse, though only small numbers were involved. DNA quantity 
decreased despite average wet biopsy mass increasing in relapse in patients 101 and 
502 (not 603) which may support the DNA change being due to bacterial changes. 
 
 
 
Figure 7.1  Disease activity levels for patients in the biopsy arm of the plantain 
clinical trial, assessed by CDAI. Changes in CDAI for the 12 patients in the biopsy 
arm of the plantain trial at different timepoints are shown (CDAI 1-7, corresponding 
to time from recruitment (month 0) until months 1,2,3,6,9 and/or relapse,withdrawal, 
or completion of the trial (twelve months of maintenance plantain therapy). The 
dashed red line indicates CDAI primary endpoint for relapse (>220), and the dashed 
blue line indicates CDAI for patients in clinical remission (CDAI <150).  As the trial 
is ongoing all patient data are blinded for plantain/placebo. 
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Table 7.1 Physical characteristics and clinical data for patients in the biopsy arm 
of the plantain clinical trial. Details shown include patient code, average quantity of 
DNA extracted from biopsies (and mucosal washings in brackets), macroscopic 
appearance of the sigmoid at endoscopy at 0 and 3 months or relapse (in brackets), 
histological appearance at 0 and 3 months or relapse (in brackets), average biopsy 
mass from patient at 0 and 3 months or relapse (in brackets), and results of screening 
stool culture for any infectious organisms. REL = relapse, WDL = withdrawal. Patient 
101 withdrew near the point of clinical relapse and 603 was clinically relapsing at the 
time of withdrawal. Colours: red = withdrawal/relapse, lavender = 3 month data. 
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7.3.3.2 Overall assessment of the reproducibility of all qPCR assays using the 
standard templates developed in chapter six 
 
The biopsy and mucus washing data collected during both clinical studies was used to 
assess the reproducibility of the template standards used to generate the qPCR assays 
for the 18S rRNA and uidA gene assays in chapter 6, and described in section 7.3.2.6. 
For both biopsy and mucus washing analysis, templates, in terms of reproducibility of 
absolute quantities, showed variation from - 4 to + 11 % for 18S rRNA genome 
templates, and from - 13 to + 8.8 % for the linearised plasmid uidA DNA templates. 
These were all within our accepted defined parameters. 
It was not possible to run actual patient biopsy DNA templates in qPCR on 
more than one occasion due to their use for multiple assays and limited DNA 
quantity. In the aphthous ulcer study (see section B) there was sometimes only a 
single biopsy from one anatomical site or feature, this made it more appropriate to 
assess inter-assay variations based on the known standard templates. 
  
7.3.3.3 Combined qPCR biopsy and mucus washing data for patients in the 
Plantain clinical trial 
 
Table 7.2 and figure 7.2A show the total uidA gene quantities standardised per million 
18S rRNA genomes present in the combined biopsies and mucus washings of patients 
who remained in remission and those who relapsed during the clinical trial for 
comparison. Figure 7.2A also shows spread and correlation. There was no statistically 
significant difference between the combined mucus and biopsy E.coli quantities of the 
three relapse patients between remission and relapse periods.  
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Figure 7.2B shows the isolated data for the patients who remained in 
remission during the plantain clinical trial. Quantities of uidA genes are standardised 
per million 18 rRNA genomes present in the biopsies of the nine patients in the 
plantain trial who did not clinically relapse or withdraw during the plantain trial. (i.e  
9 out of 12 patients, see table and figure 7.1)  Both data spread and correlating pairs 
are shown in the figure 7.2. The graphs show a significantly lower quantity of uidA 
genes present in these patient biopsies after three months involvement in the trial. 
Their treatment randomisation to plantain or placebo remains unknown, but this 
significant finding in patients who remained in remission is interesting. 
 
Table 7.2. Total uidA gene copies per million 18S rRNA genomes present in the 
combined biopsies and mucus washings of patients in the plantain clinical trial 
 
Patient 0 months 
uidA gene 
copies/million 
18S rRNA 
genomes 
3 months 
uidA gene 
copies/million 
18S rRNA 
genomes 
  Patient Remission 
uidA gene 
copies/million 
18S rRNA 
genomes 
Relapse uidA 
gene 
copies/million 
18S rRNA 
genomes 
201 2684000 115800  101 877500 446350 
202 4381000 1152000  502 84300 1149800 
601 717900 897600  603 573700 1148700 
605 583500 132100     
606 63020 2671000     
504 4673000 509000     
604 1266000 357500     
103 13190000 69310     
503 3217000 219600     
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A 
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P = 0.0273, if assume uidA would be 
lower after 3 month treatment 
Wilcoxon's signed ranks test
correlationspread
uidA genomic DNA expression level relative to 18S
 
B 
Figure 7.2 Quantification of combined biopsy and mucus wash quantities of uidA 
gene copies / million 18S rRNA genomes from the large intestinal tissues of all 
patients in the biopsy arm of the plantain clinical trial (A), and remission 
patients alone (B). Both spread and correlation are shown in both figures. Figure B 
shows the combined standardised mucus and biopsy quantities of uidA gene copies 
from patients who remained in remission at 0 and 3 months. Figures represent the 
average of 3 - 4 pooled biopsies and washings from the same location with each 
sample also having PCR performed in triplicate for each patient. (N3-4, n9-12, 
median is shown). Wilcoxon’s two sided signed rank sum test is significant for lower 
3 month uidA quantities versus month 0 uidA quantities following randomised 
treatment.  For all data shown , ‘0’ and ‘3 months’ refers to quantification timepoints 
for those patients in remission throughout, whilst the panels labelled  ‘remission’ and 
‘relapse’ refers to quantification timepoints in the three patients who relapsed 
clinically (for exact relapse time see appendix five,  and figure 7.1).   
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7.3.3.4 uidA qPCR data for biopsies taken from relapse patients in the plantain 
clinical trial 
 
 uidA gene quantities from paired biopsy samples for the three patients who 
relapsed are shown in table 7.3, and figures 7.3 and 7.4. The data are expressed per 
million 18S rRNA genomes (figure 7.3) and per mg (figure 7.4) for comparison. 
Figure 7.3 shows a 3 fold increase in uidA genes per million 18S rRNA genomes 
when patient 603 relapsed, though patient 101 experienced a 3 fold decrease in uidA 
gene quantity, with patient 502 equivocal, having relapse uidA genes 83% of 
remission quantities.  
When data were analysed by uidA genes per mg (figure 7.4), the same trends 
were seen though absolute numbers were different. The biopsies from patients 101 
and 502 had fifty one fold and five fold lower quantities of uidA genes respectively in 
relapse specimens, and similarly the uidA quantities in the relapse biopsies from 
patient 603 were eight fold elevated. This lends some support to the use of 18S rRNA 
genomes as a denominator because the trends in uidA quantity were similar to those 
produced on an analysis of uidA quantities per mg, offsetting concerns that 
inflammatory human cells, which contain the 18S rRNA gene, might distort an 
accurate denominator for biopsy size. 
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Table 7.3 uidA gene copies per million 18S rRNA genomes  and per mg large 
intestinal tissue biopsy for the three patients who relapsed during the biopsy arm 
of the plantain trial. Figures are averages of 3-4 biopsies from the same location, 
with PCR performed in triplicate for each biopsy following DNA extraction.  
 
  Remission Relapse Remission Relapse 
Patient 
number  
uidA gene copies 
/ million 18S 
rRNA genomes 
uidA gene copies 
/ million 18S 
rRNA genomes 
uidA gene 
copies/mg 
biopsy 
tissue 
uidA gene 
copies/mg 
biopsy 
tissue 
101 17500 5350 228 4.49 
502 59800 49800 350 72 
603 22700 61700 51.9 419 
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Figure 7.3 uidA gene copies per million 18S rRNA genomes for the three patients 
who relapsed during the biopsy arm of the plantain trial. Data points are averages 
of 3-4 biopsies from the same location, with PCR performed in triplicate for each 
biopsy. Patient remission and relapse samples are connected, and median is shown. 
There is approximately a 3 fold increase in gene copies for patient 603, and 3 fold 
decrease in uidA gene copies for patient 101. Analysis of data using Wilcoxon’s two 
sided signed rank sum test reveals no significant differences between remission and 
relapse data, though statistical analysis is not really appropriate for n = 3 patients. 
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Figure 7.4 uidA gene copies per mg large intestinal tissue for the three patients 
who relapsed during the biopsy arm of the plantain trial. Dots  are averages of 3-4 
biopsies from the same location, with PCR perfomed in triplicate for each biopsy for 
each patient following DNA extraction. Patient remission and relapse samples are 
connected, and median is shown. There are 5 fold and 51 fold decreases in uidA gene 
copies in patients 502 and 101 respectively when they relapse, but an 8 fold increase 
in uidA gene copies for patient 603. Analysis of data using Wilcoxon’s two sided 
signed rank sum test reveals no significant differences between remission and relapse 
data, though statistical analysis is not really appropriate for n = 3 patients. 
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7.3.3.5 qPCR mucosal washings data for patients who relapsed during the 
plantain clinical trial 
 
The mucosal washings from the biopsies of patients who had relapsed were analysed 
by qPCR and the data are shown in table 7.4 and figure 7.5. The washings from 
patients 603 and 101 showed a 2 fold increase and 2 fold decrease respectively, in the 
amount of uidA genes quantified per million 18S rRNA genomes, which corresponds  
to the findings seen with trends in the biopsy specimens from these patients. A 
disparity was seen in the washings from patient 502, a forty five fold increase was 
seen in the uidA gene quantites per million 18S rRNA genomes, whereas in the 
corresponding biopsy tissues a fall in numbers was seen. The bacterial species present 
in mucosal washings, however, may be very different to those on or in the biopsy (see 
introduction chapter 2), and a direct correlation is not necessarily expected.     
 
Table 7.4 uidA gene copies per million 18S rRNA genomes for mucosal washings 
from the three patients who relapsed during the biopsy arm of the plantain trial. 
Figures are an average of the washings from the 3-4 biopsies from the same location, 
with PCR performed in triplicate for each biopsy following DNA extraction (N3-4, 
n9-12).  
 
Patient Remission uidA gene 
copies/million 18S rRNA 
genomes 
Relapse uidA gene 
copies/million 18S 
rRNA genomes 
101 860000 441000 
502 24500 1100000 
603 551000 1087000 
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Fig 7.5 uidA gene copies per million 18S rRNA genomes for mucosal washings 
from the three patients who relapsed during the biopsy arm of the plantain trial. 
Figures are an average of the pooled washings from the 3-4 biopsies from the same 
location, with PCR performed in triplicate for each biopsy following DNA extraction 
(N3-4, n9-12) for each patient. Patient remission and relapse samples are connected, 
and median is shown. There is a 2-fold increase in gene copies from the mucus 
washings of patient 603, and a 2-fold decrease in uidA gene copies from the mucus 
washings from patient 101 following relapse. There is a 45-fold increase in the uidA 
gene copies from mucus washings in patient 502 when they relapsed. Analysis of data 
using Wilcoxon’s two sided signed rank sum test reveals no significant differences 
between remission and relapse data.  
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7.3.4 Conclusions  
 
 
 
1) The assay worked well to quantify the bacteria in biopsies and mucus washings from 
clinical trial samples of large intestinal tissue. 
 
2) There was a significantly lower quantity of E.coli bacteria in the combined mucus 
washings and biopsies from patients who were in clinical remission at three months  
compared to the same individuals (also in remission) at the start of the trial period. 
Although the data are blinded this implies a reduction in mucosa-associated bacteria 
with the trial intervention (plantain fibre or maltodextrin placebo). 
 
3) It was not possible to demonstrate a statistically significant difference in E. coli 
bacteria present in the biopsies of patients (n = 3) who relapsed clinically, compared 
to the bacteria present in the same patient during their period of remission but further 
studies are ongoing. 
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7.4 Section B. The quantification of E. coli in aphthous ulcers  
 
7.4.1 Introduction. Aphthous ulcers as the earliest lesions in active 
CD 
 
Although attempts have been made, aphthoid or aphthous ulcers are difficult to define 
in macroscopic or microscopic terms. In a previous study surface ‘erosions’ identified 
by a ‘red halo’ appearance on white light microscopic examination of  lymphoid 
tissue biopsies collected after magnifying colonoscopy were 200 µm in diameter 
(324). Radiographically they appear as a fleck of barium surrounded by a translucent 
halo (325), and they are generally regarded as 2-5 mm in diameter.  For the purpose of 
this thesis, I have pragmatically defined an aphthous ulcer as an ulcer lesion of 4 mm 
or less, as estimated by the fully open standard biopsy forceps. An aphthous ulcer is 
the earliest lesion seen in active CD, corresponding to disease activity and also the 
earliest lesion seen in recurrence of CD  after operative resection (326), and often 
seen at the site of the anastomosis within 3-18 months, usually preceding deeper 
ulceration or formation of granulomata (327). This type of lesion is not wholly 
specific to CD because it can also be seen in ulcerative colitis and diversion colitis in 
extreme cases (328). 
 
The literature on colorectal and ileal aphthous ulcers is sparse, although the 
aphthoid ulcers seen in the buccal cavity have been much more thoroughly researched 
(329-331). Oral ulcers can also be a common manifestation of IBD (332). To date, 
there have been no in depth studies characterising the colorectal microbiota occupying 
the aphthous ulcer niche, and the nature of the colonising bacteria is poorly 
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understood. Bacteria including E. coli, seen in inflamed CD tissue in periods of 
disease activity, are often increased (88), and it seems probable this would be the case 
too for aphthoid ulcers and lymphoid follicles particularly as it has been observed that 
the earliest lesions seen in CD are seen at the ileo-caecum (27), where the Peyer’s 
patches containing M cells are present. The increase in numbers of E. coli may be a 
primary phenomenon or secondary to mucosal inflammation.  In this work qPCR was 
used to quantify and compare numbers of E. coli within aphthous ulcer and ileal 
tissue, including the lymphoid follicles of Peyer’s patches, with control or non-
inflamed tissue, which would be expected to have smaller amounts. 
To evaluate CD and control tissues using the bacterial quantification qPCR 
methods developed in Chapter six, protocols for recruitment of patients to investigate 
our hypotheses were designed. The results of the biopsy quantification of E.coli 
bacterial numbers were assessed alongside endoscopic, histological, and clinical 
parameters. This clinical study is explained in more detail in method section 7.4.2.1 - 
7.4.2.2.  
 
7.4.2 Methods  
 
7.4.2.1 Patients 
  
Patients were recruited from the endoscopy lists performed routinely at the Royal 
Liverpool and Broadgreen University Hospitals NHS Trust. Requests for colonoscopy 
with or without ileoscopy were reviewed on a weekly basis, and potentially suitable 
patients who satisfied the inclusion and exclusion criteria (7.4.2.2) for CD patients 
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and controls were invited to participate in the study by letter at least 48 h in advance. 
The aim was to try and identify patients who potentially had a new diagnosis of CD, 
or who had active disease or recurrence, in order to maximise detection of aphthous 
ulcer numbers.  Appropriate patients were recruited following full informed consent. 
The study had full local ethical approval (Northwest 2- Liverpool Central, reference 
10/H1005/25) and NHS Trust approval number 3945. 
 
The clinical data collected for each patient are summarised in Appendix One, 
including indication for the procedure, current medication, bowel preparation used, 
site of disease, disease activity evaluated using the Harvey Bradshaw Index score (for 
CD patients only (333)), co-morbidities and recent C-reactive protein (CRP) 
measurement.  
Five patients were recruited (3 CD patients and 2 healthy controls, as described in 
appendix one), and samples taken as described in section 7.4.2.3. 
 
7.4.2.2 Inclusion and exclusion criteria  
 
The inclusion criteria for CD patients were as follows: 
 
1) Patients aged 18 years or over with CD diagnosed by conventional clinical, 
radiological and histological criteria. 
2) CD involving small bowel, colon or both. 
3) Patients with CD disease undergoing colonoscopy for routine clinical investigation 
(reasons for this typically included assessment of disease extent, assessment of 
possible post-operative relapse, or surveillance for colon cancer) 
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The inclusion criteria for controls were: 
 
1) Patients undergoing routine colonoscopy for other reasons, for example colonic  
symptoms such as rectal bleeding, diarrhoea and change in bowel habit, assessment of 
diverticular disease, and sporadic cancer surveillance. 
 
The exclusion criteria applied to both groups were: 
 
1) Patients aged under 18 years or unable to give informed consent.      
2) Any antibiotic use within the previous 4 weeks    
3) Any serious intercurrent infection.  
4) Warfarinised patients and patients on anti-platelet drugs 
 
7.4.2.3 Sampling procedure for intestinal samples and evaluation of the 
macroscopic appearance of colonic and ileal mucosa  
 
The methods used for macroscopic assessment, sampling and histological 
examination of colonic tissue are as described in section 7.3.2.3 and 7.3.2.4, with the 
modifications that for the aphthous ulcer study  patients  received either Klean-Prep or 
Moviprep® 24 hours prior to colonoscopy with or without ileoscopy. On the day of 
the procedure up to twelve  research biopsies were taken from small and large 
intestinal locations in each patient in a single colonoscopy session in addition to those 
clinically indicated. Particular priority was given to sampling aphthous ulcers and 
lymphoid follicles when seen.  
 188 
The macroscopic appearance at endoscopy was documented (see Appendix two), 
for later comparison with microscopic appearance and uidA gene quantification from 
biopsies at the same region of the gastro-intestinal tract. For the aphthous ulcer study, 
the entire colon and ileum was examined as indicated, using a standard Olympus 
endoscope with biopsies taken at sites of pathology and from control tissue with 
standard disposable endoscopic forceps.  
 
For results from routine histological assessment of tissue see Appendix Two. 
Laboratory processing of samples to extract DNA, and perform qPCR is described in 
sections 7.3.2.5, with assay reproducibility assessed as per section 7.3.2.6. For the 
aphthous ulcer trial a triplicate qPCR quantification of a single biopsy sample was 
performed, with human cell numbers again quantified and uidA gene copies expressed 
relative to one million 18S rRNA genome copies as well as per mg of biopsy tissue 
(wet mass). 
 
7.4.3 Results  
 
7.4.3.1 Clinical, macroscopic and histological information 
 
Five patients were recruited, 3 CD patients and 2 healthy controls. One  CD patient 
had colonic, and two had  ileo-colonic disease respectively (for patients coded from 
CD1 – CD 3, with CD 3 also having had a previous right hemicolectomy). Their basic 
clinical characteristics are outlined in Appendix One. All patients  presented with 
either abdominal pain, diarrhoea, or for disease surveillance, with control HBI index 
scores between  0-5 (CRP for both was <5, or normal) and CD patients had HBI index 
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scores between 4 and 13, with CRP’s between 9 and 37. Two out of three CD patients 
were on maintenance 5-amino salicylic acid (5-ASA) compounds, with the third 
patient having a new diagnosis. One of these patients was also on steroids 
(prednisolone) for resistant asthma rather than for gastroenterological reasons.  
 The findings from endoscopy are outlined in Appendix Two, the only 
significant macroscopic inflammatory changes are seen with patients coded CD1 and 
CD2. CD1 patient had linear CD scars, CD2 patient had active disease with multiple 
aphthous ulcers in the terminal ileum with splenic flexure ulceration as well as rectal 
inflammation and a new diagnosis of CD was made. Of the control patients CONT 1 
had a descending colon polyp, and CONT 2 had a normal appearance 
macroscopically.  
 Histologically, patients CD2 and CD3 had ileitis, with CD2 also showing 
associated colitis and granulomata in both ileum and colon, confirming the diagnosis 
made endoscopically. Tissue from CONT 1 confirmed tubulovillous adenoma with 
histological samples from CONT 2 having normal appearance. Full histological 
details are in Appendix Two. 
 
7.4.3.2 Physical details of biopsies taken 
 
Physical data of the biopsies taken, including average mass and DNA quantity 
extracted are outlined in Appendix Three. The amount of DNA extracted from the 
mucus washings of these biopsies was also quantified. 
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7.4.3.3 Assessment of uidA gene quantity in small and large intestinal tissue  
  
The results demonstrating qPCR quantification of uidA genes in small 
intestinal biopsy tissue are shown in figure 7.6 and table 7.5. uidA gene quantities 
expressed per mg small intestinal tissue are presented in table 7.6 and figure 7.7.   
 Tables 7.7, figure 7.8 and table 7.8, figure 7.9 illustrate the results obtained for 
uidA gene quantification in large intestinal biopsies per million 18S rRNA genomes 
and per mg biopsy tissue respectively.  
 
Table 7.5 uidA gene copy numbers per 1x10
6
 18S rRNA genomes in small 
intestinal samples TI = terminal ileum, AU = aphthous ulcer, B = biopsy code no, LF 
= lymphoid follicle, SI = small intestine, serp = serpingous. ND = not detected 
 
SMALL INTESTINAL TISSUE – QUANTIFICATION OF E .COLI 
-ANALYSIS PER 1X106 18S rRNA GENOMES 
  
CONTROL 
TISSUE 
uidA gene 
copies / 1x106 
18S rRNA 
genomes 
CD TISSUE  uidA 
gene 
copies / 
1x106 
18S rRNA 
genomes 
CONT 2 TI 541000 CD1 B6 TI ND 
CONT 2 LF 413000 CD2 SERP 
ULCER TI 
ND 
  
  
  
CD2 AU 11600 
CD3 TI B 109000 
CD3 SI 96100 
CD3 TI B 2060000 
CD1 B5 LF ND 
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Table 7.6 uidA gene copies per mg small intestinal samples  TI = terminal ileum, 
AU = aphthous ulcer, B = biopsy code no, LF = lymphoid follicle, SI = small 
intestine, serp = serpingous. ND = not detected 
   
SMALL INTESTINAL TISSUE - QUANTIFICATION OF E.COLI 
ANALYSIS PER MG 
  
  
CONTROL 
TISSUE 
uidA gene 
copies/mg 
tissue 
CD TISSUE uidA gene 
copies/mg 
tissue 
CONT 2 TI 108 CD1 B6 TI ND 
CONT 2 LF 1650 CD2 SERP 
ULCER TI 
ND 
  
  
  
CD2 AU 157 
CD3 TI B 86.5 
CD3 SI 60.7 
CD3 TI B 187 
CD1 B5 LF ND 
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Table 7.7 uidA gene copies per 1x10
6
 18S rRNA genomes in large intestinal 
samples. AC = ascending colon, SC = sigmoid colon, SF = splenic flexure, LI = non 
specific large intestinal sample, B = non specific colon sample. ND = not detected 
 
LARGE INTESTINAL TISSUE - QUANTIFICATION OF 
E.COLI - ANALYSIS PER 1X106 18S rRNA GENOMES 
  
CONTROL 
TISSUE 
uidA gene 
copies / 
million 18S 
rRNA 
genomes 
CD TISSUE  uidA 
gene 
copies / 
million 
18S rRNA 
genomes 
CONT1 B1 2470 CD1 B SF 4720 
CONT1 B2 29500 CD1 B2 ? ND 
CONT1 B3 ND CD1 B3 SC ND 
CONT1 B4 7940 CD1 B4 TC ND 
CONT1 B5 33300 CD2 B SF ND 
CONT1 B6 26700 CD2 B SF     
ULCER 
ND 
CONT1 B7 4230 CD3 LI 3110000 
CONT1 B8 45500 CD3 LI 2020000 
CONT2 AC 873000 CD3 LI 187000 
CONT2 AC 1090000 CD3 LI 67200 
CONT2 SC 2880000  
CONT2 SC 223000 
CONT2 SC 74000  
CONT2     
CAECUM 
1570000 
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Table 7.8 uidA gene copies per mg large intestinal tissue  AC = ascending colon, 
SC = sigmoid colon, SF = splenic flexure, LI = non specific large intestinal sample, B 
= non specific colon sample 
ND = not detected 
 
QUANTIFICATION OF E.COLI LARGE INTESTINAL TISSUE - 
ANALYSIS / MG 
  
CONTROL 
TISSUE 
uidA gene 
copies / mg 
tissue 
CD TISSUE uidA gene 
copies / mg 
tissue  
CONT1 B1 15.3 CD1 B SF 37.6 
CONT1 B2 491 CD1 B2  ND 
CONT1 B3 ND CD1 B3 SC ND 
CONT1 B4 11.6 CD1 B4 TC ND 
CONT1 B5 170 CD2 B SF ND 
CONT1 B6 200 CD2 B SF     
ULCER 
ND 
CONT1 B7 36.1 CD3 LI 702 
CONT1 B8 91.9 CD3 LI 107 
CONT 2 AC 125 CD3 LI 72.2 
CONT 2 AC 82.1 CD3 LI 172 
CONT 2 SC 111 
CONT 2 SC 79.1 
CONT 2 SC 132 
CONT2 
CAECUM 
49.9 
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Figure 7.6. A comparison of the uidA gene copy numbers seen in small intestinal 
tissue in control and CD tissue. uidA gene copies are expressed per million 18S 
rRNA genomes, and each dot represents  the average of triplicate PCR samples from a 
single biopsy. The median for the CD group and the control group  is shown as a 
horizontal line. The high outlier represents a terminal ileal biopsy from patient CD3. 
Two sided Mann-Whitney U  test did not show a significant difference between E. 
coli quantities in control vs CD tissue. Samples from a given patient are colour coded: 
Cont 2 (Green), CD1 (Red), CD2 (Orange), CD3 (Purple). The location each biopsy is 
from is given in table 7.5.  
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Figure 7.7. A comparison of the uidA gene copy numbers seen in small intestinal 
tissue in control and CD tissue. uidA genes are expressed per mg tissue, and each 
dot represents  the average of triplicate PCR samples from a single biopsy. The 
median for the CD group and the control group  is shown as a horizontal line. The 
high outlier represents a lymphoid follicle biopsy from a control patient. Two sided 
Mann-Whitney U  test did not show a significant difference between E. coli quantities 
in control vs CD tissue.  Samples from a given patient are colour coded: Cont 2 
(Green), CD1 (Red), CD2 (Orange), CD3 (Purple). The location each biopsy is from 
is given in table 7.6. 
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Figure 7.8 A comparison of the uidA gene copy numbers seen in large intestinal 
tissue in control and CD tissue. uidA genes are expressed per million 18S rRNA 
genomes and each dot represents  the average of triplicate PCR samples from a single 
biopsy. The median for the CD group and the control group  is shown as a horizontal 
line.  The highest two values were from sigmoid colon biopsies in CD patients, but in 
controls the highest two values were from ascending colon and caecum. Two sided 
Mann-Whitney U  test did not show a significant difference between E. coli quantities 
in control vs CD tissue.  Samples from a given patient are colour coded:  Cont 
1(Blue), Cont 2 (Green), CD1 (Red), CD2 (Orange), CD3 (Purple). 
The location each biopsy is from is given in table 7.7. 
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Figure 7.9 A comparison of the uidA gene copy numbers seen in large intestinal 
tissue in control and CD tissue. uidA genes are expressed per mg large intestinal 
tissue and each dot represents the average of triplicate PCR samples from a single 
biopsy. The median for the CD group and the control group  is shown as a horizontal 
line. The highest two values were from sigmoid colon biopsies in CD and control 
patients. Two sided Mann-Whitney U  test did not show a significant difference 
between E. coli quantities in control vs CD tissue.  Samples from a given patient are 
colour coded: Cont 1(Blue), Cont 2 (Green), CD1 (Red), CD2 (Orange), CD3 
(Purple). The location each biopsy is from is given in table 7.8. 
 
7.4.3.4 Mucosal wash data for the aphthous ulcer study 
 
The DNA quantities extracted from the mucosal washings of large and small intestinal 
biopsies in the aphthous ulcer study are detailed in Appendix four. The highest 
extracted concentration of DNA was seen in the washing from a biopsy taken from 
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the site of an aphthous ulcer in the patient newly diagnosed with active CD (patient 
2); the DNA quantity was a peak for the small intestinal tissue examined at 90.2ng per 
µl, though this did not translate as an increase in uidA gene quantity per million 18S 
rRNA  genomes (see figure 7.10).      
 qPCR was also performed on the washings from large intestinal biopsy 
samples  with the scatterplot produced by examining uidA genes per million 18S 
rRNA genomes shown in figure 7.11. 
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Figure 7.10 Comparison of the uidA gene copy numbers seen in small intestinal 
tissue mucus washings from control and CD tissue. uidA genes are expressed per 
million 18S rRNA genomes, and each dot represents the average of triplicate PCR 
samples from pooled mucus washings from a single location. Two sided Mann-
Whitney U  test did not show a significant difference between E. coli quantities in 
control vs CD tissue (P = 0.8) but n numbers are of course very small.  The median 
for the CD group and the control group  is shown as a horizontal line. Samples from a 
given patient are colour coded: Cont 2 (Green), CD3 (Purple). 
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Figure 7.11 comparison of the uidA gene copy numbers seen in large intestinal 
tissue mucus washings from control and CD tissue. uidA genes are expressed per 
million 18S rRNA genomes, and each dot represents the average of triplicate PCR 
samples from pooled mucus washings from a single location.   The median for the CD 
group and the control group  is shown as a horizontal line. Two sided Mann-Whitney 
U  test did not show a significant difference between E. coli  quantities for control vs 
CD tissue (P 0.84). Samples from a given patient are colour coded: Cont 1(Blue), 
Cont 2 (Green), CD3 (Purple). 
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7.4.4 Conclusions 
 
1) The results to date do not support the hypothesis of increased E. coli quantities in 
aphthous ulcer tissue, or within small intestinal tissue in CD patients compared with 
controls. However these results are based on small numbers which are inadequate to 
allow statistical comparison, or to allow comparison between ulcer and non ulcer 
tissue within the CD patient tissue group. 
 
2) (i) The assay is working well for quantification of E.coli on endoscopic biopsy 
samples from small and large intestine. 
(ii) Patients who are negative for E. coli at one site are negative throughout the 
intestine. 
 
3) The assay works well to quantify the bacteria in mucus washings from endoscopic 
biopsy samples of small and large intestine.  
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7.5 Discussion  
 
The principal aim of the work in this chapter was achieved when the qPCR assays 
developed in chapter six were successfully utilised to quantify uidA genes in biopsies 
and mucosal washings from different types of CD tissue, in both periods of disease 
remission and relapse over time and also in small and large intestinal tissue at the 
same timepoint. This was done in a robust and reproducible way. It is conceivable that 
quantification of uidA genes in tissue could be used at different stages of CD activity 
and to assess responses to pharmacological treatments as well as potentially a 
prognostic indicator of disease progress.  
 Though each study involved small numbers of patients, there were interesting 
findings in both. Primarily there was a significantly lower quantity of E.coli bacteria 
in the combined mucus washings and biopsies from patients who were in clinical 
remission at three months compared to the same individuals who were also in 
remission at the start of the trial period. Although the data are blinded this implies a 
reduction in mucosa-associated bacteria with the trial intervention (plantain fibre or 
maltodextrin placebo), and also does not refute the principal hypothesis that increased 
E.coli bacterial quantities may be associated with CD disease activity; conversely 
lower E. coli quantities were associated with patients being in sustained remission. It 
will be even more informative when the clinical trial is unblinded and the effect of 
plantain fibre on both clinical relapse, and uidA gene quantity can be assessed in more 
detail.  
 Examining the uidA gene quantities by qPCR for the three relapse patients  
showed mixed results. Mucus washings tended to show increased uidA gene quantities 
in relapse even though examination of relapse biopsies produced the opposite trend. 
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Small numbers were involved, too small to demonstrate a statistically significant 
difference in standardised E.coli numbers between tissues during remission and 
relapse. The finding of lower DNA quantities in sigmoid biopsies from relapsing 
patients is not straightforward to explain, but may be associated with lower bacterial  
DNA, particularly reduced diversity associated with dysbiosis (47). 
   The numbers of patients recruited in the aphthous ulcer study were clearly too 
small to demonstrate statistically significant differences in uidA gene quantities 
between control and CD tissue, or to evaluate differences between ulcer and non ulcer 
tissue in CD patients. This applied for both small and large intestinal tissues, and it is 
probable that the number of patients recruited needs to be increased in order to detect 
any differences if they exist. There is further ongoing work to increase the patient 
number and biopsy sample size and recruit further patients based on the approved 
protocol and these increased numbers may show statistically significant discernible 
differences in the microbiota found in control and CD tissue, particularly aphthous 
ulcers. 
There were points of interest. uidA quantities in small intestinal tissue of CD 
and control patients demonstrated a peak number of uidA genes in the terminal ileal 
biopsy from the CD3 patient. This patient had a macroscopically normal ileum, but 
microscopically had features of ileitis; the identification of high uidA gene quantities 
in the terminal ileal biopsy of a patient with a macroscopically normal ileum but 
histological ileitis, and some clinical markers of disease activity (HBI of 13 and CRP 
of 37) raises the possibility of whether bacterial uidA qPCR may eventually be used as 
an accessory predictive tool in pathology. The high quantities of uidA gene copies 
noted in a lymphoid follicle (control patient 2) also suggests a possible role for these 
sorts of assays in the study of pathophysiological processes, given that this is the key 
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tissue in the small and large intestine involved in pathophysiological bacterial 
translocation (125).   
 Quantification of E. coli from the mucosal washes of biopsy tissue from CD 
and control patient tissue also showed points of interest. The highest extracted 
concentration of DNA was seen in the washing from a biopsy taken from the site of 
an aphthous ulcer in the patient newly diagnosed with active CD (CD patient 2); the 
DNA quantity was a peak for the small intestinal tissue examined at 90.2ng per µl, 
though this did not translate as an increase in uidA gene quantity per million 18S 
rRNA  genomes This suggests that the DNA extracted at this site was either from 
other bacterial species, or human cells in the mucus washings from the biopsy. As the 
washings were taken from a biopsy with low mass, a source of bacterial DNA other 
than E.coli seems likely, and may reflect colonisation of the aphthous ulcer site.     
uidA quantities were highest in both ascending colon, sigmoid colon and 
caecum in the control patient 2 for both the denominator  methods used. High uidA 
level in the in sigmoid colon biopsies from both CD and the control patients, coupled 
with the findings from qPCR performed on washings from large intestinal biopsy 
samples confirmed expected findings from what is known about bowel bacterial 
colonisation numbers in the small and large intestine (334), though again patient 
numbers were small. Also, the finding that patients who are negative for E. coli at one 
site are negative throughout the intestine,  is in accord with a recent study (226).  
 
 The use of qPCR to quantify uidA genes, and by proxy E. coli quantities in CD 
may become a powerful tool, and perhaps could be used to quantify E. coli in clinical 
trials of antibiotics, as well as to measure the effects of steroids, immunomodulators, 
and anti-TNF agents on the quantities of E. coli in CD.  The development of primers 
for qPCR targeting genes present in ever more specific groups of E. coli involved in 
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CD pathogenesis, for example the long polar fimbriae (lpf) gene, in AIEC (335), may 
refine the use of the qPCR technique yet further.  
In terms of choice of denominator for E.coli quantification, when data were 
analysed by quantifying uidA genes per mg or per million 18S rRNA genomes as in 
(218), the same trends were seen, particularly when relapse patient data were 
examined though absolute numbers were different. This lends some support to the use 
of 18S rRNA genomes as a denominator. Initially there was a concern that 
inflammatory human cells, present in areas of intestinal inflammation might produce 
an overestimation of total cell numbers, with corresponding underestimation of 
microbial density, particularly in inflamed tissue, which would complicate assessment 
of diseases such as Crohn’s. The use of mass as a denominator  would not be distorted 
by the presence of inflammatory cells per se, but could also be affected by the 
inflammatory process. The use of both denominators together showing similar trends 
was a strength of this work. 
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CHAPTER EIGHT : THE EFFECT OF ANTIBIOTICS 
AND IMMUNOMODULATORS ON E. COLI 
REPLICATION WITHIN MACROPHAGES IN-VITRO 
 
 
 
8.1 Hypothesis : 
 
 
Drugs may have efficacy in CD if they can kill E. coli within macrophages. These 
may include antibiotic combinations but also may include some of the drugs that are 
commonly used in CD maintenance therapy including immunosuppressives.  
  
 
 
8.2 Aim :  
 
To evaluate the effect of antibiotics and immunomodulators at clinically relevant 
concentrations on in-vitro replication of Crohn’s disease (CD) mucosally-associated E 
coli within macrophages.  
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8.3 Introduction 
 
 
8.3.1 The use of antibiotics in CD 
 
 
If CD is caused by bacteria then it would be reasonable to expect a therapeutic 
response to antibiotics. There is however a relative lack of good controlled evidence 
to show efficacy. Best evidence probably exists for ciprofloxacin, metronidazole and 
for the non-absorbed antibiotic rifaximin. This evidence has been reviewed in a recent 
meta-analysis, discussed in section 2.9 (269). It is evident from the diversity of 
antibiotics selected to treat Crohn’s that the target is unclear, both in respect of the 
type of bacteria (aerobic, anaerobic  or a mixture of both), and in respect of their site 
(systemic infection or bacteria in the faecal stream, extracellular or intracellular). 
Without a clearly defined target and appropriate use of combination therapy to reduce 
development of antibiotic resistance, this approach to therapy is unlikely to make 
much progress. It should also be noted that metronidazole has anti-inflammatory 
effects, including blockade of neutrophil recruitment (336) and conversely it is also 
possible that immunosuppressant drugs might have anti-bacterial effects. 
 
Recent studies have identified mucosa-associated E. coli as a potential pathogenic 
factor in CD. Many independent groups, reviewed in (125) have shown that their 
presence is markedly increased in Crohn’s mucosa compared with mucosa from 
healthy controls. These particular E. coli have an adherent, invasive phenotype, hence 
their designation as AIEC (337), that also includes an ability to replicate within 
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macrophages (206;208;242;338). Moreover immunohistochemical (88) and qPCR 
studies (205) have shown E. coli within granulomata in CD tissue, with the exemplar  
ileal AIEC, LF82, having been shown to induce granuloma formation in vitro (339). 
Proof that these E. coli have a causative role rather than gaining entry secondary to 
inflammation, depends on showing remission of disease in response to appropriate 
therapy targeting these E. coli replicating within macrophages. Similar adherent, 
invasive E. coli have also been found in the analogous granulomatous colitis that 
affects Boxer dogs (340) and responds to antibiotics (341). Choosing an effective and 
well tolerated combination of antibiotics which minimises risks of bacterial resistance 
can be difficult, but offers therapeutic alternatives in CD therapy.  
 
8.3.2 Immunomodulators in CD 
  
There is some evidence that the immunosuppressive azathioprine, a drug 
commonly used to treat CD (151), may have an anti-bacterial effect (286) – Jarnerot 
and colleagues described an antibiotic effect of resected Crohn’s disease tissue 
sampled at respective surgery from Crohn’s disease patients receiving azathioprine. It 
is notable that azathioprine seems particularly effective when used to treat fistulating 
perianal disease (342), a complication of Crohn’s where bacteria are likely to have a 
major role. Conversely, prolonged or excessive use of corticosteroids has been shown 
to substantially increase the risk of serious sepsis in patients with CD (343) and is 
associated with increased mortality (data from TREAT i.e. The Crohn's Therapy, 
Resource, Evaluation, and Assessment Tool Registry). Steroid use in CD is discussed 
in 1.7.2 and the effects of steroids on macrophages are also discussed in section 
2.10.2. 
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This chapter describes studies performed (i) to assess optimal combinations of 
antibiotics designed to target CD mucosa-associated E. coli replicating within 
macrophages, (ii) to assess the effects of immunosuppressive drugs commonly used in 
CD on E. coli survival and replication in macrophages. The antibiotic studies were 
performed to aid design of a clinical trial of use of antibiotics to prevent relapse of 
CD. Whilst our group had already developed antibiotic regimens, used both 
individually and in combination, and demonstrated in vitro efficacy of their ability to 
kill intra-macrophage Crohn’s E. coli (242), their clinical use in treatment of Crohn’s 
has been limited by potential drug-drug interactions or toxicity profiles, such as the 
bone marrow suppressing effect of trimethoprim when co-administered with 
azathioprine (344), and the effect of metronidazole to produce ethanol intolerance 
(345). Long term use of metronidazole has also been associated with peripheral 
neuropathy (346), whilst ciprofloxacin has a number of neurological side effects (347) 
and causes tendonopathy (348).   
The combination of ciprofloxacin and metronidazole had not been evaluated 
previously in vitro, against E. coli and, although metronidazole is specific for 
anaerobic bacteria, there is a theoretical possibility that E. coli might be metabolising 
anaerobically when within macrophage vesicles. All the antibiotics and 
immunosuppressive agents used were evaluated at clinically relevant concentrations. 
 
8.4 Aims:  
 
1) To assess optimal combinations of antibiotics, designed to target E. coli replicating 
within macrophages at clinically relevant levels.  
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2) To assess the effects of immunosuppressive drugs commonly used in CD on E. coli  
replication in macrophages, again at clinically relevant levels. 
 
8.5 Methods 
 
8.5.1 Evaluation of Crohn’s mucosa-associated E. coli replication within 
macrophages in the absence or presence of antibiotics 
 
Murine macrophages (J774-A1) cultured in vitro (described in section 5.1.2) on 
standard 24 well plates were infected with adherent, invasive Crohn’s E. coli isolate 
HM605 for 2 h (at a multiplicity of infection (MOI) at a ratio of two hundred and fifty 
to one (bacteria to macrophage), to allow bacterial internalisation. This was  followed 
by removal of extracellular bacteria by three successive PBS washes and gentamicin 
(20 µg/ml) treatment for 1 hour. This was followed by a further five PBS washes and 
a further gentamicin treatment as described previously (242). Macrophages were then 
incubated for a further 3 hours in either the presence of antibiotics at Cmax, either 
metronidazole (20 µg/mL) alone, ciprofloxacin (4 µg/mL) alone, or metronidazole in 
combination with ciprofloxacin, in comparison to DMSO/RPMI media  vehicle 
control (see section 5.1.2). Cmax is defined as the peak plasma concentration of a 
therapeutic agent achievable by a conventional dosing regimen), with doses used as 
stated in references (242;349;350), Antibiotics were also assessed at 10% Cmax. 
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8.5.2 Examining the effects of immunomodulators on intra-macrophage 
replication of E. coli.  
 
The action of a range of the therapeutics used in the treatment of CD were assessed 
which included clinically useful concentrations. Drug concentrations used were; 
azathioprine (AZA, 4.2x10
-12
 to 4.2 µM, but also initially concentrations up to 210 
µM), 6-mercaptopurine (6-MP, 0.042 to 4.2 µM), hydrocortisone (HC, 0.06 to 6 µM), 
as well as one of the end metabolites of azathioprine, 6-thioguanine (6-TG, at 8.2 x 
10
-5
 - 820 fmoles/8x10
8
 macrophage cells).  Following pre-incubation of J774-A1 
murine macrophages for 24 hours with these drugs, they were infected with Crohn’s  
E. coli again as per section 8.5.1.  
 
All immunomodulator dose ranges tested included  levels that are of clinical relevance 
in CD. For azathioprine and 6-MP, 1.05 µM and lower (287) were of most relevance 
as therapeutic concentrations of azathioprine are in the range of up to 2 µM (351). For 
6-TG, the concentration of interest is 82 fmol per 8x10
8 
cells, which is the equivalent 
of a therapeutic level of the active metabolite 6-TG seen with conventional dosing of 
patients with azathioprine or 6-MP at 1.5-2 mg/kg per day (352-354). 
 
A daily dose of 40 mg prednisolone, an oral steroid commonly used to control IBD 
relapse is equivalent to a 6µM
 
concentration of Hydrocortisone when used in vitro 
(355). 
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8.5.3 Quantifying the effects of immunomodulatory agents and antibiotics on E. 
coli replication within macrophages 
 
Following infection, macrophages were lysed (after 6 h) with 1% (v/v) Triton X-100  
and internalised bacteria enumerated by overnight growth on LB agar.  
The actual number of E coli added on the day of the infection was confirmed by 
performing serial one in ten subdilutions of the neat bacteria and plating 50µl of these 
dilutions on standard LB agar with the resulting number counted after overnight 
incubation at 37ºC. These counts were used to produce a correction factor so that 
numbers could be directly counted inter-experiment. 
Data were finally analysed with bacterial numbers present in macrophages treated 
with experimental antibiotics and/or drugs compared to untreated infected cells at 6 
hours. The datasets were statistically analysed using Kruskal-Wallis non-parametric 
ANOVA followed by post-hoc pairwise comparison of all treatment means  (Conover 
Inman). Differences were considered significant when P<0.05.  
 
8.5.4 Assessment of the effect of therapeutic agents on macrophage growth and 
viability 
 
To establish whether the differences in treatment on E. coli replication within 
macrophages were due to a real treatment effect rather than secondary to  significant 
differences in toxic effect to the macrophages between untreated and drug treated 
groups viability and growth were assessed. J774-A1 macrophage growth rate was 
estimated by direct haemocytometry over three days. On three separate occasions 
J774-A1 macrophages were seeded into 24 well plates at the same concentration 
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(1x10
5
/ml with 1 ml added). On day 2 and day 3 a proportion of these wells were used 
to perform cell counts after cells were carefully removed using cell scrapers with cells 
counted by direct vision under the microscope/haemocytometer. Cell numbers and 
growth rate were assessed for untreated cells and for cells pre-treated with the 
maximum concentration and clinically useful concentrations of hydrocortisone and 
azathioprine used in the replication assay (8.5.2). Cell numbers in each group were 
averaged from replicate triplicates on the three occasions and analysed using  
Kruskal-Wallis ANOVA.  
 
As a further measure to assess J774-A1 macrophage viability after exposure to 
the pharmacological agents the Toxilight™ adenylate kinase assay kit was used. The 
principle of the kit is that if a concentration of drug results in greater toxicity, cell 
damage results in leakage out of the cell, particularly increased leakage of adenylate 
kinase to the cell culture medium. 
          Cell supernatants were evaluated as per manufacturers instructions (protocol 2, 
of kit LT07 – 217), after identical experimental exposures. The macrophage cells had 
been treated identically to the standard experiments above but toxicity was measured 
in place of replication for peak doses of therapeutic agents.  Adenylate kinase levels 
produced by RPMI growth media, PBS, and the bacterial E.coli suspension alone 
were used to measure background adenylate kinase release in the absence of treatment 
and the effect of cell damage caused by bacterial infection of the macrophages alone.  
Following exposure relative luminescence units were measured.   
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8.5.5 Assessment of any direct bacteriocidal effect of immunomodulator drugs on 
bacterial viability outside macrophages 
 
In order to examine whether the drugs used had a direct bacteriocidal effect, 
independent of modulation of macrophage function, a series of experiments  were 
conducted. E. coli HM605 were used at the same bacterial quantity per ml as was 
used to infect macrophages, but scaled down for use in a 96 well plate. They were  
inoculated into RPMI media, without antibiotics, containing the immunomodulator 
drugs used in the macrophage experiment at their peak doses. Hydrocortisone was 
made up tested at 6 µM, azathioprine at 210 µM, ciprofloxacin at Cmax  4µg/mL, and 
6-MP at 4.2 µM with 6-TG used at the equivalent concentration of 820 fmol per 8x108 
cells, and drug solutions were pipetted into a 96 well plate in the same ratio as in the 
macrophage experiment, in a ratio of ten to one, i.e. 18 µl bacteria added to 180µl of 
drug containing media and these were incubated at 37ºC for up to 6 h. A series of 
replicate wells were set up with identical drug concentration and initial inoculum, and 
50µl of each well were removed at sequential timepoints. These timepoints were 
1,2,3,4,5, and 6 h to mirror the period of time the E.coli were exposed to drugs in the 
intra-macrophage replication experiments, in sections 8.5.1 – 8.5.2. Overall the E.coli 
were exposed to the immunomodulator drugs for 6 h and ciprofloxacin for 3 h. These 
samples were subdiluted, 10 fold, up to 6 times, in PBS in further 96 well plates to 
produce countable colonies, and these were plated out on standard LB agar, incubated 
at 37ºC overnight, and enumerated the following day, standardised as CFU /ml.  
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The actual number of E. coli added on the day of the infection was confirmed as per 
the macrophage assay, to allow inter-experiment comparison (as described in section 
8.5.3). 
 
8.6 Results  
 
Table 8.1 Cmax of antibiotics used in this thesis  
 
Antibiotic  Cmax (µg/ml) Reference 
Ciprofloxacin 4 (242) 
Metronidazole 20 (350) 
 
 
8.6.1 The effect of antibiotics on E. coli replication within J774-A1 macrophages  
  
When ciprofloxacin was used alone to treat macrophages at Cmax, there was a 
significant inhibition of E.coli replication within macrophages. When ciprofloxacin 
and metronidazole were used in combination to treat macrophages at Cmax, there was 
no statistically significant difference between the use of ciprofloxacin alone, 
compared to its use in combination with  metronidazole. This was perhaps because the 
level of intra-macrophage killing by ciprofloxacin was so high at Cmax that it would be 
difficult to detect a difference (figure 8.1). So the experiments were repeated again at 
10% Cmax (figure 8.2). The effect of metronidazole at Cmax on E.coli replication was 
not significantly different from the bacterial replication in the untreated macrophage 
group, so it could be predicted that it would have no effect either at 10% Cmax, which 
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was confirmed (figure 8.2). Similarly at 10% Cmax, there was no additional effect in 
combination with ciprofloxacin seen with metronidazole either (figure 8.2). In fact it 
inhibited the effect of ciprofloxacin, though not with statistically significant 
difference between these two treatment groups, though the combination therapies 
significance value at 10% Cmax was p = 0.07 relative to untreated macrophages. The 
level of replication seen within the untreated macrophages was similar to that seen 
previously (242). 
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Figure 8.1 The effect of antibiotics used at Cmax on replication of HM605 E coli 
within J774-A1 macrophages at 6 h. Kruskal Wallis non parametric ANOVA N4, 
n12, (where N = no of different experimental days, and n = total number of wells used 
overall per experimental exposure, usually 3 wells per experimental day). **p<0.01, 
***p<0.001 Inhibitory effects are assessed compared with untreated cells at 6 h. 
Mean CFU/ml ± SE are shown. 
 
 
*** 
 
Antibiotic effects assessed at 6 h 
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Figure 8.2 Crohn’s E. coli HM605 replication within J774 murine macrophages 
at 6 h in the absence or presence of antibiotics used at 10% Cmax  
 The effect of both antibiotics used at 10% Cmax on HM605 E coli replication within 
J774-A1 macrophages expressed as fold replication relative to untreated macrophages 
at 6 h. Kruskal Wallis non-parametric ANOVA: **p<0.01  (N3, n9). Mean fold 
replication ± SE is shown.   
 
 
8.6.2 The effect of immunomodulators on intra-macrophage E.coli replication. 
 
The use of supra-therapeutic (> 2 µM) concentrations of azathioprine resulted in 
inhibition of the replication of E.coli within macrophages. This was statistically 
significant at all the doses used apart from the 70 µM dose, which showed non 
statistically significant inhibition (figure 8.3). The inhibitory effect seen with 
azathioprine was evaluated at therapeutic levels and below, and in fact an inhibitory 
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effect on intra-macrophage E.coli replication was seen at concentrations as low as 4.2 
x10
-9  µM, with the effect lost when azathioprine was used at a 1000x lower dilution 
than this (figure 8.4).  
         Interestingly there was no significant effect observed on intra-macrophage E 
coli replication when macrophages were exposed to  6-MP doses at clinically useful 
concentrations compared to untreated macrophages. Ciprofloxacin was used as a 
positive control and significantly inhibited E. coli replication (p=0.0054) within 
murine macrophages (figure 8.5).  
       The active metabolite of azathioprine, 6-TG, significantly inhibited the 
replication of E.coli within macrophages in a dose dependent fashion (figure 8.6). The 
peak suppression of E.coli replication was seen at a 6-TG concentration of 82 fmol 
per 8 x10
8 
cells, which is the level expected in the blood with a standard dosing 
regime of azathioprine, and inhibition of replication was maintained at up to 1000-
fold lower concentrations. Interestingly a 10 fold higher concentration than the usual 
therapeutic level produced less suppression of E. coli replication though not of 
statistical significance (figure 8.6). 
         Hydrocortisone also inhibited intra-macrophage replication of E.coli in a dose 
dependent fashion, which was maximal at a 0.6 µM concentration (figure 8.7). A 6 
µM hydrocortisone concentration in vitro is approximately equivalent to a 
conventional  IV hydrocortisone dose of 100 mg,  or an oral daily prednisolone dose 
of 40mg (355). 
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Figure 8.3 The effect of high dose azathioprine on intra-macrophage E.coli 
replication.  The effects of pre-incubation of J774-A1 macrophages with high doses 
of azathioprine  for 24h on E. coli HM605 replication are shown. All fold replication 
is expressed relative to CFU seen at 6h in untreated macrophages. Ciprofloxacin (4 
µg/ml) is the positive control. Kruskal Wallis non parametric ANOVA: 
*p<0.05,**p<0.01, ***p<0.001. N3, n9. Mean fold replication ± SE is shown.   
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Figure 8.4 The effect of 24h pre-incubation of J774-A1 macrophages with 
clinically relevant concentrations of azathioprine on HM605 E. coli replication. 
Ciprofloxacin is the positive control. All doses examined (4.2x10
-12
-4.2µM) with the 
exception of the 4.2x10
-12 µM  dose had a statistically significant inhibitory effect on 
E.coli replication. Kruskal Wallis non parametric ANOVA: **p<0.01, ***p<0.001. 
N3-8, n9-24. Fold replication is expressed relative to CFU numbers at 6 h in untreated 
macrophages. Mean fold replication ± SE is shown.   
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 6-MP concentration (µM) 
 
Figure 8.5 The effect of 24h pre-incubation of J774-A1 macrophages with 6-MP 
on intra-macrophage E coli replication. Kruskal Wallis non parametric ANOVA:  
***p<0.001. N3, n9. Fold replication is expressed relative to CFU numbers at 6 h in 
untreated macrophages. Mean fold replication ± SE is shown.   
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Figure 8.6 The effect of 24h pre-incubation with 6- TG on intra-macrophage E. 
coli HM605 replication Kruskal Wallis non parametric ANOVA: *p<0.05,**p<0.01, 
***p<0.001. N3, n9. The 820 fmol/8x10
8
 cells dose is 10x the usual clinically 
therapeutic level. Fold replication is expressed relative to CFU numbers at 6 h in 
untreated macrophages. Mean fold replication ± SE is shown.   
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Figure 8.7 The effect of 24h pre-incubation with hydrocortisone on intra-
macrophage E. coli HM605 replication. Kruskal Wallis non parametric ANOVA: 
*p<0.05,**p<0.01, ***p<0.001. N4, n12. Fold replication is expressed relative to 
CFU numbers at 6 h in untreated macrophages. Mean fold replication ± SE is shown.   
  
 
8.6.3 Assessment of the effect of therapeutic agents on macrophage growth and 
viability 
 
To confirm absence of a direct toxic effect on macrophage cells of the 
immunomodulator drugs, two experiments were performed. Firstly an experiment was 
performed to assess cell growth, and secondly toxicity was assessed using an 
enzymatic assay.   
          Azathioprine and hydrocortisone were investigated for any potential toxic 
effects on macrophage cells that would alter interpretation of results. There were no 
effects seen with pre-incubation with these immunomodulator drugs on J774-A1 
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macrophage cell number and growth rate (Table 8.2). No significant differences were 
seen between treatment and control groups when compared on day 2 of the assay. Day 
2 was when macrophages were infected after pre-incubation with the 
immunomodulators.    
        The possible cytotoxic effects of azathioprine and hydrocortisone as well as the 
E coli HM605 effect on macrophage viability was also assessed using the Adenylate 
Kinase Cytotoxicity assay (Table 8.3). The kit uses luciferin to generate fluorescence 
when adenylate kinase is released from non viable cells. No significant differences 
were seen between cells treated with immunomodulator, E. coli and control groups. 
Signals produced by PBS, RPMI media, and the bacterial suspension alone are shown 
for comparison (Table 8.3). 
 
Table 8.2 Experiment to evaluate the effect of peak concentrations (µM) of 
immunomodulator on J774-A1 macrophage cell growth. Kruskal Wallis non 
parametric ANOVA. N3, n12-18.  AZA = azathioprine. HC = hydrocortisone. Cell 
numbers are expressed as average cell numbers per well ± SEM. At day one cell 
counts were only assessed in untreated wells to confirm ongoing replication. 
 
                                                       Drug exposure  
 Untreated AZA 210 µM AZA 4.2 µM HC 6 µM  
Day     
0 1x10
5 
± 0 1x10
5 
± 0 1x10
5 
± 0 1x10
5 
± 0 
1 1.82x10
5 
± 0.342 N/A N/A N/A 
2 3.27x10
5 
± 0.856 2.26x10
5 
± 0.392 2.14x10
5 
± 0.406 2.56x10
5 
± 0.597 
 
 226 
Table 8.3 Adenylate Kinase (AK) Cytotoxicity Assay. AK signals in relative 
luminescence units (RLU) from PBS, E.coli and RPMI media are shown for 
comparison, expressed as mean ± SE. AZA = azathioprine, HC = hydrocortisone. 
Kruskal Wallis non parametric ANOVA. N2, n6-27 (assessed on day 2 of 
experiments)  
 
Cell 
exposure 
Untreated AZA 
210 
µM  
AZA 
210 
µM + 
E.coli 
AZA 
4.2 
µM  
AZA 
4.2 
µM + 
E.coli 
HC 6 
µM   
HC 
6 µM 
+ 
E.coli 
E.coli 
alone 
PBS RPMI 
AK level 
Average 
RLU ± 
SEM 
23700 ± 
7510 
34400 
± 
8690 
38100 
± 
5450 
26600 
± 
11200 
30900 
± 
2690 
20100 
± 
6660 
34800 
± 
9420  
6530 
± 
557 
2860 
± 
1490 
5370 ± 
1560 
 
 
8.6.4 Experiments to quantify any directly bacteriocidal effects of 
immunomodulator drugs on E. coli HM605  
 
The effects of azathioprine, hydrocortisone, 6-MP and 6-TG when directly co-
incubated with E.coli over a 6 h timecourse are shown in figures 8.8 and 8.9. 
Ciprofloxacin at 4 µg/ml was used as a positive control. Hydrocortisone had no 
significant effect on E.coli  survival compared with control at any timepoint. 
Interestingly azathioprine had a statistically significant killing effect on E.coli at 4 h 
and a similar effect at 5/6 h which, however, was not statistically significant (figure 
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8.9). 6-MP also demonstrated a statistically significant E.coli killing effect at 3,5, and 
6 h (figure 8.8), which was interesting as its’ modulation of macrophage phenotype 
had not produced a significant result (figure 8.5). 6-TG had an inhibitory effect on 
E.coli replication at 4-6 h which was statistically significant at 5 h (figure 8.8).  
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Figure 8.8 Exploration of a direct bacteriocidal effect of the immunomodulators 
6-TG and 6-MP on E.coli. C = control, Cip = Ciprofloxacin. Ciprofloxacin 
concentration was Cmax  4µg/mL, 6-MP at 4.2 µM, and 6-TG at the equivalent 
concentration of 820 fmol per 8x10
8 
cells. Kruskal Wallis non parametric ANOVA 
used to test significance relative to untreated bacteria. *p<0.05,**p<0.01, 
***p<0.001. N2, n6. Absolute corrected CFU numbers are shown as mean ± SE. 
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Figure 8.9 Exploration of a direct bacteriocidal effect of the immunomodulators 
Azathioprine and Hydrocortisone on E.coli growth. C = control, Cip = 
Ciprofloxacin. Ciprofloxacin concentration was Cmax  4µg/mL,  hydrocortisone 
concentration 6 µM, and azathioprine 210 µM. Kruskal Wallis non parametric 
ANOVA was used to test significance relative to untreated bacteria, 
*p<0.05,**p<0.01, ***p<0.001. N2, n6. Absolute corrected CFU numbers are shown 
as mean ± SE. 
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8.7 Conclusions 
 
Metronidazole did not demonstrate an inhibitory effect on intra-macrophage E.coli 
replication in vitro either as a sole agent, nor any additional effect when used in 
combination with ciprofloxacin, either at Cmax or 10% Cmax.    
 
This work demonstrates a significant inhibition of intra-macrophage E.coli replication 
in vitro at clinically relevant concentrations of the immunosuppressives azathioprine 
and 6-TG, but not 6-MP. 
 
Hydrocortisone unexpectedly inhibited intra-macrophage E.coli replication. The 
effects of hydrocortisone during sepsis in vivo may be mediated by other effects on 
the immune system. 
 
The inhibitory effects of these drugs were not due to cytotoxic effects on macrophage 
cells. 
 
At a clinically relevant concentration, 6-MP demonstrated a degree of direct 
bacteriocidal effect on E.coli despite absence of effect on intra-macrophage 
replication. 
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8.8 Discussion  
 
Ciprofloxacin at Cmax and 10% Cmax concentrations significantly inhibited the 
replication of CD E coli within murine macrophages, but metronidazole had no effect 
on E.coli killing within macrophages either when used alone or in combination with 
ciprofloxacin at Cmax and 10% Cmax.. Azathioprine suppressed intra-macrophage 
E.coli replication at therapeutic concentrations (> 2 µM), but also at concentrations 
much lower than this, even as low as 4.2 x10
-9 
µM. 6-MP did not significantly inhibit 
E. coli replication within macrophages at the clinically relevant concentrations used, 
but 6-TG did, with peak suppression at 6-TG concentration of 82 fmogles per 8 x10
8 
cells, the magnitude it is measured at in steady state for normal thiopurine dosing. The 
steroid hydrocortisone inhibited the replication of CD E.coli within macrophages at  
0.6 µM but also at the clinically relevant concentration of 6 µM. Experiments did 
not show any adverse effect of the drugs used on macrophage growth or viability with 
or without addition of E.coli. This confirmed that the inhibitory effects on bacterial 
replication seen with immunomodulators were due to true modulation of bacterial 
survival within macrophages. Hydrocortisone had no direct bacteriocidal effect on 
E.coli replication over a 6 h timecourse though the other immunomodulator drugs 
used, azathioprine, 6-MP and 6-TG did have a bactericidal effect at intermittent 
timepoints, with 6-MP having the earliest bacteriocidal effect after 3 h, in contrast to 
its negative effect on macrophage modulation. 6-MP was the only drug that 
demonstrated an inhibitory effect at a clinically relevant concentration, and produced 
39 to 43% inhibition at 3, 5 and 6 h timepoints. 
Ciprofloxacin was effective both at Cmax and 10% Cmax at inhibiting 
replication of E.coli within macrophages compared to bacterial replication in 
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untreated macrophages, this supports previous work from this laboratory and suggests 
the  importance of this antibiotic’s use in clinical trials.  The use of metronidazole as 
an antibiotic to target the E.coli potentially relevant in CD pathogenesis is not 
supported by this in vitro work, as there is no evidence that it confers any additional 
benefit to intra-macrophage killing over ciprofloxacin used alone. Metronidazole 
might conceivably have had efficacy against E. coli in the microaerophilic 
environment within macrophage vesicles but this was not seen. However it has 
probable clinical efficacy in CD and this may be due to the effective killing of 
anaerobic bacteria which may infect tissue secondarily after mucosal ulceration has 
been initiated in response to other pathogenic agents. It also may have immunological 
effects, such as blockade of neutrophil recruitment which give it efficacy independent 
of its antibiotic effect (336). It may be valuable for treatment of  anaerobic infection 
in abscesses and perianal disease (356). The use of metronidazole to control relapse in 
CD also has the support of meta-analysis (269), but can be limited by the 
unwillingness of patients to abstain from alcohol during a therapeutic course, or 
complications from protracted use such as peripheral neuropathy. Further clinical 
trials of antibiotic combinations in CD which target E.coli specifically are warranted. 
Constructing these trials and selecting antibiotic combinations needs careful 
consideration of issues including side effect profiles, microbial resistance, and 
interactions with drugs used in maintenance therapy in CD.    
It was, and is, to some extent, difficult to determine what therapeutically 
relevant concentration of thiopurines are. There are many metabolic alternate cycling 
pathways and intermediaries (section 2.10.1) between azathioprine and its terminal 
metabolites which include thioguanine, and the level of activity in these enzymatic 
pathways can differ between patients (357), making modelling of thiopurine usage in 
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the in vivo system with in vitro techniques difficult. In this work data was utilised 
which demonstrated average thioguanine levels in thiopurine treated patients (352) 
and applied this to the macrophage cell numbers in our experiments which we had 
quantified, assuming these concentrations approximated to quantities found in 
erythrocytes. For azathioprine and 6-mercaptopurine, concentrations of clinical 
relevance had been defined in previous work (287;351). 
 The in vitro data examining the immunomodulators raise some interesting 
questions about the mode of action of some of the pharmacological agents used to 
treat IBD. The differing effects of azathioprine and its metabolites 6-MP and 6-TG are 
explicable. All these compounds generally had some bacteriocidal effect when 
directly co-incubated with bacteria, though generally tested at concentrations above 
those that were clinically relevant. The effect of 6-MP which was used at a 
concentration close to its therapeutic concentration was interesting as it had not 
modified intra-macrophage replication of E.coli. It may be that 6-MP is not taken up 
by cells in the in vitro model, and certainly azathioprine is intracellularly cleaved into 
its active metabolites following cell uptake. The presence of hypoxanthine in the 
RPMI culture media (358) may have effectively diluted  the 6-MP before it could be 
utilised by the macrophage cells, as 6-MP is a hypoxanthine analogue. It may also be 
that high levels of xanthine oxidase, found in most murine tissues (359), reduced 
quantities of 6-MP in our in vitro model with their purine catabolising activity. 
Regarding the agents used in this work separately as an ‘antibiotic’ or as an 
‘immunomodulator’ may also be an artificial simplification as they may possess 
properties of both, which has to some extent already been described. The mode of 
action of all the ‘immunomodulators’ to some extent seems to be related to altering 
sensitivity to reactive oxygen species (287;288), affecting the activity levels of iNOS 
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(292), and modulation of phagocytosis. This works prompts further examination of 
these mechanisms of action of azathioprine and its metabolites. Perhaps further in 
vitro murine work examining the effects of 6-MP on intra-macrophage E.coli 
replication would be improved co-incubation with allopurinol, to inhibit xanthine 
oxidase effects and careful selection or dialysis of FCS before use in culture media to 
avoid problems with hypoxanthine rich sera. 
 The suppression of intra-macrophage E.coli replication by hydrocortisone is 
interesting, as it is associated with an increased risk of sepsis in vivo. This work 
supports previous data suggesting steroids are pro-phagocytic (293), and their effects 
on sepsis in vivo may be more related to their suppression of neutrophil recruitment. It 
is probable that their effect on the body’s response to sepsis may be mediated by 
blockade of the recruitment of neutrophils to a site of injury (360), which is mediated 
by IL-8 (202), or inhibition of macrophage recruitment (294), rather than by any 
direct effect on the ability of phagocytic leucocytes to kill bacteria. They were non 
bactericidal in direct co-incubation with bacteria, and this may be related to the 
timecourse they take to produce an effect rather than a genuine absence of effect. 
Alternatively it may be that steroids have differential effects on bacterial phagocytosis 
and killing at different timepoints.  
It would be interesting to define the effects of other drugs on intra-macrophage 
E.coli replication, particularly those which have efficacy in CD  such as anti-TNFα 
therapies, or other immunosuppressives such as ciclosporin or tacrolimus. It would 
also be informative to define the effects of the therapies used on the cell-bacterial 
cytokine signalling pathways involved.   
Finally, it is intriguing that many of the pharmacological agents investigated 
here, demonstrate either a direct E.coli killing effect, or an indirect inhibition of the 
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intra-macrophage survival of bacteria. These drugs also have proven clinical efficacy 
in CD management, either in maintaining remission or treating relapse. This gives 
some indirect support to the hypothesis that E.coli growth and replication, and its 
regulation is fundamental in CD pathogenesis.  
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CHAPTER NINE : THE EFFECT OF SOLUBLE FIBRES 
ON ADHESION OF DIARRHOEAL PATHOGENS TO 
CACO2 CELLS  
 
 
9.1 Hypothesis: 
 
Soluble plant fibres (NSP), such as those from Plantain bananas, oats and apples may 
affect the adhesion of diarrhoeal pathogens to intestinal epithelial cells.  
 
9.2 Aim: 
 
To assess, using various in vitro modalities, whether dietary soluble fibres (Non-
starch polysaccharide, NSP) block or promote the adherence of diarrhoea-causing 
bacteria and Crohn’s-associated  E. coli to intestinal epithelial cell lines. 
 
9.3 Introduction 
 
 
9.3.1 The effect of NSP on AIEC adherence to intestinal cell lines 
 
 
 
Previous experiments by our group have demonstrated the inhibitory effect of soluble 
plantain fibre on the adhesion of CD-specific AIEC bacteria to intestinal cell lines 
(232), as well as an inhibitory effect on the translocation of AIEC and diarrhoeal 
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pathogens across M (microfold) cell epithelium both in vitro, and in ex vivo human 
Peyer’s patches (69). The M cell is a specialised epithelial cell that accounts for about 
5% of cells in the surface “dome” epithelium that overlies the lymphoid follicles of 
the colon, and the Peyer’s patches in the small intestine which maintain immune 
homeostasis in the bowel (Introduction chapter 2). These initial findings prompted the 
current clinical trial of plantain fibre supplementation for maintenance of remission in 
CD (discussed in chapter 7). Plantain fibre was not the only foodstuff that 
demonstrated an inhibitory effect on bacterial adhesion in vitro, as broccoli NSP also 
demonstrated efficacy but apple and leek NSP did not show a significant effect (69). 
The effect of apple pectin on E.coli adherence to intestinal cell lines was uncertain as 
it had caused haemolysis in the haemagglutination assay used as a proxy for 
adherence and had not been further tested (232). Pectins are a specific form of NSP, 
being dietary and functional fibre composed of complex heteropolysaccharides and 
containing 1,4-linked α-D-galactosyluronic acid residues (361;362). They are also 
extractable from citrus fruits and have a known mild antibacterial effect against 
E.coli. In other work beta-D-glucans derived from oats have been shown to increase 
the Nuclear factor kappa B (NFKB) signalling in the small intestines of mice, but not 
the colon (363). As this signalling is generally pro-inflammatory, it was interesting to 
consider the possible effects of oat fibre on E.coli adhesion to intestinal cell lines. 
   
9.3.2 Different Pathotypes of E.coli  
 
 There are a number of different pathotypes of E coli whose pathogenicity and 
method of epithelial interactions vary usually according to their virulence factors (See 
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introduction chapter 2, section 2.5 for a detailed account). Enteropathogenic E. coli 
(EPEC) and enterotoxigenic E.coli (ETEC) interact with, colonise and invade 
gastrointestinal tissue in diverse ways to cause disease. Diarrhoeal illness is a 
common cause of illness and death worldwide, particularly in developing countries 
(244), and infantile diarrhoea cases are rising (245). In some series E coli was 
detected in 20% of cases where a bacterial cause was suspected (244;246) and 
diarrhoeogenic E.coli pathotypes (DEP) represent a high disease burden, particularly 
in areas like sub-Saharan Africa (244;247).  
 
9.3.2.1 Types of EPEC 
 
EPEC  can be divided into ‘typical’ and ‘atypical’ types. They are distinguished from 
entero-haemorrhagic  E. coli (EHEC) by absence of the phage borne shiga toxins 
(244).  Typical EPEC strains carry genes for the LEE (locus for enterocyte 
effacement), virulence plasmids bearing genes encoding bfp (bundle-forming pili) and  
EAF (EPEC-adherence factor) whilst atypical EPEC do not have the EAF-plasmid or 
EAF-associated virulence plasmid (244;249).  Their unique interaction with epithelia 
are described in section 2.5.1. 
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9.3.2.2 Types of ETEC  
 
ETEC are amongst the most common causes of travellers’ diarrhoea (244;254), and 
also a common cause of infantile diarrhoea, spread by contaminated food and water 
sources (255). Their pathogenesis is toxin mediated and is discussed in section 2.5.2. 
Although they promote diarrhoea by the effects of their toxins rather than by mucosal 
invasion, inhibition of bacterial proximity to the intestinal mucosa should reduce 
pathogenicity.  
 
9.3.3  C. Difficile and Campylobacter jejuni 
 
C. Difficile is the main cause of antibiotic-associated diarrhoea in hospitalised 
patients, commonly due to suppression of the normal gastrointestinal microbiota by 
broad spectrum antibiotics. It is a spore forming organism, and has the potential to 
cause pseudomembranous colitis which can be fatal (303;364). The diarrhoeal illness 
caused is toxin-mediated, utilising enterotoxin (toxin A) and cytotoxin (toxin B) (365), 
though approximation of the bacterium to the mucosa is probably mandatory for 
pathogenesis  (366). C. Difficile PCR ribotype 027, (the ribotype investigated here) 
amongst others, is hypervirulent and is associated with increased mortality (367), 
probably through much higher levels of toxin production (368). This infection 
represents a significant financial burden to the NHS, with C. Difficile associated 
diarrhoea associated with costs of around £4107 per patient affected in the UK (369).  
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Campylobacter jejuni is a bacterium associated with enormous morbidity 
worldwide.  It is a microaerophilic spiral shaped bacterium, that colonises birds, 
(chickens are important in the human food chain) and is associated with 14% of acute 
infectious cases of diarrhoea worldwide. It can produce watery diarrhoea, an 
appendicitis like syndrome, and neurological complications, namely the Guillain-
Barré syndrome. Its methods of pathogenicity are under investigation as it lacks 
typical toxins or plasmid sited invasion factors, yet is able to invade and damage 
intestinal tissue (370). 
 The inhibitory effects of the NSP on CD AIEC bacterial adhesion have been 
examined, but the effect of NSP on other diarrhoeal pathogens has not previously 
been described. In the experiments described here the inhibitory effects of oat and 
plantain NSP as well as apple pectin on the adhesion of ETEC, EPEC, C. difficile and 
Campylobacter jejuni were evaluated as well as further assessment of AIEC inhibition 
by fluorescence-activated cell sorting (FACS). The utility of FACS for measuring 
bacterial to cell adherence had been demonstrated previously for C.difficile (303). 
 
9.4 Methods 
 
9.4.1 Cell culture 
 
 
Caco2 cells were maintained as described in section 5.1.1.  
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9.4.2 Bacterial strains and growth conditions 
 
EPEC, ETEC, Campylobacter jejuni and C. difficile strains were obtained and 
prepared as discussed in section 5.2.3, as was K12, (section 5.2.2) an indolent 
laboratory E.coli strain used as a negative control in the EPEC adhesion experiments. 
AIEC HM605 were prepared on LB agar as described in sections 5.2.1 – 5.2.2. 
 
Prior to infection of cultured epithelial cells, bacteria were washed three times, re-
suspended in sterile PBS and adjusted to an OD 550 nm or OD 570 nm equating to 1 
x 10
9 
CFU/mL. They were then diluted as necessary to produce an appropriate 
multiplicity of infection (MOI as per section 9.4.3). 
 
9.4.3 Adherence assays  
 
Bacterial strains were tested for their ability to adhere to, and/or invade, Caco2 cells 
in the presence of plantain NSP. Cells were maintained in complete DMEM at 37°C, 
5% CO2. Cells were initially seeded into 24-well tissue culture plates at 1x10
5 
cells 
per well and grown overnight in DMEM (without antibiotics). The monolayers were 
then washed twice with sterile PBS. Bacteria were grown overnight on agar, washed 
twice in sterile PBS,  and  added to the well. Bacteria were added to each monolayer 
at an MOI of 10 - 500. For EPEC studies, bacteria were initially added at MOI of 10 
but due to low adherence of EPEC to Caco2 cells, studies were repeated at higher 
MOI of 100 and 500. After 4 h of infection at 37°C, cell monolayers were washed 3 
times with sterile PBS, and to enable quantification of total adherent and invasive 
bacteria they were lysed by adding 1% (v/v) Triton X-100 for 5 min to release 
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internalized bacteria. Ten-fold dilutions of the cell lysate were performed, and 50 μL 
from each was plated onto LB agar plates. Plates were incubated at 37°C, and CFU 
were enumerated after 24 h.  
 
The effect of apple pectin and oat or plantain NSP on bacterial adhesion to Caco2 
cells was assessed by pre-incubating Caco2 cells for 0.5 h with these NSPs before 
bacterial infection.  
 
9.4.4 Preparation of soluble dietary fibre from plantain and oats, and apple 
pectin  
 
Non-starch polysaccharide (NSP) from plantain, the banana family (Musa spp.) and 
oats were provided (Dr Niamh O’Kennedy, Provexis UK) as water soluble freeze 
dried powders. Concentrations tested were within the range of intraluminal 
concentrations that would be readily achievable with dietary supplementation (69). 
For the experiments evaluating the effect of plantain fibre on ETEC and EPEC 
bacterial adhesion, these concentrations were 0.005, 0.05, 5 and 50 mg/ml (ETEC 
experiments performed with Dr Carol Roberts). For the oat fibre and apple pectin 
experiments, a single 5 mg/ml concentration was used. 5 mg/ml was the dose which 
reflected likely luminal plantain concentrations present in the distal colon following a 
5g twice daily patient supplementation with plantain, as per the clinical trial (chapter 
seven). The fibres and pectin were dissolved in PBS and sterile filtered before use. 
Apple pectin was used at a one in ten dilution of the stock concentration used in (232) 
i.e. at 5 mg/ml to facilitate dissolution.  
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9.4.5 Standardisation and analysis of results 
 
The number of E coli added on the day of the infection was confirmed by performing 
ten-fold dilutions of the neat bacterial suspensions and plating 50µl of these dilutions 
on standard LB agar with the resulting number counted after overnight incubation at 
37ºC. These counts were used to produce a correction factor so bacterial numbers 
could be directly counted inter-experiment. 
 
Data were analysed with total bacterial numbers (invasive and adherent)  in Caco2 
cells treated with NSP fibres or pectin compared to untreated cells. The datasets were 
statistically assessed using the Kruskal-Wallis non parametric ANOVA when multiple 
groups were involved. When two groups were directly compared, for example a 
comparison of bacterial strain and bacterial strain adherence following inhibitor pre-
incubation with Caco2 cells, the analysis used depended on the variance present in the 
observations. Where variance was equal a paired t-test was used, and when data were 
not normally distributed a Mann-Whitney U test was performed to assess significance 
of the results. Differences were regarded as statistically significant when 2-tailed P 
values were < 0.05.  
 
9.4.6 FACS adherence experiments  
 
The potential inhibitory effect of plantain NSP on bacterial adhesion to Caco2 cells 
was evaluated for the bacteria AIEC (HM605), ETEC, Clostridium difficile, and 
Campylobacter jejuni using  FACS. The method was based on (303). The sources of 
the bacteria, and their growth conditions are described in sections 5.2.1 – 5.2.3. 
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9.4.6.1 Cell culture for FACS  
 
Caco2 cells were maintained as described in section 5.1.1 until 80% confluent in 
flasks. 24 h before adherence assays, DMEM medium was removed, cells were 
washed three times in cold PBS, and cells were incubated with antibiotic-free 
medium. Cells were then washed three times again with PBS and removed from 
tissue-culture flasks with a trypsin solution (as described in section 5.1.1). Cells were 
counted using a haemocytometer and adjusted to 1x10
5 
cells/ml using antibiotic free 
DMEM. 
 
9.4.6.2 Preparation of NSP for FACS 
 
During pilot experiments it was noticed that NSP at concentrations of 20 mg/ml on its 
own produced a FACS signal (results not shown). This was not seen when NSP was 
prepared at 5 mg/ml. 
 
Plantain derived NSP (NSP#3G, batch 17+18 containing 55.7 % plantain fibre and 
plantain-derived maltodextrin at 33.4 %) was dissolved in sterile PBS to give a 
concentration of 20 mg/ml (for a final experimental concentration of 10 mg/ml). 
Other plantain concentrations were prepared by appropriate dilution of this initial 
solution with sterile PBS, i.e. 10, 5 and 2 mg/ml, for final experiment concentrations 
of 5, 2.5, and 1 mg/ml. 
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9.4.6.3 Bacterial preparation for FACS experiments 
 
C. difficile was cultured by placing one Protect bead into 50 ml Fastidious Anaerobe 
Broth and culturing anaerobically without shaking for 36 h at 37ºC. 
ETEC also had been stored on Protect beads at -80
o
C and were cultured by placing 
one bead into 40 ml LB broth and culturing aerobically without shaking for 24 h at 
37ºC. 
AIEC HM605 were cultured by placing a loop-full of inco-loop from Protect beads 
into 40 ml LB broth and culturing aerobically without shaking for 24 h at 37ºC. 
 
9.4.7 Harvesting bacteria and fluorochrome labelling 
 
Bacteria were harvested by centrifugation at 9000 rpm (19017g) for 5 min and 
resuspension in sterile PBS. Bacteria in suspension were then quantified by OD 
reading at 550 nm, and were adjusted to 1x10
8
 bacteria/ml (OD=0.825, then diluted 
ten fold for fluorochrome labelling.  
 
1 mM 2',7'-bis-(2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester  
(BCECF/AM) stock solution (supplied by Invitrogen), had been divided into 50 μl 
aliquots which were stored in a well-sealed container and protected from the light 
with aluminium foil and stored in the -20ºC freezer. For a 1 μM working 
concentration 10 μl stock solution of BCECF/AM was added for every 10 ml bacterial 
suspension (1x10
8
 bugs/ml).  
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Bacteria were labelled with BCECF/AM fluorochrome at 37ºC for 60 min ensuring 
that tubes were protected from the light with aluminium foil prior to incubation. 
Excess fluorochrome was removed by 5 sequential washes in PBS followed by 
centrifugation at 9000 rpm (19000 g) for 5 min.   
 
9.4.8 NSP plantain treatment of the bacterial suspensions 
 
After the penultimate wash, each bacterial suspension was split into an appropriate 
number of aliquots (for the plantain concentrations assessed on the day of the 
experiment, 2-5) before centrifugation. After the final wash bacteria were re-
suspended in PBS containing 20,10,5, or 2mg/ml plantain NSP, or PBS alone and 
were incubated for 30 min ensuring tubes were protected from the light using 
aluminium foil.  
 
9.4.9 FACS Adherence assay 
 
An equivalent volume of Caco2 cells at 1x10
5
 cells/ml was added to the fluorescently 
labelled bacteria and incubated at 37ºC for 1 h. (i.e MOI 1000) After incubation, cells 
were washed by centrifugation at 1200 rpm (340 g) for 5 mins x 3 in PBS to remove 
any non-adherent bacteria. After the final wash the pellets were resuspended in 0.5 ml 
PBS and were transferred into individual 1 ml tubes. 
 
Caco2 cells with and without adherent C. Difficile, ETEC, Escherichia coli or 
Campylobacter jejuni in the presence or absence of varying concentrations of plantain 
fibre were measured in a FACScan flow cytometer.  A total of 10,000 events were 
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acquired per cell and bacterial suspension, and the data were analysed with the Cell 
Quest software programme. Results were expressed as Mean Fluorescent intensity 
(MFI) using the geometric mean of each sample to assess bacterial adherence to 
Caco2 cells.  Student’s t-test was used to compare differences in bacterial adherence 
in the presence or absence of soluble plantain fibre, for C . difficile and ETEC FACS 
studies, but when multiple NSP concentrations were used, a multiple group 
comparison with a non parametric ANOVA was used, (Kruskal Wallis), with 
significance noted for p values < 0.05. 
 
Fluorescence of HM605 E coli, C.difficile, ETEC and Campylobacter alone was also 
measured but could not be compared directly to the other experimental groups due to 
different FACS gating requirements to measure bacteria alone. These samples were 
kept in case of any problems with getting a positive fluorescence signal for cells and 
bacteria together, but this problem did not materialise. 
 
9.5 Results 
 
9.5.1 The effect of plantain NSP, oat NSP, and apple pectin on ETEC adhesion to 
Caco2 cells 
 
Pre-incubating the Caco2 cells with a 5 and 50 mg/ml concentration of plantain NSP 
significantly inhibited the adherence of ETEC bacteria to the cells (figure 9.1).  
          Pre-incubation of Caco2 cells with a 5 mg/ml concentration of apple pectin did 
not significantly inhibit the adhesion of ETEC to the Caco2 cells (figure 9.2). Oat 
NSP fibre also had a non-significant inhibitory effect when it was used to pre-
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incubate Caco2 cells at a concentration of 5 mg/ml prior to infection of the cells with 
the ETEC bacteria (figure 9.3). 
 
 
 
                              Plantain concentration mg/ml 
 
Figure 9.1 The effect of plantain NSP on ETEC adhesion to Caco2 cells at 
differing doses. ETEC adhesion to Caco2 cells was significantly inhibited at  
concentrations of 5 and 50 mg/ml plantain NSP. (N3,n9 Kruskal Wallis non 
parametric ANOVA * = p<0.05 ** = p<0.01). Mean % adhesion ± SE is shown.   
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Figure 9.2 Apple pectin non significantly inhibited the adherence of ETEC to 
Caco2 cells. Apple pectin used at a concentration of 5 mg/ml non significantly 
inhibited (p = 0.22) the adhesion of ETEC to Caco2 cells (N2, n6 Mann-Whitney U 
test).  Mean cfu/ml ± SE are shown.   
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Figure 9.3 Oat NSP non significantly inhibited the adherence of ETEC to Caco2 
cells. Oat NSP used at a dose of 5 mg/ml non significantly inhibited (p=0.30) the 
adhesion of ETEC to Caco2 cells (N3, n9 Mann-Whitney U test). Mean cfu/ml ± SE 
are shown.       
 
9.5.2 The effect of plantain NSP on EPEC adhesion to Caco2 cells 
 
Plantain NSP had no effect on the binding of the typical D55 (figure 9.4), or atypical 
e2348/69 (9.5), EPEC strains to Caco2 cells in vitro at any dose investigated (0 - 50 
mg/ml). The AIEC HM605 has significantly greater binding to Caco2 cells than both 
the EPEC bacteria and the negative control bacterium K12. Increasing the EPEC MOI 
to 500:1 did not affect this result (data not shown). Pre-incubating the Caco2 cells 
with a 5 mg/ml concentration of plantain NSP significantly inhibited the binding of 
the AIEC HM605 to Caco2 cells, as had been seen previously, demonstrating that  
both the positive and negative controls worked. Pre-incubating the Caco2 cells with a 
5 mg/ml concentration of plantain NSP did not significantly inhibit the adherence of 
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the K12 bacteria to the Caco2 cells. In the absence of inhibitor AIEC CD E. coli 
HM605 bacteria were significantly more adherent to Caco2 cells than both the K12 
and EPEC bacteria. 
 
 
 
                 
Figure 9.4 Plantain NSP has no effect on the binding of the EPEC strain D55 to 
Caco2 cells. Histogram bars are labelled with the name of the bacterial strain + 
concentration in mg/ml of NSP used in preincubation of cells if present. No dose of 
plantain in the range tested (0.05-50 mg/ml) had any effect on the binding of EPEC 
strain D55 to the Caco2 epithelial cells (N3, n9 Kruskal Wallis non parametric 
ANOVA * = p<0.05 ** = p<0.01 *** = p<0.001). Mean cfu/ml ± SE are shown.    
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Figure 9.5 Plantain NSP has no effect on the binding of the atypical EPEC strain 
e2348/69 to Caco2 cells. Histogram bars are labelled with the name of the bacterial 
strain + concentration in mg/ml of NSP used in preincubation of cells. No dose of 
plantain in the range used (0.05-50 mg/ml) had any effect on the binding of the 
atypical EPEC strain to the Caco2 epithelial cells. (N3, n9 Kruskal Wallis non 
parametric ANOVA). Mean cfu/ml ± SE are shown.   
 
 
9.5.3 FACS assessment of bacterial adherence and its inhibition by soluble fibres 
 
9.5.3.1 The effect of NSP plantain fibre on AIEC adherence to Caco2 cells 
 
When AIEC bacteria were pre-incubated with plantain NSP concentrations between 
2.5 and 10 mg/ml, inhibition of AIEC adherence to Caco2 cells was observed at all 
concentrations with a peak inhibition seen at 2.5 mg/ml (with P value 0.054 just 
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failing to reach conventional significance, (figure 9.6). The reduced inhibition of 
AIEC bacteria at higher NSP concentrations was not typical for an inhibitor, and was 
not consistent with previously published results that demonstrated a dose response 
effect (69). This was perhaps explained by the FACS signals observed from plantain 
fibre used alone at higher concentrations (9.4.6.2). The results seen with inhibition at 
5 mg/ml are in agreement with the tissue culture results in section 9.5.2 (figures 9.4 
and 9.5). 
 
Figure 9.6 The effect of plantain NSP at different doses on AIEC adhesion to 
Caco2 cells. Concentration of plantain NSP used in pre-incubation of AIEC before 
addition to Caco2 cells is noted below each histogram bar. Adherence is expressed as 
geometric mean fluorescence intensity ± S.E. The signal from Caco2 cells alone, cells 
with E. coli added and the effect of pre-incubating the bacteria for 30 min before 
addition to the cells with doses from 2.5 – 10 mg NSP plantain is shown. There is an 
inhibition of E. coli.  binding to Caco2 cells when plantain NSP is used at a dose of 
2.5 mg/ml (p=0.054), which is seen at higher doses to a lesser extent (N2-4, 10000 
events per experiment, Kruskal Wallis non parametric ANOVA.  
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9.5.3.2 The effect of plantain NSP on Campylobacter jejuni adhesion to Caco2 
cells 
 
When Campylobacter jejuni bacteria were pre-incubated with plantain NSP 
concentrations between 1 and 10 mg/ml, non significant inhibition of Campylobacter 
jejuni  adherence to Caco2 cells was observed at all concentrations. The higher FACS 
signals seen at higher plantain NSP concentrations  in figure 9.6 were not seen in the 
FACS experiments with Campylobacter.                     
 
Figure 9.7 The effect of plantain NSP at different doses on Campylobacter jejuni 
adherence to Caco2 cells. Camp = campylobacter. Concentration of plantain NSP 
used in pre-incubation of Campylobacter jejuni  before addition to Cac02 cells is 
noted below each histogram bar. Adherence is expressed as geometric mean 
fluorescence intensity ± S.E. The signal from Caco2 cells alone, cells with. 
Campylobacter jejuni added and the effect of pre-incubating the bacteria for 30 min 
before addition to the cells with doses from 1 - 10mg NSP plantain is shown. (N2-4, 
10000 events, Kruskal Wallis non parametric ANOVA. 
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9.5.3.3 The effect of plantain NSP on Clostridium difficile and ETEC adhesion to 
Caco2 cells 
 
The effect of pre-incubation with plantain NSP on Clostridium difficile and ETEC 
adhesion to Caco2 cells is shown in figure 9.8. There was a statistically significant 
inhibition of C. difficile and ETEC binding to Caco2 cells following pre-incubation 
with plantain NSP at 10 mg/ml (p = 0.01 and p = 0.016 respectively).  
 
 
Figure 9.8 The effect of plantain NSP on C.difficile and ETEC adhesion to Caco2 
cells. The bacterial species is noted below each histogram bar. In these experiments a 
plantain NSP concentration of 10 mg/ml was used to pre-incubate the bacterial 
species before addition to the Caco2 cells. Adherence is expressed as geometric mean 
fluorescence intensity ± S.E. The signal from Caco2 cells alone, cells with. C. difficile 
or ETEC added, and the signal produced when  the bacteria had been pre-incubated 
for 30 min with a concentration of plantain NSP of 10 mg/ml are shown (N4, 10000 
events per experiment, students t test * = p<0.05). 
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9.5.3.4 FACS signals seen from NSP plantain fibre in isolation                     
 
In addition, (data not shown), FACS signals from NSP plantain fibre in isolation were 
seen when a concentration of 20 mg/ml were used, but not with a concentration of 5 
mg/ml. These were the only concentrations evaluated, but this effect may conceal 
significant inhibitory effects of plantain at concentrations greater than 5 mg/ml, and 
clearly represents a significant drawback of FACS as a technique for estimating 
inhibition of adherence by soluble fibre. 
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9.6 Conclusions  
 
NSP plantain has a statistically significant dose dependent inhibitory effect on the 
adhesion of ETEC to Caco2 intestinal cells, and inhibits ETEC adherence at 
concentrations that would be readily achievable in the colonic lumen (5 mg/ml) with 
dietary supplementation. This inhibitory effect was seen with two types of in vitro 
assay, both culture plate assays and FACS. 
 
Oat NSP and apple pectin, both used at concentrations of 5 mg/ml, inhibited the 
binding of ETEC bacteria to Caco2 cells, but not with statistical significance. Further 
experiments to increase replication numbers are indicated but were limited during this 
work due to time constraints.  
 
Plantain NSP had no effect on the binding of EPEC bacteria to Caco2 cells at any 
concentration between 0.05 and 50 mg/ml, though these experiments confirmed 
earlier work demonstrating a statistically significant inhibitory effect of plantain on 
CD AIEC bacteria adherence at concentrations of 5 mg/ml.  
 
The FACS experiments demonstrated a statistically significant inhibition of ETEC 
bacteria with NSP plantain at 10 mg/ml, which supported the cell culture results, and 
also a significant inhibitory effect of plantain fibre on C.difficile adherence to Caco2 
cells, also at 10 mg/ml.  
 
FACS methods did not demonstrate a significant inhibition by plantain NSP of AIEC 
adhesion to Caco2 cells at any dose, though a 2.5 mg/ml concentration was almost 
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significant. No inhibitory effect of plantain on Campylobacter jejuni adherence to 
Caco2 cells was seen either though doses above 10 mg/ml were not used in either of 
these experimental series.   
  
The significant FACS fluorescent signal generated by NSP plantain fibre in isolation 
has to be considered a significant drawback with the FACS assay. Conclusions based 
on the FACS assay alone have to be made with caution. It is not a suitable assay to 
use in further experiments to assess inhibition by soluble fibres. 
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9.7 Discussion 
  
These experiments confirm that plantain NSP fibre has inhibitory effects on adhesion 
of AIEC and also some diarrhoeal pathogens to an intestinal cell line in vitro. The 
plantain fibre inhibited the adhesion of ETEC and C. difficile to Caco2 cells. It would 
be advantageous to perform further experiments with apple pectin and oat NSP fibre 
as there may be a real difference in the effects of these foods on ETEC bacterial 
adhesion to intestinal cells that can only be demonstrated with further replication. 
Dose response curves would also provide additional information. These experiments 
were restricted here due to time constraints. 
The absence of an inhibitory effect of NSP plantain fibre on the adherence of 
both typical and atypical EPEC bacteria to Caco2 cells has some biological 
plausibility, as the EPEC bacteria use a unique mechanism of interaction with host 
epithelial cells. By secretion of its own translocation intimin receptor onto the host 
cell, which functions as a receptor for its intimin ligand (253), the EPEC may bypass 
the ‘mucosal blockade’, or cross linking of its’ own bacterial cell surface receptors, 
which will include lectin carbohydrate moieties. Soluble plantain fibre is a complex 
mixture of oligosaccharides, and any of these, perhaps particularly mannose, could 
interfere with the EPEC adhesion to the mucosal surface if the bacterium didn’t utilise 
these alternate host interaction strategies. Perhaps the atypical EPEC uses the proteins 
expressed from its mobility and resistance plasmids to avoid plantain cross linkage. 
The fact that both the negative and positive control experiments in the EPEC 
experiments gave the anticipated results supports the conclusion that this is a true 
result. 
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It was of interest that the oat fibre did not stimulate bacterial adhesion to 
Caco2 cells as might be hypothesised from its stimulatory effects on NFKB in mice 
(363). This may result from different modulation of NFKB signalling in mice and 
humans. Also of note, the ETEC and C.difficile adherence to Caco2 cells was 
inhibited by plantain NSP, and this could be clinically very useful, partly because 
there are suggestions that toxin production is not the sole mechanism for disease 
activity, but also because mucosal proximity is a factor in toxin-mediated damage.  
 The observation that NSP plantain fibre has its own FACS fluorescence signal 
when higher concentrations are used makes it difficult to use this technique in 
quantitative assays, and is a significant drawback. However, the plantain fibre could 
be run on its own as a control in each FACS adhesion experiment. The signal seen 
with higher plantain concentrations did not seem to distort FACS results, except 
perhaps with AIEC. Overall it does not seem appropriate to use the technique in 
further plantain adhesion assays, but the ability to measure 10000 cell-bacterial events 
in an experiment was a powerful technique and dual labelling both cells and bacteria 
in FACS adhesion experiments with fluorochrome is a possible alternative for future 
assays.   
 
The potential for translating the results of these in vitro experiments into clinical trials 
investigating the prophylaxis of diarrhoeal pathogen infection, to complement the 
trials already underway investigating the use of plantain fibre in CD is clear (see 
chapter seven). When a 5 g twice daily supplement of NSP plantain fibre is given to a 
patient, the resultant minimum intra-luminal concentration  of the foodstuff is 
estimated to be at least  5 mg/ml, even in the distal colon (232), and the work in this 
chapter has demonstrated in vitro efficacy at those concentrations of soluble fibre. 
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Diarrhoeal illness is a large burden worldwide, in terms of morbidity, 
mortality and cost, and antibiotics are often implicated as a cause of diarrhoeal illness. 
Additional strategies for prophylaxis of infective diarrhoea would augment current 
infectious disease prevention strategies. If dietary supplements are shown to be 
effective, it would result in lower incidence of multi-resistant bacteria and be very 
cost-effective. It could be of particular interest to focus on at risk groups, for example 
hospitalised patients over the age of sixty five who are on antibiotics, African infants 
and children in areas of poor sanitation, or people travelling frequently to endemic 
areas. Many of these diarrhoeal pathogens can also trigger a relapse of UC or CD 
(47;224) so the benefit would not solely be confined to those patients at risk of 
diarrhoeal illness, but could also prevent CD relapses.  
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CHAPTER TEN : SUMMARY OF PRINCIPAL FINDINGS  
 
 
The development of qPCR assays for the quantification of E. coli 
bacteria and human tissue 
 
There was a lengthy period of development, which involved assessment of  a number 
of different techniques, for the development of standardised assays suitable for 
quantification of uidA genes and therefore by proxy E.coli in CD biopsies.  
 
 The optimal assay for producing standards for quantification of uidA 
genes proved to be the multi-step process of producing a suitable 
amplicon, splicing it into DNA, transforming cells to accept plasmid DNA 
and ultimately extracting the plasmid DNA from these clones and 
confirming the presence of the amplicon by qPCR with or without 
restriction enzyme digest.  
 
Bacterial numbers could be quantified with great precision with this assay with 
appropriate sensitivity (1140 copies), efficiency (104%), error (0.130), coefficient of 
variation or reproducibility (3.72 %), and correlation coefficient (0.995). The 
linearisation of the standard circular plasmid DNA template proved critical for the 
uidA assay, and this assay fulfilled the specified statistical pre-requisites for 
quantification of E.coli in the biopsies from CD tissue. 
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The removal of bacterial CFU quantification from the standardisation process 
improved assay performance substantially, as did accurate genomic and plasmid DNA 
quantification. 
  
The use of the 18S rRNA kit to produce standardisation curves for quantification of 
human tissue produced an assay with a sensitivity of 5 human genomes, efficiency 
104%, error 0.185, correlation coefficient 0.992, and coefficient of variation or 
reproducibility of 2.84 %, which fulfilled requirements for the denominator assay for 
biopsies from CD tissue. Using biopsy mass as a denominator did not produce 
differences in graph shape, supporting the contention that the 18S rRNA genome 
denominator was unaffected by presence or absence of human inflammatory as well 
as total cells. 
 
Comprehensive experimental details were provided so that all these PCR assays could 
be repeated by other laboratories, along with the detailed statistical information above 
in line with published (MIQE) guidelines for PCR work.  
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Use of the qPCR assays for quantification of E. coli bacteria in CD 
biopsies  
 
 The assay works well to quantify the bacteria in biopsies and mucus 
washings from clinical trial samples of large intestinal tissue.  
 
There was a significantly lower quantity of E.coli bacteria in the combined mucus 
washings and biopsies from patients who were in clinical remission at three months 
compared to the same individuals (also in remission) at the start of the trial period. 
Although the data are blinded this implies a reduction in mucosa-associated bacteria 
with the trial intervention (plantain fibre or maltodextrin placebo). 
 
It was not possible to demonstrate a statistically significant difference in E. coli 
bacteria present in the biopsies of (n=3) patients who relapsed clinically, compared to 
the bacteria present in the same patient during their period of remission but further 
studies are ongoing. 
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The effects of antibiotics and immunomodulators on CD E.coli 
replication within macrophages  
 
 Ciprofloxacin at Cmax and 10% Cmax concentrations significantly inhibited 
the replication of CD E coli within murine macrophages, but 
metronidazole had no effect on E.coli killing within macrophages either 
when used alone or in combination with ciprofloxacin at Cmax and 10% 
Cmax.. 
 
 Azathioprine suppressed intra-macrophage E.coli replication at 
therapeutic concentrations. 6-MP did not significantly inhibit E. coli 
replication within macrophages at the clinically relevant concentrations 
used, but 6-TG inhibited bacterial replication within macrophages at 
therapeutically relevant levels  
 
 
 Hydrocortisone inhibited the replication of CD E.coli within macrophages 
at clinically relevant concentrations.  
 
The macrophage cell viability experiment and adenylate kinase toxicity assay did not 
demonstrate any direct cellular toxicity from incubating macrophage cells with peak 
concentrations of azathioprine and hydrocortisone even after 24 h. This was not 
affected by the addition of E.coli to the cells, confirming that the inhibitory effects on 
bacterial replication seen with immunomodulators were due to modulation of bacterial 
survival within macrophages, rather than macrophage cell death. 
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Hydrocortisone had no direct bacteriocidal effect on E.coli replication over a 6 h 
timecourse though the other immunomodulator drugs used, azathioprine, 6-MP and 6-
TG did have a bactericidal effect at intermittent timepoints. 6-MP was the only drug 
assessed near its usual therapeutic concentration and had the earliest bacteriocidal 
effect after 3 h, in contrast to the negative effect seen with the drug on macrophage 
modulation. 
 
 
The effects of soluble fibres on AIEC and diarrhoeal pathogen 
adhesion to intestinal cells  
 
 NSP plantain has a dose dependent inhibitory effect on the adhesion of  
ETEC to Caco2 ileocaecal intestinal cells, and inhibits ETEC adherence 
at concentrations that would be readily achievable in the colonic lumen (5 
mg/ml) with dietary supplementation. This inhibitory effect was seen with 
two types of in vitro assay, both culture plate assays and FACS. 
 
 Oat NSP and apple pectin, both used at concentrations of 5 mg/ml, inhibited 
the binding of ETEC bacteria to Caco2 cells, but not with statistical 
significance and further studies are needed to assess this further. 
 
 Plantain NSP had no effect on the binding of EPEC bacteria to Caco2 cells at 
any concentration between 0.05 and 50 mg/ml, though these experiments 
confirmed earlier work demonstrating a statistically significant inhibitory 
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effect of plantain on CD AIEC bacteria adherence at concentrations of 5 
mg/ml   
 
 The FACS experiments demonstrated a statistically significant inhibition of 
ETEC bacteria with NSP plantain at 10 mg/ml, which supported the cell 
culture results, and also a significant inhibitory effect of plantain fibre on 
C.difficile adherence to Caco2 cells, also at 10 mg/ml. 
  
 FACS methods did not demonstrate a significant inhibition by plantain NSP of 
AIEC adhesion to Caco2 cells at any dose, though a 2.5 mg/ml concentration 
was almost significant. No inhibitory effect of plantain on Campylobacter 
jejuni adherence to Caco2 cells was seen either though doses above 10 mg/ml 
were not used in either of these experimental series.   
 
A fluorescent effect of the plantain fibre itself made interpretation of the FACS 
adherence experiments problematic, and suggests that it is an unsuitable assay to use 
in further experiments assessing the inhibition by soluble fibres of bacterial adhesion 
to intestinal cells. 
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CHAPTER ELEVEN : DISCUSSION AND 
IMPLICATIONS FOR FUTURE STUDIES 
 
  
The qPCR assays of linearised plasmid DNA (chapter 6) were developed to 
examine the quantities of E. coli in colonic tissue from areas of inflamed and 
uninflamed intestinal biopsy tissue from patients participating in clinical trials which 
included periods of relapse and remission. This also afforded the opportunity to 
correlate change in E. coli numbers with histological findings and clinical state 
(chapter 7).    
  The crucial issues in the development of an assay for absolute quantification 
of E coli uidA genes (and hence E. coli bacteria) using qPCR, were assay sensitivity, 
accurate DNA and gene copy quantification and the denominator used. In a previous 
study molecular quantification (218) of uidA genes in CD ileal and colonic tissue 
generated 0.5-5x10
6
 uidA genes per million human cells in ileal biopsies and 
approximately 1.25x10
4
 cells in colonic tissue, with 0.75x10
4
 uidA genes in healthy 
tissue. The biopsies used in this work overall produced an average of 187000 18S 
rRNA genes per biopsy, or 937 human genomes (cells). From these figures, it is clear 
that the 18S rRNA assay used here was comfortably sensitive enough for CD biopsy 
samples, whilst the uidA gene assay was potentially more borderline, with a 
sensitivity of 1140 uidA gene copies. A further concern was that in one study looking 
at uidA genes in twins (226), levels of  E. coli were significantly higher in patients 
with ileal CD than colonic CD but in support of this work however, the authors also 
conclude that when E.coli was detectable for either colonic or ileal disease it was 
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present at all areas of the gastrointestinal tract (ileum, ascending colon, transverse 
colon, descending colon and rectum), which is what was found here (chapter 7).  
 Reviewing the literature revealed that different studies use different 
denominators, which makes direct comparisons difficult for microbial ecology and 
absolute quantification. As an example, 16S rRNA gene copies have been expressed 
in a twin study per β-globin gene present (226), whereas in other studies E.coli 
quantities are expressed per 18S rRNA genomes (218). Whilst it is valid to use  
different or combined housekeeping genes even, the differing denominators for each 
gene quantity expressed make direct comparisons difficult, and ultimately one of the 
improvements of the assays used in this work are that they can be directly compared 
with other studies as each component examined was independently absolutely 
quantified.  
 The use of FISH analysis produces only semiquantitative answers. In one 
study (311) only categorical data was presented and the authors remarked that 
accurate quantification could not be achieved, particularly in the tissues with high 
bacterial concentration. Other authors have attempted to quantify E. coli and other 
bacterial numbers by specifying the percentage of biopsies examined with the 
specified bacterial species present within the tissue, without quantifying the actual 
quantity within each biopsy (200), also a categorical measure, in future work FISH 
could be of value in correlating absolute quantification, and defining spatial 
arrangement of bacteria.  
Eventually, in view of these considerations, it was decided that the best 
solution was to aim for the maximum sensitivity possible for an absolute 
quantification assay (three bacteria), but that an acceptable sensitivity would 
approximate 1000 bacteria (per biopsy). The other targets were coefficient of 
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variation, or reproducibility <20%, and efficiency between 90-110%, error <0.2 and 
correlation coefficient >0.95. This was very difficult and pushed the limit of detection 
for qPCR to the extreme but all were eventually achieved. 
 The first quantification method resulted in a very poor standard curve, which 
may have been due to the crude method of DNA extraction used, or the fact that CFU 
counting can be inherently variable. The assay was clearly improved using an 
efficient commercial DNA extraction kit, but this still resulted in assay with poor 
efficiency, a key factor in PCR. 
 The switch to purely molecular techniques meant that there was removal of 
some of the variability seen when using methods involving CFU counting. The 
published genome size of E. coli, along with accurate quantification of extracted DNA 
using the Nanodrop ™, allowed good approximation of bacterial quantities, with a 
technique similar to that used previously (306). Unfortunately, this ultimately 
produced an assay with unacceptable error despite good efficiency and lower limits of 
detection (3530 copies) 
 Finally, the use of plasmid technology produced the definitive solution. The 
use of adapted plasmid DNA containing the uidA amplicon to transform cells was 
complicated, but meant that bacterial numbers could be quantified with great 
precision using these DNA standard templates and this approach was rewarded with a 
useable assay with appropriate sensitivity, efficiency, coefficient of variability and 
correlation coefficient. This technique is regarded as the gold standard currently 
(309;310) though it is in general vital to linearise plasmid DNA, as plasmid secondary 
and tertiary structure can preclude against sensitive target sequence annealing. This 
technique does have a drawback in that it can produce an over-estimation of gene 
numbers if the plasmid DNA is left in the supercoiled circular non-linear form, 
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because PCR amplification is less efficient when DNA is in this form (320) in the 
early stages of PCR amplification. For future work quantifying E.coli or broader 
bacterial groups, this would be the technique of choice. 
 
 Given its successful application to uidA quantification, it was appropriate to 
use the plasmid technology for the 16S rRNA gene assay. This reached the stage of 
development where a suitable clone had been produced for plasmid DNA and 
linearised, but when the plasmid DNA templates were used the qPCR did not reach 
acceptable performance statistics. Primer selection (as seen when different 
concentrations of primers were used with the uidA assays) and alteration of qPCR 
reaction conditions could improve this, though template quantity did not prove a 
crucial factor. Optimisation of this assay would provide useful denominator 
quantification of all bacteria present in biopsy DNA, and allow assessment of 
bacterial subset percentage changes in CD human tissue at different longitudinal 
timepoints and at different levels of disease activity, and would be an appropriate and 
expedient next step for analysis of microbiota in other biopsy samples, be they UC, 
CD, normal controls, or other gastrointestinal diseases. Both these and the uidA 
plasmid templates could also be used for microbial quantification for other diseases 
where solid organ tissue could be homogenised followed by DNA extraction and the 
techniques are not limited to gastrointestinal disease.  
          In contrast to the other assays the human 18S ribosomal RNA assay was 
straightforward, perhaps highlightling the importance of appropriate primers in qPCR, 
as this was a commercially developed kit with a probable high level of primer 
development. Its use as a housekeeping gene to standardise human tissue amounts 
was combined with standard biopsy mass measurement when CD biopsies were 
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processed, and concerns about its suitability as a denominator were not justified here, 
as both denominators yielded similar results. This assay could also be used in further 
quantitative studies of human tissue biopsies.  
It was important to define a lower limit of detection for the assays and in this 
work this was simply defined as the limit where a fluorescence curve for a given 
template could be clearly and repeatedly differentiated from a PCR water control and 
also form part of a set of repeatedly useable templates that satisfied the statistical 
requirements for the PCR assay. The difficulties involved in looking at the lower limit 
of detection in qPCR are discussed in the literature. All appropriate statistics and 
methods are provided for this work so that these assays  can be reproduced, consistent 
with good qPCR standards   
  
When the qPCR standards were used successfully with human biopsy tissue 
for bacterial quantification, the main objectives of the first two chapters were 
achieved. The quantification was done in a robust and reproducible way.  Though the 
numbers in both studies used as a source for biopsy data were small, nevertheless 
there were points of interest. The identification of high uidA gene quantities in the 
terminal ileal biopsy of a patient, with a macroscopically normal ileum but 
histological ileitis, and clinical markers of disease activity raises the possibility of 
whether bacterial uidA qPCR may eventually be used as an accessory predictive tool 
in pathology. The high quantities of the uidA gene in a lymphoid follicle suggests a 
possible role for these sorts of assays in the study of pathophysiological processes, 
given that this is the key tissue involved in pathophysiological bacterial translocation. 
When the microbiota of patients in the plantain clinical trial were examined, 
an interesting finding was noted in the patients in sustained remission. The biopsies 
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were examined by the qPCR assay after pooling together mucus washings and biopsy 
material, and showed significantly reduced quantities of uidA genes. It will be even 
more informative when the clinical trial is unblinded and the effect of plantain fibre 
on both clinical relapse, and uidA gene quantity can be assessed in more detail, but 
certainly the fact that lower levels of the putative causative organism, E. coli, in CD, 
were noted in patients in remission was fascinating. and invites further work.  
The use of qPCR to quantify uidA genes, and by proxy E.coli quantities in CD 
tissue from different lesions, in both periods of disease remission and relapse over 
time and also in small and large intestinal tissue at the same timepoint, may become a 
powerful tool. It could be used in examination of disease aetiology, and natural 
history, and perhaps could be used to quantify E.coli in clinical trials of antibiotics, as 
well as to measure the effects of steroids, immunomodulators, and anti-TNF agents on 
the quantities of E.coli in CD. It could also be used to quantify microbial changes 
with other clinical trial agents as well as these conventional drugs as a distinct 
endpoint in future clinical trials. It is also conceivable that microbiota quantification 
may have use as prognostic indicators of disease type, severity, or progress. As the 
AIEC group of bacteria become better characterised in terms of key genes involved in 
pathogenesis, for example the long polar fimbriae (lpf) gene (335), they will offer 
more specific targets for quantification. Subsequently the development of primers for 
qPCR of E.coli involved in CD, may be refined yet further.  
 
In experiments evaluating the effects of drugs on E.coli replication within 
macrophages Ciprofloxacin was inhibitory and effective both at Cmax and 10% Cmax 
concentrations supporting previous work from this laboratory and also suggesting the  
importance of this antibiotic’s use in clinical trials. The use of metronidazole as an 
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antibiotic to target the E.coli potentially relevant in CD pathogenesis is not supported 
by this in vitro work, as there is no evidence that it confers any additional benefit to 
intra-macrophage killing over ciprofloxacin used alone. Metronidazole has probable 
clinical efficacy in CD and has the support of meta-analysis (269), which may be due 
to the effective killing of anaerobic bacteria. These bacteria may infect tissue 
secondarily after mucosal ulceration has been initiated in response to other pathogenic 
agents. It also may have immunological effects, such as blockade of neutrophil 
recruitment which give it efficacy independent of its antibiotic effect (336), and it 
may be valuable for treatment of  anaerobic infection in abscesses and perianal 
disease (356).   
There is merit in clinical trials of combination antibiotics including 
ciprofloxacin for treatment of CD relapse. Further clinical trials of antibiotic 
combinations in CD which target E.coli specifically are warranted. Constructing these 
trials and selecting antibiotic combinations needs careful consideration of issues 
including side effect profiles, microbial resistance, and interactions with drugs used in 
maintenance therapy in CD.    
The in vitro data examining the immunomodulators raise some interesting 
questions about the mode of action of some of the pharmacological agents used to 
treat IBD. Azathioprine and its metabolites 6-MP and 6-TG generally had some 
bacteriocidal effects when directly co-incubated with bacteria. Regarding the agents 
used in this work separately as an ‘antibiotic’ or as an ‘immunomodulator’ may also 
be an artificial simplification as they may possess properties of both, which has to 
some extent already been described. The mode of action of all the 
‘immunomodulators’ to some extent seems to be related to altering sensitivity to 
reactive oxygen species (287;288), affecting the activity levels of iNOS (292), and 
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modulation of phagocytosis. This works prompts further examination of the 
mechanisms of action of azathioprine and its metabolites. In terms of effects on 
phagocytosis steroids had some interesting and unexpected effects. The suppression 
of intra-macrophage E.coli replication by hydrocortisone supports the data suggesting 
that steroids are pro-phagocytic (293), and that their effects on sepsis may be more 
related to their suppression of neutrophil recruitment in patients. It is probable that 
their effect on the body’s response to sepsis may be mediated by blockade of the 
recruitment of neutrophils to a site of injury (360), which is mediated by IL-8 (202), 
or inhibition of macrophage recruitment (294), rather than by any direct effect on the 
ability of phagocytic leucocytes to kill bacteria. They were non bactericidal in direct 
co-incubation with bacteria, and this may be related to the timecourse they take to 
produce an effect rather than a genuine absence of effect. Alternatively it may be that 
steroids have differential effects on bacterial phagocytosis and killing at different 
timepoints. Many of the drugs used in this study demonstrate either a direct E.coli 
killing effect, or an indirect inhibition of the intra-macrophage survival of bacteria, 
and also already have proven clinical efficacy in CD management, either in 
maintaining remission or treating relapse. It is tempting to speculate that E.coli 
growth and replication, and its regulation is fundamental in CD pathogenesis, and that 
the evidence herein supports this. It would be useful to perform further experiments 
evaluating the effect on E.coli replication of other drugs or foods with proven CD 
efficacy, such as infliximab and enteral feeds, to delineate pathogenesis further. It is 
appropriate to quantify E.coli numbers in in vitro assays with the qPCR techniques 
developed in the first chapters of this work as they are highly specific and 
reproducible.    
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Work evaluating the effects of foodstuffs on diarrhoeal pathogens and AIEC 
adhesion to intestinal cells demonstrated that plantain NSP fibre has an inhibitory 
effect on the adhesion of AIEC, ETEC and C. difficile to intestinal cells. This was 
confirmed with both the in vitro modalities used, FACS and tissue culture, in the case 
of ETEC.  
The absence of an inhibitory effect of NSP plantain fibre on the adherence of 
both typical and atypical EPEC bacteria to Caco2 cells has some biological 
plausibility, as the EPEC bacteria use a unique mechanism of interaction with host 
epithelial cells. Intimin receptor translocation onto the host cell functions as a receptor 
for its intimin ligand (253), and this may help the EPEC organism bypass the 
‘mucosal blockade’, produced by plantain fibre by cross linkage of bacterial cell 
surface receptors, which will include lectin carbohydrate moieties. Soluble plantain 
fibre is a complex mixture of oligosaccharides, and any of these, perhaps particularly 
mannose, could interfere with the EPEC adhesion to the mucosal surface if the 
bacterium didn’t utilise these alternate host interaction strategies.  Perhaps the atypical 
EPEC uses the proteins expressed from its mobility and resistance plasmids to avoid 
plantain cross linkage (252). The fact that both the negative and positive control 
experiments in the EPEC experiments gave the anticipated results supports the 
conclusion that this is a true result. 
           The non-significant inhibitory effects seen with apple pectin and oat NSP on 
ETEC inhibition need further development with dose response curves and further 
experimental repetition. It was of interest that the oat fibre did not stimulate bacterial 
adhesion to Caco2 cells as might be hypothesised from its’ stimulatory effects on 
NFKB in mice (363). Potentially and probably this results from different modulation 
of NFKB signalling in mice and humans. Also of note, the ETEC and C.difficile 
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adherence to Caco2 cells was inhibited by plantain NSP, and this supports the 
suggestion that toxin production is not the sole mechanism for disease activity, or at 
least that mucosal proximity is a factor in toxin production, as there certainly seemed 
to be ligands for mucosal adhesion that could be inhibited. 
 FACS results complemented tissue culture well results, but with some 
important exceptions. The ability to measure 10,000 cell-bacterial events in an 
experiment was a powerful technique, but the finding of a fluorescent signal 
generated by the plantain fibre in isolation was a significant drawback. This argues 
against future use of the assay in assessment of inhibition of bacterial adhesion by 
soluble fibres.  
To further develop standard cell culture experiments they could be performed 
with qPCR techniques used to quantify final bacterial numbers to improve specificity, 
though for species not included in chapters six and seven, specific primers would need 
to be developed.   
The potential for translating the results of these in vitro experiments into 
clinical trials investigating the prophylaxis of diarrhoeal pathogen infection, to 
complement the trials already underway investigating the use of plantain fibre as 
maintenance therapy in CD is clear (see chapter seven). A 5 g twice daily supplement 
of NSP plantain fibre would easily achieve intra-luminal concentrations demonstrated 
to have in vitro efficacy in this work (69;232). Diarrhoeal illness is a large burden 
worldwide, in terms of morbidity, mortality and cost, and antibiotics are often 
implicated as a cause of diarrhoeal illness. Additional strategies for prophylaxis of 
infective diarrhoea would augment current infectious disease prevention strategies. If 
dietary supplements are shown to be effective, it would result in lower incidence of 
multi-resistant bacteria and be very cost-effective.  It could be of particular interest to 
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focus on at risk groups, for example hospitalised patients over the age of sixty five 
who are on antibiotics, African infants and children in areas of poor sanitation, or 
people travelling frequently to endemic areas. Many of these diarrhoeal pathogens can 
also trigger a relapse of UC or CD (47;224) so the benefit would not solely be 
confined to those patients at risk of diarrhoeal illness, but could also prevent CD 
relapses. The health and cost benefit from clinical trials of plantain and other 
foodstuffs is potentially vast, and again could use the highly developed qPCR assays 
from this work to quantify the microbiota as a genuine endpoint augmenting other 
conventional clinical measures.  
 The strengths of this study are that multiple elements of prevention of 
diarrhoeal illness were examined in vitro and in vivo.  Attention was made to make in 
vitro experiments relevant clinically. The development of a precise method to 
quantify E.coli in tissue has far reaching potential in pathophysiological work. The 
weaknesses of the study include the relatively small number of patients recruited to 
the clinical trials, making demonstrations of differences in E.coli quantities between 
patient groups and between types of tissue difficult. In addition in the in vitro work, a 
limited number of E.coli strains were used due to time constraints.      
 Future work could include quantification of the AIEC pathotype in CD tissue 
using specific primers and quantification of total bacterial numbers would help 
delineate dysbiosis in CD tissue. Clarification of the differential cytokine expression 
by macrophages when incubated with current drugs used in CD therapy would be 
informative. The effect of drugs on labelled cellular components of the autophagy 
machinery, including the lysosome and phagosome should be addressed. Replication 
of other E.coli strains within macrophage tissue should be investigated, as should 
dose-response effects of apple-pectin and oat fibre on diarrhoeal pathogens.  
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APPENDIX ONE : CLINICAL DATA FROM THE 
APHTHOUS ULCER STUDY  
 
Information listed is in order of clinical indication,  HBI score (all HBI's original 
scoring), bowel preparation taken, co-morbidities, medication, and CRP value. Cont = 
control patient, CD = Crohn’s patient 
 
PATIENT CODE CLINICAL DETAILS 
CONT1 Sigmoid polyp evaluated, HBI=0, kleenprep, Renal dialysis patient, Multiple 
medications – Quinine Clonazepam Sodium Bicarbonate Salmeterol Salbutamol 
Fludrocortisone Omeprazole Chlorpheniramine Aspirin Senna Frusemide Aranesp 
Atrovent Atorvastatin Calcichew Diltiazem retard , CRP -5 
CONT2 Left iliac fossa and general abdominal pain associated with offensive stools and weight 
loss, HBI = 5, Moviprep, Helicobacter pylori positive and had bladder repair and 
hysterectomy for fibroid, Lansoprazole Movicol Senna and Metoclopramide, CRP < 5 
CD1 CD surveillance - Crohn's colitis, HBI = 4, Moviprep, taking Salzopyrine, Vitamin B12 
and Folate, CRP 14 
CD2 Diarrhea mouth ulcers and arthralgia - new endoscopic diagnosis CD,  
HBI = 12, Moviprep, taking Microgynon, CRP 9 
CD3 Previous right hemicolectomy symptomatic with diarrhea and abdominal pain, HBI = 
13, Moviprep,  Asthma and Obstructive sleep apnoea, Multiple medications - Pentasa 
Calcichew B12 Folic acid Salbutamol Seretide Tranexamic acid Cetirizine Cocodamol 
Terbutaline Salmeterol Carbocysteine Montelukast Bumetanide Lansoprazole 
Citalopram Domperidone Prednisolone Questran CRP 37 
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APPENDIX TWO : MACROSCOPIC AND 
MICROSCOPIC APPEARANCE OF TISSUE IN THE 
APHTHOUS ULCER STUDY 
 
Macroscopic appearance of colonic ± ileal tissue in recruited patients 
 
Cont = control, CD = CD patient. 
 
PATIENT CODE MACROSCOPIC APPEARANCE AT ENDOSCOPY 
CONT1 Descending colon polyp. Nil else. 
CONT2 Normal appearance 
CD1 Some linear CD scars, otherwise quiescent appearance 
CD2 Ileal and rectal CD - aphthous ulcers in the terminal ileum and splenic 
flexure ulceration typical of CD. Rectal inflammation 
CD3 Quiescent CD, no ulcers or inflammation 
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Microscopic appearance of biopsy samples taken from large and 
small intestinal tissue of recruited patients 
 
Cont = control, CD= CD patient. 
  
PATIENT CODE MICROSCOPIC APPEARANCE OF TISSUE 
CONT1 Tubulovillous adenoma showing low grade dysplasia, excision 
complete 
CONT2 Normal large bowel colonic mucosa 
CD1 Large intestinal tissue from caecum to rectum showed mild crypt 
architectural distortion. Small numbers of muciphages  in the recto-
sigmoid. No active or significant inflammation 
CD2 Focal chronic active colitis and ileitis with granuloma formation.  
Highly suspicious for CD. Ileal mucosa ulcerated with granulation 
tissue. Moderately severe chronic active inflammation seen. 
Transverse colon normal. Rectal mucosa focal chronic active colitis 
with small numbers of poorly formed granulomas within the lamina 
propria and submucosa. 
CD3 Focal active inflammation in the ileum. Fragments of ileum show 
villous atrophy together with foci of ulceration and 
polymorphonuclear cells in the lamina propria and acute cryptitis. 
Normal large bowel mucosa 
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APPENDIX THREE : PHYSICAL CHARACTERISTICS 
OF BIOPSY SAMPLES FROM THE APHTHOUS ULCER 
STUDY 
 
 
Physical characteristics of Small Intestinal biopsied 
 
Mass and total quantity of DNA extracted from large and small intestinal tissues were 
quantified.  
TI = terminal ileum, AU = aphthous ulcer, B = biopsy code no, LF = lymphoid 
follicle, SI = small intestine, serp = serpingous. 
CODE MASS/mg DNA EXTRACTED 
ng/µL 
CONT 2 TI 44.7 46.4 
CONT 2 LF 7.2 31.2 
CD1 B6 TI 64 129 
CD2 SERP ULCER TI 36 25.4 
CD2 AU 17.7 102 
CD3 TI B 37.8 11.6 
CD3 SI 44.8 14.5 
CD3 TI B 56.1 14.2 
CD1 B5 LF 32 46.3 
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Physical characteristics of Large Intestinal tissue biopsies 
AC = ascending colon, SC = sigmoid colon, SF = splenic flexure, LI = non specific 
large intestinal sample, B = non specific colon sample 
CODE MASS/mg DNA EXTRACTED ng/µL 
CONT1 B1  81 14 
CONT1 B2 20 107 
CONT1 B3 12 43.7 
CONT1 B4 113 55.5 
CONT1 B5 27 37.6 
CONT1 B6 27 101 
CONT 1 B7 56 104 
CONT 1 B8 96 109 
CONT2 AC 55.5 27.1 
CONT2 AC 70.3 n/a 
CONT2 SC 59.3 11.6 
CONT2 SC 59.2 2.19 
CONT 2 SC 31.1 3.18 
CONT2 CAECUM 112 33.5 
CD1 B SF 63 87.9 
CD1 B2 30 178 
CD1 B3 SC 41 255 
CD1 B4 TC 29 63.6 
CD2 B SF 30.1 143 
CD2 B SF ULCER 8.2 54.5 
CD3 LI 24.5 18.6 
CD3 LI 60.6 26.2 
CD3 LI 59.7 9.28 
CD3 LI 47.8 10.6 
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APPENDIX FOUR : QUANTITIES OF DNA EXTRACTED 
FROM MUCOSAL WASHINGS FROM SMALL AND 
LARGE INTESTINAL SAMPLES IN THE APHTHOUS 
ULCER STUDY 
 
Small Intestinal Samples 
 
Cont = control, CD = Crohn’s patient, TI = terminal ileum, AU = aphthous ulcer, B = 
biopsy code no, LF = lymphoid follicle, SI = small intestine, serp = serpingous. 
 
CODE DNA 
QUANTITY 
ng/µL 
 CODE DNA 
QUANTITY 
ng/µL 
CONT 2 TI 5.72  CD3 SI 3.6 
CONT 2 LF n/a  CD3 TI B 1.6 
CD1 B6 TI 10.9  CD1 B5 LF 5.7 
CD2 SERP ULCER 
TI 
9.3 
CD2 AU 90.2 
CD3 TI B 4.57 
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Large Intestinal Samples 
 
cont  = control, CD = Crohn’s patient AC = ascending colon, SC = sigmoid colon, SF 
= splenic flexure, LI = non specific large intestinal sample, B = non specific colon 
sample 
 
CODE DNA 
QUANTITY 
ng/µL 
 CODE DNA QUANTITY ng/µL 
CONT1 B1 6.2  CONT2 SC 11.6 
CONT1 B2 14  CONT 2 
CAECUM 
2.50 
CONT1 B3 7.9  CD1 B SF 85 
CONT1 B4 10.4  CD1 B2  16.3 
CONT1 B5 9  CD1 B3 SC 46.3 
CONT1 B6 10.2  CD1 B4 TC 3.8 
CONT1 B7 9.9  CD2 B SF 22.9 
CONT1 B8 5.3  CD2 B SF     
ULCER 
10.8 
CONT2 AC 4.61  CD3 LI 3.6 
CONT2 AC 4.1  CD3 LI 3.88 
CONT2 SC 4.2  CD3 LI 2.62 
CONT2 SC 3.6  CD3 LI 10.6 
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APPENDIX FIVE : PATIENTS STOPPING THE 
PLANTAIN CLINICAL TRIAL BEFORE TWELVE 
MONTHS 
 
PATIENT 
CODE 
REASON FOR TRIAL CESSATION 
101 Patient withdrawal after one month. Near relapse CDAI 
= 213.5 
201 Withdrawal after 5 months, with adverse effects (nausea 
and bloating). CDAI 76.8 
202 Withdrawal after 6 months. CDAI rise of  >100 to 141. 
502 Relapse after 3 months. CDAI 363.7 
603 Clinically relapsing at the time of withdrawal after 2 
months. CDAI 311.3 
 
 
 
 
 
 
 317 
APPENDIX SIX : CONSTITUENTS OF CULTURE 
MEDIA, AGAR, AND BUFFERS USED IN THIS THESIS 
 
 
Culture Media  
 
For Caco2 cells: 
 
Dulbecco’s modified Eagle’s medium (DMEM), was supplemented with 10% vol/vol 
fetal bovine serum (FBS), 4 mM L-glutamine, 100 U/ml penicillin and 100 μg/mL 
streptomycin.   
 
For J774-A1 macrophage cells 
 
Cells were maintained in Roswell Park Memorial Institute RPMI-1640 medium, 
supplemented with 10% (v/v) FBS, 8 mM L-glutamine, 100 U/mL penicillin and 100 
μg/mL streptomycin.  
 
Agar used  
  
LB agar  consisted of the following components (per litre): Bacto-agar (20g), Yeast 
extract (5g), Bacto tryptone (10g) and Sodium Chloride (10g). 
 
For liquid cultures, LB alone was used, omitting the Bacto-agar. 
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Amp-X-gal agar 
 
500 ml of standard LB agar was prepared and autoclaved. After it was sufficiently 
cooled, but still in the liquid phase  400 ml was taken and 400 µl Ampicillin (prepared 
at 100 mg/ml) added, together with 400 µl X-Gal (80 mg/ml) and 200 µl Isopropyl β-
D-1-thiogalactopyranoside (IPTG, 100mM). This was mixed by swirling and agar 
plates were poured.  
  
Buffer Composition 
 
QIAprep Spin Miniprep (27104) buffer composition for plasmid DNA extraction 
 
P1: 
50 mM Tris-HCl pH 8.0  
10 mM EDTA  
100 μg/ml RNaseA  
  
P2:  
200 mM NaOH  
1% SDS  
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N3: 
4.2 M Gu-HCl  
0.9 M potassium acetate  
(pH 4.8)  
  
PE:  
10 mM Tris-HCl (pH 7.5)  
80% ethanol  
  
Qiagen DNA mini-kit (51304) buffer composition 
 
ATL: 
Proprietary chemical, contains: 
EDTA 
SDS 
 
AL:  
Proprietary chemical, contains: 
Quanidium chloride 
 
AW1: 
Proprietary chemical, contains: 
Quanidium chloride 
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AW2: 
Proprietary chemical, composition unknown 
 
Phosphate buffered saline composition (PBS): 
Made up in 1 l sterile water 
NaCl 8.01 g/l (137 mmol/l 
KCl 0.20 g/l (2.7 mmol/l) 
Na2HPO4 – 2 H20 1.78 g/l (10 mmol/l) 
KH2PO4 0.27 g/l (2.0 mmol/l) 
pH 7.4 
 
Tris-acetate-EDTA (TAE): 
Prepared as a 50X stock solution   
242g Tris base in sterile water 
57.1mL glacial acetic acid 
100mL of 500mM EDTA (pH 8.0) solution 
Final volume made up to 1 l with sterile water   
(diluted 50:1 with sterile water to make a 1X working solution)  
This 1X solution will contain 40mM Tris, 20mM acetic acid, and 1mM EDTA. 
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Tris-Borate-EDTA (TBE): 
Prepared as 5X stock solution 
54 g of Tris base 
27.5 g of boric acid 
20 ml of 0.5 M EDTA (pH 8.0) 
TBE diluted to 1X or 0.5X with sterile water. 
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APPENDIX SEVEN : FIGURES AND TABLES USED IN 
THIS THESIS 
 
Figures 
 
Figure 1.1 Site of CD in children and adults 
Figure 1.2 NOD/TLR signalling in a mammalian host cell.  
Figure 2.1 M cell interactions in CD 
Figure 2.2 Transmission electron micrograph of an A/E lesion formed by EPEC   
infection of intestinal epithelial cells. 
Figure 2.3 Signal transduction following EPEC Tir –intimin binding  
Figure 2.4 Virulence Factors for ETEC  
Figure 2.5  Illustration of the Metabolism of thiopurines. 
Figure 2.6 Gene–environment interactions in CD: defining new therapeutic targets. 
Figure 2.7 A model for bacterial involvement in UC.   
Figure 6.1  Screening of the ileo-colonic CD isolates for presence of the uidA gene.  
Figure 6.2  The bacterial control Klebsiella pneumonia (HM534) is PCR-negative for 
the uidA gene 
Figure 6.3  Primer optimisation experiment using an acquisition temperature of 60°C 
showing poor signal from 50nM primers and optimal signal with 300 and 900nM 
concentration primers.  
Figure 6.4  Final primer optimisation experiment 
Figure 6.5  qPCR evaluation of DNA extracted crudely from bacterial suspensions 
Figure 6.6  The standard curve obtained using method one 
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Figure 6.7 Demonstration of a linear relationship between CFU and dilution of 
bacterial suspension 
Figure 6.8 Fluorescence curves generated by qPCR of DNA extracted from E. coli 
bacterial suspensions using the Qiagen tissue minikit (method 2) 
Figure 6.9  Standard curve generated by method 2  
Figure 6.10 qPCR fluorescence curves produced by E. coli genomes and negative 
bacterial controls used in quantification method three  
Figure 6.11 The standard curve generated using genomic E. coli DNA and the 
nanodrop to quantify bacterial numbers  
Figure 6.12. Melt Curve demonstrating uniqueness of uidA amplicon product from 
genomic E. coli DNA 
Figure 6.13 DNA electrophoresis following PCR amplification of plasmid DNA to 
confirm uidA amplicon insertion 
Figure 6.14 Restriction enzyme digest of plasmid uidA amplicon 2 DNA extracted 
from transformed electrocompetent cells  
Figure 6.15 Comparison of the fluorescence curve genrerated by non-linearised 
plasmid uidA amplicon 1, NTC, and probiotic bacteria  
Figure 6.16  Melt curve obtained using uidA amplicon 1 plasmid DNA  
Figure 6.17 Fluorescence curves generated using plasmid uidA amplicon 2 DNA in 
qPCR  
Figure 6.18 The standard curve generated from non linear plasmid uidA amplicon 2 
DNA  
Figure 6.19 Figure showing representative examples of linearised uidA amplicon 
containing plasmid DNA  
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Figure 6.20 Linearised plasmid uidA amplicon 2 fluorescence curves (A), and  
correlation co-efficient (B)  
Figure 6.21 Schema of method for absolute quantification of bacterial gene numbers 
using plasmid-amplicon DNA to generate standard curves 
Figure 6.22 Linearisation of the 16S rRNA gene containing plasmid 
Figure 6.23 Best result for 16S rRNA gene eubacterial assay fluorescence curves (A)   
Figure 6.24 Fluorescence curves produced by the 18S rRNA genome standards 
Figure 6.25 standard curve derived from Cp’s of fluorescence curves from 18S rRNA 
qPCR 
Figure 7.1  Disease activity levels for patients in the biopsy arm of the plantain 
clinical trial, assessed by CDAI 
Figure 7.2 Quantification of combined biopsy and mucus wash quantities of uidA 
gene copies / million 18S rRNA genomes from the large intestinal tissues of all 
patients in the biopsy arm of the plantain clinical trial (A), and remission patients 
alone (B) 
Figure 7.3 uidA gene copies per million 18S rRNA genomes for the three patients 
who relapsed during the biopsy arm of the plantain trial  
Figure 7.4 uidA gene copies per mg large intestinal tissue for the three patients who 
relapsed during the biopsy arm of the plantain trial  
Figure 7.5 uidA gene copies per million 18S rRNA genomes for mucosal washings 
from the three patients who relapsed during the biopsy arm of the plantain trial  
Figure 7.6. A comparison of the uidA gene copy numbers seen in small intestinal 
tissue in control and CD tissue  
Figure 7.7. A comparison of the uidA gene copy numbers seen in small intestinal 
tissue in control and CD tissue (per mg tissue) 
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Figure 7.8 A comparison of the uidA gene copy numbers seen in large intestinal 
tissue in control and CD tissue  
Figure 7.9 A comparison of the uidA gene copy numbers seen in large intestinal 
tissue in control and CD tissue  
Figure 7.10 Comparison of the uidA gene copy numbers seen in small intestinal tissue 
mucus washings from control and CD tissue  
Figure 7.11 comparison of the uidA gene copy numbers seen in large intestinal tissue 
mucus washings from control and CD tissue  
Figure 8.1 The effect of antibiotics used at Cmax on replication of HM605 E coli 
within J774-A1 macrophages at 6 h 
Figure 8.2 Crohn’s E. coli HM605 replication within J774 murine macrophages at 6 h 
in the absence or presence of antibiotics used at 10% Cmax  
Figure 8.3 The effect of high dose azathioprine on intra-macrophage E.coli 
replication 
Figure 8.4 The effect of 24h pre-incubation of J774-A1 macrophages with clinically 
relevant concentrations of azathioprine on HM605 E. coli replication  
Figure 8.5 The effect of 24h pre-incubation of J774-A1 macrophages with 6-MP on 
intra-macrophage E coli replication  
Figure 8.6 The effect of 24h pre-incubation with 6- TG on intra-macrophage E. coli 
HM605 replication  
Figure 8.7 The effect of 24h pre-incubation with hydrocortisone on intra-macrophage 
E. coli HM605 replication 
Figure 8.8 Exploration of a direct bacteriocidal effect of the immunomodulators 6-TG 
and 6-MP on E.coli 
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Figure 8.9 Exploration of a direct bacteriocidal effect of the immunomodulators 
Azathioprine and Hydrocortisone on E.coli growth    
Figure 9.1 The effect of plantain NSP on ETEC adhesion to Caco2 cells at differing 
doses  
Figure 9.2 Apple pectin non significantly inhibited the adherence of ETEC to Caco2 
cells 
Figure 9.3 Oat NSP non significantly inhibited the adherence of ETEC to Caco2 cells  
Figure 9.4 Plantain NSP has no effect on the binding of the EPEC strain D55 to 
Caco2 cells  
Figure 9.5 Plantain NSP has no effect on the binding of the atypical EPEC strain 
e2348/69 to Caco2 cells 
Figure 9.6 The effect of plantain NSP at different doses on AIEC adhesion to Caco2 
cells  
Figure 9.7 The effect of plantain NSP at different doses on Campylobacter jejuni 
adherence to Caco2 cells  
Figure 9.8 The effect of plantain NSP on C.difficile and ETEC adhesion to Caco2 
cells  
 
Tables 
 
Table 1.1 Prevalence of pathology in CD by location and surgery risk   
Table 1.2 Differing location of CD lesions with age 
Table 1.3 The Vienna classification of CD 
Table 1.4 Extra-Intestinal Manifestations of IBD, and significant  differences 
between disease groups 
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Table 5.1 Primers used in PCR assays, all sequences specified in 5’-3’ direction 
Table 5.2 Summary of primers (from table 5.1) used in specific assays and 
quantification methods in this thesis 
Table 6.1 Ideal minimum qPCR standards checklist   
Table 6.2  Coefficients of variation for the CFU plating component of standardisation 
methods 1 and 2.  
Table 6.3 Performance of assays for uidA genes  
Table 6.4 Performance from the 16S rRNA gene and 18S rRNA gene assays 
Table 7.1 Physical characteristics and clinical data for patients in the biopsy arm of 
the plantain clinical trial 
Table 7.2 Total uidA gene copies per million 18S rRNA genomes present in the 
combined biopsies and mucus washings of patients in the plantain clinical trial 
Table 7.3 uidA gene copies per million 18S rRNA genomes  and per mg large 
intestinal tissue biopsy for the three patients who relapsed during the biopsy arm of 
the plantain trial 
Table 7.4 uidA gene copies per million 18S rRNA genomes for mucosal washings 
from the three patients who relapsed during the biopsy arm of the plantain trial    
Table 7.5 uidA gene copy numbers per 1x10
6
 18S rRNA genomes in small intestinal 
samples 
Table 7.6 uidA gene copies per mg small intestinal samples   
Table 7.7 uidA gene copies per 1x10
6
 18S rRNA genomes in large intestinal samples   
Table 7.8 uidA gene copies per mg large intestinal tissue 
Table 8.1 Cmax of antibiotics used in this thesis  
Table 8.2 Experiment to evaluate the effect of peak concentrations (µM) of 
immunomodulator on J774-A1 macrophage cell growth  
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Table 8.3 Adenylate Kinase (AK) Cytotoxicity Assay  
 
 
 
 
 
 
 
 
 
 
 
 
 
